Development of theranostics nanomaterials by Yang, Qiuhong





Submitted	   to	   the	   graduate	   degree	   program	   in	   Pharmaceutical	   Chemistry	   and	   the	  
Graduate	   Faculty	   of	   the	   University	   of	   Kansas	   in	   partial	   fulfillment	   of	   the	  
requirements	  for	  the	  degree	  of	  Doctor	  of	  Philosophy.	  
	  
________________________________	  	  	  	  	  	  	  	  
	  	  	  	  Chairperson	  Dr.	  Laird	  Forrest	  	  	  	  	  	  	  
________________________________	  	  	  	  	  	  	  	  
Dr.	  Jeff	  Krise	  
________________________________	  	  	  	  	  	  	  	  
Dr.	  Teruna	  J.	  Siahaan	  
________________________________	  	  	  	  	  	  	  	  
Dr.	  Thomas	  Tolbert	  
________________________________	  	  
Dr.	  Shenqiang	  Ren	  
	  	  
Date	  Defended:	  October	  6th,	  2014	  
	  
	   ii	  
The	  Dissertation	  Committee	  for	  Qiuhong	  Yang	  











	  	  	  	  	  	  ________________________________	  
	  Chairperson	  Dr.	  Laird	  Forrest	  
	  
	  
	  	  	  	  	  	  	  





	   iii	  
Abstract	  
Clinical	   outcomes	   of	   conventional	   anticancer	   therapies	   are	   often	  
compromised	   due	   to	   off-­‐target	   toxicity	   and	   adaptive	   drug	   resistance.	   Moreover,	  
currently	   there	   are	   no	   imaging	   modalities	   that	   can	   be	   utilized	   for	   real-­‐time	  
monitoring	  of	  therapeutic	  responses	  in	  the	  human	  body.	  Therefore,	  there	  is	  a	  critical	  
need	   to	   develop	   a	   novel	   generation	   of	   personalized	   medicine	   that	   combines	  
functionalities	   of	   diagnosis	   and	   therapy,	   with	   an	   ultimate	   goal	   of	   early	   detection,	  
accurate	  treatment	  and	  timely	  assessment	  of	  therapeutic	  efficacy.	  Over	  the	  last	  few	  
decades,	  a	  variety	  of	  nano-­‐medical	  materials	  or	  devices	  such	  as	  liposomes,	  micelles,	  
quantum	   dots,	   magnetic	   nanoparticles	   and	   plasmonic	   nanobubbles	   have	   been	  
developed	   to	   deliver	   therapeutic	   products	   or	   diagnostic	   agents	   to	   the	   sites	   of	  
disease	   in	   a	   controlled	  manner	  with	   reduced	   or	   eliminated	   side	   effects	   to	   normal	  
tissues.	   This	   dissertation	   focuses	   on	   the	   development	   of	   functional	   molecular	  
imaging	   probe	   and	   nanoparticles-­‐based	   therapeutic	   agent	   delivery	   systems	   for	  
effective	  theranostics	  of	  lymphatically	  metastatic	  cancer,	  thus	  opening	  new	  avenues	  
to	  combat	  cancer.	  	  	  
In	   chapter	   2,	   a	   near-­‐infrared	   (NIR)	   absorbing	   dye	   -­‐based	   caspase-­‐9	   image	  
probe	   was	   synthesized	   in	   11	   steps	   to	   directly	   detect	   apoptotic	   cells	   with	   high	  
specificity.	   This	   cell-­‐permeable	   molecular	   contrast	   agent	   has	   demonstrated	   the	  
feasibility	   of	   monitoring	   cancer	   cell	   apoptosis	   induced	   by	   chemotherapeutics	   in	  
mice	   bearing	   head	   and	   neck	   squamous	   cell	   carcinoma	   (HNSCC),	   via	   non-­‐invasive	  
	   iv	  
photoacoustic	  imaging	  (PAI)	  within	  24	  h	  after	  treatment,	  thus	  to	  predict	  treatment	  
efficacy.	  	  
In	   chapter	   3,	   a	   biocompatible	   core/shell	   FePt@Fe3O4	   magnetic	  
nanoparticles	   (MNPs)	   was	   developed	   as	   a	   robust	   probe	   for	   magnetic	   resonance	  
imaging	   (MRI)	   and	   to	   mediate	   hyperthermia	   treatment	   against	   breast	   tumor.	  
Enhanced	   anti-­‐tumor	   effectiveness	  was	   demonstrated	   in	   a	  mouse	  model	   of	   4T1.2	  
Neu	  breast	   tumor	   as	   a	   consequence	   of	   the	  high	  magnetic-­‐thermal	   energy	   transfer	  
capability	   of	   MNPs.	   In	   addition,	   increased	   MRI	   contrast	   in	   the	   tumor	   region	  
potentiated	  the	  clinical	  application	  of	  MNPs	  for	  cancer	  diagnosis.	  	  
In	   chapter	   4,	   Cabozantinib	   (XL-­‐184),	   a	   poorly	   water-­‐soluble	   pan-­‐kinase	  
inhibitor,	   was	   encapsulated	   into	   a	   DSPE-­‐PEG2000	   micellar	   formulation	   with	  
excellent	   colloidal	   stability.	   Compared	  with	   the	   free	   XL-­‐184	   solution,	   drug-­‐loaded	  
micelles	  exhibited	  increased	  intracellular	  drug	  uptake	  and	  higher	  cytotoxicity	  in	  one	  
human	   lung	   adenocarcinoma	   epithelial	   cell	   line	   and	   two	   human	   malignant	  
glioblastoma	  cell	  lines.	  	  
In	   chapter	   5,	   a	   high	  molecular-­‐weight	   hyaluronic	   acid-­‐deferoxamine	   (DFO)	  
conjugated	   was	   synthesized	   for	   sustained	   release	   delivery	   of	   DFO,	   whose	   potent	  
iron-­‐chelating	   capability	   can	   be	   utilized	   to	   reverse	   the	   radiotherapy-­‐induced	  
pathologic	   effects.	   The	   HA-­‐DFO	   conjugate	   exhibited	   significantly	   decreased	  
cytotoxicity	  to	  normal	  cells	  and	  excellent	  biodegradability.	  In	  addition,	  localized	  HA-­‐
DFO	   injection	   stimulated	   vascularity	   and	   improved	   bony	   regeneration	   and	   union	  
after	  radiotherapy.	  	  
	   v	  
In	   chapter	   6,	   a	   nano-­‐hyaluronic	   acid	   (HA)-­‐based	   anticancer	   drug,	   HA-­‐
Cisplatin,	   was	   subcutaneously	   injected	   in	   an	   in-­‐vivo	   murine	   model	   for	   locally	  
advanced	   melanoma.	   Compared	   with	   the	   untreated	   control	   group	   and	   cisplatin-­‐
treated	  group	  (intravenous	  or	  subcutaneous	  injection),	  significant	  tumor	  shrinkage	  
was	  observed	   in	   the	   subcutaneous	  peri-­‐tumoral	  HA-­‐cisplatin	   group,	   offering	  great	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1.	  Cancer	  theranostics:	  
Cancer	  is	  the	  second	  leading	  caused	  of	  death	  in	  the	  USA.	  The	  number	  of	  death	  
in	  2013	  alone	  has	  reached	  over	  half	  a	  million,	  and	  American	  Cancer	  Society	  has	  
estimated	  that	  there	  will	  be	  585,720	  cancer	  deaths	  and	  over	  1.6	  million	  newly	  
diagnosed	  patients	  in	  the	  USA	  this	  year	  [1].	  For	  this	  reason,	  the	  successful	  
development	  of	  cancer	  therapeutic	  strategies	  requires	  effective	  anticancer	  agents	  
with	  minimal	  related	  side	  effects	  and	  informative	  diagnostic	  imaging	  methods	  with	  
improved	  specificity	  and	  sensitivity	  [2].	  Cancer	  theranostics,	  as	  the	  name	  indicates,	  
is	  an	  evolving	  multidisciplinary	  field	  that	  combines	  diagnostics	  and	  therapeutic	  
approaches	  to	  the	  treatment	  of	  cancer	  [3].	  The	  aim	  of	  cancer	  theranostics	  is	  to	  guide	  
pharmacological	  treatment	  of	  cancer	  based	  on	  molecular	  diagnostic	  tests.	  This	  
collaborative	  platform	  offers	  numerous	  advantages	  such	  as	  single-­‐step	  procedures,	  
targeted	  drug	  delivery	  and	  real-­‐time	  monitoring	  of	  early	  treatment	  responses.	  It	  can	  
be	  a	  therapeutic	  product	  administered	  following	  diagnosis	  to	  distinguish	  the	  disease	  
subtype	  and	  select	  treatment	  regimens	  accordingly.	  It	  can	  also	  be	  a	  diagnosis	  
following	  therapy	  to	  assess	  how	  the	  patients	  respond	  to	  the	  treatment	  and	  thus	  its	  
ongoing	  efficacy.	  It	  is	  also	  possible	  that	  therapeutic	  and	  diagnostic	  products	  are	  
used	  concurrently.	  For	  example,	  the	  combination	  of	  Genentech’s	  Herceptin®,	  with	  
DakoCytomation’s	  HercepTest®	  is	  the	  best-­‐known	  example	  of	  a	  commercialized	  
theranostic.	  Herceptin®	  is	  an	  anti-­‐HER-­‐2/neu	  humanized	  monoclonal	  antibody,	  
which	  effectively	  reduces	  growth	  of	  breast	  tumors	  with	  HER-­‐2/neu	  overexpression.	  
HercepTest	  ®	  is	  a	  semi-­‐quantitative	  immunohistochemical	  test	  that	  employs	  the	  
A0485	  polyclonal	  antibody	  against	  HER-­‐2/neu.	  Breast	  cancer	  patients	  with	  high	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tumor	  scores	  in	  the	  HercepTest	  ®	  tend	  to	  respond	  well	  to	  Herceptin®,	  thus	  achieving	  
increased	  efficacy	  of	  anticancer	  treatment	  and	  reducing	  adverse	  events	  associated	  
with	  the	  therapy.	  
With	  recent	  advances	  in	  materials	  science	  and	  biomedical	  nanotechnology,	  a	  
variety	  of	  models	  of	  duo-­‐purpose	  nanomedicines	  have	  been	  reported	  as	  theranostic	  
agents	  [4,	  5]	  that	  implement	  therapeutics	  and	  diagnostic	  modalities	  into	  the	  same	  
nanoparticle.	  A	  schematic	  illustration	  of	  a	  typical	  theranostic	  agent	  is	  shown	  in	  
Figure	  1.	  On	  one	  hand,	  the	  diagnostic	  functionality	  of	  theranostic	  nanoparticles	  
includes	  locating	  the	  present	  disease,	  phenotyping	  the	  disease	  status	  and	  reporting	  
the	  disease’s	  response	  to	  the	  current	  treatment.	  The	  ways	  that	  theranostic	  
nanoparticles	  achieve	  their	  therapeutic	  role,	  on	  the	  other	  hand,	  may	  entail	  several	  
methods.	  First,	  anticancer	  agents	  (e.g.	  doxorubicin,	  docetaxel,	  paclitaxel,	  therapeutic	  
siRNA)	  that	  are	  encapsulated	  into	  the	  nanoparticles	  are	  released	  from	  their	  carriers	  
into	  the	  targeted	  disease	  sites.	  Second,	  therapeutic	  antibodies	  (e.g.	  Herceptin)	  
attached	  to	  the	  surface	  of	  the	  nanoparticles	  can	  specifically	  bind	  with	  high	  affinity	  to	  
the	  corresponding	  surface	  receptors	  of	  cancer	  cells,	  thereby	  disrupting	  cell	  
regulation	  [6].	  In	  another	  route,	  nanoparticles	  with	  intrinsic	  magnetic	  or	  
thermoablative	  capabilities	  can	  respond	  to	  external	  stimuli	  and	  convert	  magnetic	  or	  
light	  energy	  into	  heat	  energy	  to	  induce	  cancer	  cell	  death	  [7-­‐11].	  	  







Figure	  1.	  Schematic	  illustration	  of	  typical	  theranostic	  agents	  for	  cancer	  diagnosis	  
and	  therapy.	  Figure	  originally	  published	  in	  reference	  [5]	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   The	  key	  advantages	  of	  cancer	  theranostic	  nanoparticles	  are	  excellent	  
stability,	  large	  payloads,	  high	  surface	  area	  to	  volume	  ratio,	  and	  most	  importantly,	  
their	  nanoscale	  size,	  which	  facilitates	  the	  nanoparticles	  to	  extravasate	  through	  the	  
leaky	  vasculature	  and	  preferentially	  accumulate	  in	  the	  solid	  tumors	  (often	  termed	  
the	  enhanced	  permeability	  and	  retention	  effect)	  to	  achieve	  tumor-­‐selective	  
imaging/therapy	  [12-­‐14].	  Cancer	  theranostic	  nanoparticles	  reported	  to	  date	  mainly	  
include	  magnetic	  nanoparticles	  (MNPs),	  quantum	  dots	  (QDs),	  carbon	  nanotubes	  
(CNTs),	  gold	  nanoparticles,	  silica	  etc,	  and	  they	  have	  opened	  new	  avenues	  for	  the	  
development	  of	  effective	  cancer	  treatment.	  Listed	  in	  Table	  1	  [5,	  15]	  are	  a	  variety	  of	  
trials	  involving	  biomedical	  applications	  of	  theranostic	  agents.	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Table	  1.	  Examples	  of	  theranostic	  agents	  used	  for	  biomedical	  applications.	  
Contrast	  agent	   Drug	  used	   Applications	  
Manganese	  oxide	   siRNA	   MRI	  and	  RNA	  delivery	  [16]	  
Gold	  Nanoparticles	   Doxorubicin	  
Diagnosis	  tumor	  targeting	  and	  photo	  
thermal	  therapy	  [17-­‐20]	  
Magnetic	  
Nanoparticles	  




Drug	  carrier,	  X-­‐ray/CT	  imaging	  and	  
Photodynamic	  therapy	  [19,	  26,	  27]	  
Carbon	  nanotubes	  
DNA	  plasmid,	  doxorubicin,	  
paclitaxel	  
Diagnosis,	  DNA	  and	  drug	  delivery	  [28-­‐
31]	  




Doxorubicin	   MRI	  and	  therapy	  [35,	  36]	  
Isotopes	  of	  rhenium	  
-­‐186Re	  
Doxorubicin	  
Radionuclide	  imaging	  and	  
chemoradionuclide	  therapy	  [37]	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2.	  Molecular	  imaging	  in	  cancer	  theranostics	  
Within	   the	   field	   of	   diagnostic	   imaging,	   molecular	   imaging	   technology	   is	  
rapidly	   emerging	   as	   a	   potent	   tool	   to	   actively	   target	   biomolecules	   and	  molecularly	  
based	  events	  critical	  to	  a	  tumor	  biology.	  Molecular	  imaging	  possesses	  the	  potential	  
for	  in	  vivo	  cancer	  detection,	  staging,	  treatment	  selection	  and	  real-­‐time	  assessment	  of	  
treatment	   response.	   Conventional	   anatomic	   imaging	   techniques	   such	   as	  
mammography,	  computed	  tomography	  (CT)	  and	  magnetic	  resonance	  imaging	  (MRI)	  
have	   been	   widely	   used	   in	   clinical	   medicine	   and	   radiology	   as	   standards	   of	   care.	  
Anatomic	  imaging	  modalities	  rely	  on	  tumor	  size,	  shape	  or	  density	  for	  diagnosis	  and	  
to	   evaluate	   therapeutic	   response	   by	  measuring	   changes	   in	   these	   parameters	   over	  
time,	   which	   often	   occur	   with	   a	   delay	   due	   to	   molecular	   changes	   and	   lack	   of	  
specificity.	   In	   comparison,	   functional	   molecular	   imaging	   technologies	   measure	  
tumor-­‐related	   abnormalities	   and	   anatomic	   locations	   of	   specific	   molecules	   of	  
interest,	   such	   as	   cellular	   proliferation,	   growth	   factor	   expression,	   hypoxia-­‐induced	  
gene	  expression,	  occurrence	  of	  cell	  apoptosis	  or	  autophagy	  in	  vivo	  and	  monitor	  their	  
changes	  over	  the	  course	  of	  treatments	  [38,	  39].	  Modalities	  that	  have	  been	  used	  for	  
molecular	   imaging	   include	  MRI,	  magnetic	   resonance	  spectroscopy	   (MRS),	  positron	  
emission	   tomography	   (PET),	   single	   photon	   emission	   CT	   (SPECT),	   ultrasound	   and	  
photoacoustic	   imaging.	   These	   modalities	   offer	   a	   versatile	   platform	   to	   generate	  
images	  with	  details	  of	  physiology,	  biological	  processes	  and	  molecular	  characteristics	  
of	  tumors	  [40-­‐43].	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Molecular	  imaging	  can	  be	  performed	  using	  both	  endogenous	  and	  exogenous	  
probes.	   Proton	   (1H)	   MRS	   imaging,	   for	   example,	   utilizes	   endogenous	   protons	   to	  
distinguish	  malignant	  tissues	  from	  benign	  tissues.	  In	  vivo	  levels	  of	  taurine,	  choline,	  
creatine	  and	  lactate	  can	  be	  acquired	  on	  1H	  MRS	  spectra,	  where	  tumor	  tissues	  often	  
show	   higher	   counts	   of	   choline	   and	   lactate	   [44,	   45].	   To	   enhance	   the	   signal	   and	  
contrast	   of	   the	   imaging,	   however,	   most	   clinical	   molecular	   imaging	   applications	  
employ	   exogenous	   imaging	   agents	   that	   comprise	   two	   components:	   one	   targeting	  
moiety	   (e.g.	   small	  molecules,	   peptide	  or	   antibody)	   for	   localization	   and	  an	   imaging	  
modality	   (e.g.	   fluorochrome,	   radionuclide	   or	   paramagnetic	   chelate)	   to	   enable	  
visualization.	   Broadly,	   molecular	   imaging	   contrast	   agents	   can	   be	   categorized	   into	  
four	   groups:	   (1)	   phenotypic	   probes	   to	   monitor	   characteristic	   changes	   of	   tumor	  
physiology,	   exemplified	   by	   a	   radiotracer,	   18F-­‐fluoro-­‐2-­‐deoxy-­‐D-­‐glucose	   [FDG],	   for	  
PET/CT	   cross-­‐sectional	   imaging	   [46-­‐49];	   (2)	   targeted	   probes	   to	   detect	   specific	  
biomolecules	  of	  tumors,	  such	  as	  a	  receptor-­‐targeting	  fluorescent	  peptide	  for	  optical	  
tumor	   imaging	   [50],	   or	   99mTc-­‐RP-­‐527,	   a	   bombesin-­‐based	   tripeptide	   to	   target	  
bombesin/gastrin-­‐releasing	   peptide	   receptor	   overexpressing	   breast	   carcinomas	  
[51];	  (3)	  cell-­‐tracking	  probes	  to	  track	  cell	  motions	  critical	  to	  tumor	  survival,	  such	  as	  
fluorophore	  labeled	  peptides	  [52]	  and	  MNPs-­‐based	  CD	  8+	  T	  lymphocytes	  [53];	  and	  
(4)	  reporter	  gene	  to	  show	  whether	  a	  therapeutic	  gene	  remains	  intact	  after	  reaching	  
its	  target	  [54].	  	  
	  
3.	  Therapeutics	  delivery	  to	  lymphatically	  metastatic	  cancers	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The	  lymphatic	  system	  is	  a	  sub-­‐system	  of	  the	  circulatory	  system	  central	  to	  
maintaining	  tissue	  homeostasis	  and	  immunofunction	  [55],	  including	  removing	  
excess	  extravascular	  fluid;	  presenting	  to	  the	  immune	  system	  foreign	  bodies	  and	  
pathogens;	  maturation	  of	  lymphocytes,	  and	  absorption	  of	  lipid-­‐soluble	  nutrients	  
from	  the	  digestive	  tract.	  The	  lymphatic	  system	  consists	  of	  an	  extensive	  network	  
(Figure	  2)	  of	  lymphatic	  vessels,	  lymph	  nodes,	  lymph,	  lymphatic	  organs	  (e.g.	  spleen	  
and	  thymus),	  and	  lymphoid	  tissues	  (e.g.	  tonsils	  and	  Peyer’s	  patches).	  







Figure	  2.	  The	  human	  lymphatic	  system.	  Reproduced	  from	  [56].	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   The	  lymphatic	  system	  has	  distinctive	  physiological	  functions	  in	  lipid	  
absorption	  and	  micro-­‐particulate	  uptake,	  which	  could	  be	  harnessed	  as	  an	  
alternative	  route	  for	  the	  delivery	  of	  pharmaceuticals	  to	  enhance	  their	  bioavailability	  
and	  efficacy.	  Drug	  agents	  that	  would	  benefit	  from	  lymphatic	  concentration,	  such	  as	  
vaccines	  and	  anti-­‐cancer	  chemotherapeutics,	  could	  be	  engineered	  for	  preferential	  
uptake	  into	  the	  lymphatic	  system	  to	  improve	  efficacy	  with	  reduced	  systemic	  
distribution.	  In	  addition,	  with	  the	  increase	  in	  resolution	  and	  specificity	  of	  imaging	  
technologies,	  there	  is	  the	  potential	  to	  monitor	  tumor	  cells	  that	  migrate	  through	  the	  
lymphatic	  system	  and	  accumulate	  in	  the	  lymph	  nodes,	  which	  could	  detect	  very	  early	  
micrometastatic	  disease.	  Two	  approaches	  are	  generally	  proposed	  to	  modify	  drug	  
molecules	  for	  targeted	  accumulation	  in	  the	  lymphatic	  system.	  One	  approach	  is	  to	  
chemically	  tailor	  the	  structures	  of	  the	  drug	  molecules	  and	  synthesize	  an	  inactive	  
precursor	  of	  the	  drug,	  “prodrug”,	  with	  enhanced	  lipophilicity,	  primarily	  used	  to	  
improve	  gastric	  lymphatic	  absorption	  [57,	  58].	  Another	  approach	  is	  to	  develop	  
particulate	  drug	  carriers	  to	  encapsulate	  drug	  molecules.	  With	  recent	  advances	  in	  
materials	  science	  and	  technology,	  a	  variety	  of	  models	  of	  drug	  delivery	  to	  the	  
lymphatic	  system	  have	  been	  reported	  in	  the	  literature	  including	  drug-­‐polymer	  
conjugates	  [59-­‐65],	  drug-­‐loaded	  emulsions	  [66-­‐74],	  liposomes	  [75-­‐99],	  solid	  lipid	  
nanoparticles	  [100-­‐106],	  nanostructured	  lipid	  carriers	  [107-­‐113],	  polymeric	  
micelles	  [114-­‐117],	  	  polymeric	  nanoparticles	  [118-­‐124]	  and	  microparticles	  [125-­‐
130],	  carbon	  nanotubes	  [131,	  132],	  and	  nanocapsules.	  	  
	   Multiple	  factors	  including	  the	  physiological	  state	  of	  the	  interstitial	  space,	  
immunological	  state,	  the	  lymph	  flow	  rate,	  the	  administration	  routes,	  the	  distance	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between	  the	  injection	  site	  and	  the	  lymph	  nodes	  and	  the	  physicochemical	  
parameters	  of	  the	  drug	  carrier/particles	  may	  alter	  the	  effectiveness	  of	  lymphatic	  
drainage	  and	  transport	  of	  a	  drug	  carrier/particle.	  However,	  numerous	  studies	  have	  
established	  that	  the	  physicochemical	  characteristics	  of	  a	  drug	  carrier	  play	  a	  
predominant	  role	  in	  determining	  its	  efficiency.	  These	  predominant	  characteristics	  
lie	  in	  three	  key	  aspects:	  particle	  size,	  surface	  charge	  and	  hydrophobicity	  [69,	  82,	  
120,	  133-­‐135].	  	  
To	  achieve	  targeted	  drug	  lymphatic	  delivery,	  a	  desired	  carrier	  should	  possess	  
the	  following	  features:	  
• Low-­‐	  or	  non-­‐toxicity	  to	  healthy	  tissues	  and	  organs;	  
• High	  colloidal,	  chemical	  and	  biological	  stability;	  
• Rapid	  drainage	  into	  the	  lymphatic	  capillaries	  from	  the	  injection	  site;	  
• High	  lymph	  nodal	  retention;	  
• Efficient	  delivery	  and	  release	  of	  therapeutic	  agents	  to	  the	  tissues	  or	  organs	  of	  
interest.	  
	  
	   In	  the	  process	  of	  creating	  an	  optimal	  drug	  carriers,	  nano-­‐sized	  particles,	  
especially	  being	  lipid	  and	  polymer-­‐based,	  have	  distinct	  advantages	  over	  alternative	  
models.	  These	  advantages,	  such	  as	  tunable	  size	  control	  and	  facile	  surface	  
modifications	  with	  targeting	  molecules,	  have	  attracted	  intense	  interest.	  Summarized	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in	  Table	  2	  is	  the	  development	  of	  nanocarriers	  for	  lymphatic	  system	  delivery	  with	  a	  
special	  focus	  on	  liposomes	  and	  polymer-­‐based	  nanoparticles.	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Table	  2.	  Examples	  of	  anticancer	  drug-­‐loaded	  nanoparticles	  that	  have	  have	  
demonstrated	  enhanced	  chemotherapeutic	  efficacies	  in	  tumor	  models.	  
Formulations	   Encapsulated	  Drugs	   Tumor	  Models	   References	  
Liposomes	  




ovarian,	  KB	  oral	  
carcinoma,	  and	  
Kaposi’s	  sarcoma	  
[76-­‐78,	  81,	  84,	  
137-­‐141]	  
Muramyl-­‐tripeptide	  
phosphoethanolamine	   Ovarian	   [85]	  
DNA	   Ovarian	   [86]	  
Melphalan	   Mammary	  adenocarcinoma	   [142]	  
Cisplatin	   Colon,	  lung	   [87,	  143]	  
Combination	  of	  
Vitamin	  E	  analogue	  
and	  9-­‐nitro	  
camptothecin	  
Lung	  metastasis	   [144]	  
Combination	  of	  
Vitamin	  E	  analogue	  
and	  paclitaxel	  
Lung	  metastasis	   [145]	  
Polymeric	  
Micelles	  
Cisplatin	   Tongue	   [114]	  








Paclitaxel	   Ovarian	   [122]	  
Cisplatin,	  doxorubicin	   Head	  and	  neck,	  breast,	  melanoma	   [60,	  64,	  65]	  
Chitosan	  
Nanoparticles	   Camptothecin	   Liver,	  soft	  tissues	   [119]	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3.1	  Liposomes	  
A	  liposome	  is	  a	  spherical	  self-­‐enclosed	  vesicle	  with	  a	  lipid	  bilayer	  composed	  
of	  amphiphilic	  monomers	  (e.g.	  phospholipids).	  The	  average	  diameter	  of	  small	  
unilamellar	  liposomes	  ranges	  from	  25	  to	  100 nm	  [146].	  As	  shown	  in	  Figure	  3,	  
liposomes	  possess	  a	  structure	  with	  the	  long	  hydrocarbon	  chains	  of	  phospholipids	  
lining	  up	  against	  one	  another	  to	  form	  a	  membrane	  and	  the	  charged	  hydrophilic	  
groups	  on	  both	  sides	  orienting	  towards	  aqueous	  medium.	  Such	  a	  unique	  structure	  
makes	  the	  liposomes	  especially	  suitable	  to	  encapsulate	  water-­‐soluble	  molecules	  in	  
the	  hydrophilic	  core	  and	  to	  trap	  lipophilic	  molecules	  within	  the	  bilayer.	  The	  
structures	  of	  liposomes	  impart	  high	  colloidal	  stability,	  rendering	  the	  nanoparticles	  
less	  sensitive	  to	  exterior	  environment	  change	  than	  micellular	  structures	  or	  
emulsions.	  Additionally,	  polymer	  coatings	  on	  the	  surface	  can	  further	  sterically	  
stabilize	  liposomes	  for	  prolonged	  blood	  retention.	  	  







Figure	  3.	  Typical	  structure	  of	  liposomes.	  Adapted	  from	  Encyclopedia	  Britannica	  
[147].	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Drug-­‐encapsulated	  liposomes	  are	  typically	  prepared	  by	  a	  four-­‐step	  film-­‐
rehydration	  method,	  which	  consists	  of	  (1)	  dissolving	  the	  drug	  and	  phospholipids	  
(e.g.	  phosphatidylcholine	  or	  phosphatidylethanolamine)	  or	  cholesterol	  in	  a	  organic	  
solvent	  such	  as	  chloroform	  or	  methanol,	  (2)	  removal	  of	  the	  solvent	  by	  rotary	  
evaporation	  under	  reduced	  pressure	  to	  form	  a	  uniform	  and	  thin	  film,	  (3)	  hydration	  
of	  the	  film	  in	  an	  aqueous	  medium,	  and	  (4)	  size-­‐reduction	  via	  sonication	  or	  extrusion.	  	  
Liposomes	  are	  generally	  considered	  as	  a	  promising	  drug	  carrier	  for	  
lymphatic	  delivery,	  due	  to	  their	  biocompatibility,	  tunable	  size,	  and	  dual	  loading	  
capacity	  for	  both	  hydrophilic	  and	  hydrophobic	  drugs.	  A	  variety	  of	  liposomal	  
formulations	  of	  anticancer	  drugs	  have	  been	  approved	  by	  drug	  administration	  
agencies	  or	  are	  currently	  in	  the	  advanced	  stages	  of	  clinical	  trials.	  For	  example,	  
Doxil®,	  the	  first	  FDA-­‐approved	  nano-­‐drug,	  is	  a	  doxorubicin-­‐encapsulated	  liposomal	  
formulation	  coated	  with	  PEG.	  Doxil®	  has	  been	  used	  as	  a	  first-­‐line	  anticancer	  drug	  
administered	  via	  IV	  infusion	  to	  treat	  a	  series	  of	  cancers	  including	  Kaposi’s	  sarcoma,	  
breast	  cancer,	  gastric	  cancer,	  ovarian	  cancer,	  and	  head	  and	  neck	  squamous	  cell	  
carcinoma	  [37,	  81,	  137-­‐140].	  
Unmodified	  and	  polymer-­‐coated	  liposomes	  drain	  into	  the	  lymphatic	  
capillaries	  and	  then	  are	  internalized	  by	  macrophages	  in	  the	  regional	  lymph	  nodes	  
and	  tumor	  cells.	  Most	  tumor	  cells,	  tumor	  lymphatic	  and	  tumor-­‐associated	  
macrophages	  express	  specific	  membrane	  associated	  proteins	  such	  as	  receptors,	  
membrane	  transporters,	  and	  adhesion	  molecules.	  Therefore,	  conjugation	  of	  
targeting	  motifs	  to	  the	  surface	  of	  liposomes	  could	  specifically	  target	  the	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encapsulated	  drugs	  to	  the	  tumor	  lymphatics	  via	  receptor-­‐mediated	  interactions	  and	  
consequently	  enhance	  the	  therapeutics	  efficacy.	  	  
LyP-­‐1,	  for	  example,	  is	  a	  cyclic	  nanopeptide	  (CGNKRTRGC)	  that	  possesses	  
specific	  binding	  ability	  with	  the	  p32/gC1q	  receptor	  overexpressed	  in	  tumor	  cells,	  
lymphatics	  vessels	  and	  tumor-­‐associated	  macrophages	  [148-­‐150].	  	  	  Yan	  et	  al	  [76,	  
77]	  synthesized	  LyP-­‐1-­‐conjugated	  PEG-­‐DSPE	  and	  prepared	  a	  lymphatic-­‐targeting	  
liposomal	  formulation	  of	  doxorubicin,	  which	  has	  demonstrated	  superior	  
chemotherapeutic	  efficacy	  in	  animal	  models	  implanted	  with	  lymphatic	  metastatic	  
breast	  and	  lung	  tumors,	  in	  part	  by	  suppressing	  lymph	  node	  metastases	  and	  
disrupting	  tumor	  lymphatics.	  Surface	  modification	  with	  antigen	  presenting	  cell-­‐
specific	  antibodies	  is	  another	  approach	  to	  enhancing	  the	  lymphatic	  delivery	  of	  
liposomes.	  Coupling	  a	  non-­‐specific	  IgG	  to	  PEG-­‐bearing	  liposomes	  has	  been	  found	  to	  
increase	  its	  retention	  in	  both	  the	  primary	  and	  secondary	  lymph	  nodes	  [79].	  A	  closer	  
examination	  of	  the	  immuno-­‐PEG-­‐liposomes	  structure	  revealed	  that	  IgG	  chains	  
orient	  randomly	  on	  the	  liposomes	  surface	  and	  expose	  its	  Fc	  region	  to	  facilitate	  the	  
recognition	  by	  Fc	  receptors	  on	  the	  surface	  of	  macrophages.	  Immunoliposome-­‐
mediated	  lymphatic	  targeting	  to	  specific	  tumor	  cells,	  on	  the	  other	  hand,	  could	  be	  
enhanced	  by	  attaching	  Fab’	  fragments	  of	  monoclonal	  antibodies	  that	  are	  directed	  
against	  specific	  a	  antigen	  present	  on	  the	  cancer	  cells	  [83,	  84].	  Bestman-­‐Smith	  et.	  al	  
[83]	  reported	  an	  elevated	  accumulation	  of	  the	  anti-­‐HLA-­‐DR-­‐coupled	  PEG-­‐liposomes	  
in	  lymph	  nodes	  over	  plain	  liposomes	  or	  PEG-­‐liposomes.	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In	  addition	  to	  ligand-­‐attached	  liposomes,	  cationic	  liposomes	  prepared	  from	  
DOTAP	  and	  DOPC	  have	  been	  shown	  to	  preferentially	  target	  tumor	  endothelial	  cells	  
and	  vessels	  [82,	  86,	  136,	  151].	  However,	  the	  mechanism	  underlying	  their	  selective	  
targeting	  has	  not	  yet	  been	  fully	  elucidated.	  	  
	  
3.2	  Polymer-­‐based	  carriers	  
Numerous	  therapeutic	  agents	  have	  been	  conjugated	  or	  encapsulated	  into	  
polymer-­‐based	  nanoparticles	  for	  targeted	  and	  sustained	  lymphatic	  delivery	  to	  
inhibit	  tumor	  growth	  and	  metastases.	  The	  widely	  utilized	  polymers	  are	  categorized	  
into	  natural	  polymers	  such	  as	  dextran	  [61,	  62],	  hyaluronic	  acid	  (HA)	  [60,	  63,	  152],	  
and	  synthetic	  polymers	  including	  poly	  (ethylene	  glycol)-­‐block-­‐poly	  (3-­‐caprolactone)	  
(PEG-­‐PCL)	  [117],	  poly	  (L-­‐lactic	  acid)	  [125],	  poly	  (lactide-­‐co-­‐glycolide)	  (PLGA)	  [120,	  
121,	  153],	  poly	  (hexylcyanoacrylate)	  nanoparticles	  (PHCA)	  and	  poly	  
(methylmethacrylate)	  (PMMA)	  [154].	  
	  
3.2.1	  Natural	  polymers	  
Polysaccharide-­‐based	  nanoparticles,	  such	  as	  dextran	  and	  HA	  (Figure	  4),	  have	  
gained	  popularity	  in	  developing	  controlled-­‐release	  drug	  delivery	  systems,	  attributed	  
to	  their	  biocompatibility,	  biodegradability,	  broad	  range	  of	  physicochemical	  
properties	  and	  their	  versatile	  modification	  by	  simple	  chemical	  conjugations	  with	  
drug	  molecules.







Figure	  4.	  Structures	  of	  Dextran	  and	  Hyaluronan	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The	  feasibility	  of	  mitomycin	  C-­‐dextran	  conjugate	  (MMC-­‐D)	  as	  a	  lymphatic	  
drug	  delivery	  system	  has	  been	  earlier	  demonstrated	  by	  Takakura	  et	  al	  [61].	  
Anticancer	  antibiotic,	  mitomycin	  C,	  was	  first	  conjugated	  to	  dextran	  with	  molecular	  
weights	  of	  10	  to	  500	  kDa	  via	  ε-­‐aminocaproic	  acid	  as	  a	  spacer,	  and	  then	  administered	  
by	  IM	  injection	  to	  rats	  inoculated	  with	  leukemia	  cells.	  In	  contrast	  to	  the	  free	  drug	  
and	  MMC-­‐D	  prepared	  with	  the	  lowest	  molecular	  weight	  (10	  kDa),	  larger	  MMC-­‐Ds	  
afforded	  significantly	  higher	  drug	  concentrations	  in	  the	  thoracic	  lymph	  as	  well	  as	  
substantially	  enhanced	  accumulation	  in	  the	  regional	  lymph	  nodes,	  resulting	  in	  a	  
more	  efficient	  suppression	  of	  tumor	  growth	  and	  metastasis.	  	  
Hyaluronic	  acid	  (HA)	  is	  another	  type	  of	  natural	  polysaccharide	  that	  consists	  
of	  alternating	  D-­‐glucuronic	  acid	  and	  N-­‐acetyl	  D-­‐glucosamine.	  HA	  is	  present	  
throughout	  the	  body	  with	  particularly	  high	  concentrations	  in	  the	  connective	  tissues.	  
In	  the	  process	  of	  clearance	  by	  the	  lymphatic	  system,	  HA	  is	  catabolized	  in	  the	  lymph	  
nodes	  by	  receptor-­‐mediated	  endocytosis	  and	  lysosomal	  degradation.	  Some	  invasive	  
tumors	  such	  as	  breast	  and	  head	  and	  neck	  tumors,	  preferentially	  uptake	  HA	  over	  
normal	  tissues	  due	  to	  their	  surface	  overexpression	  of	  the	  HA	  receptor	  CD44.	  
Therefore,	  conjugation	  of	  chemotherapeutic	  agents	  to	  HA	  could	  provide	  an	  
efficacious	  approach	  to	  treating	  lymphatic	  metastases.	  Cai	  et	  al	  synthesized	  two	  HA-­‐
cytotoxic	  drug	  nanoconjugates,	  HA-­‐cisplatin	  [65,	  152,	  155,	  156]	  and	  HA-­‐doxorubicin	  
[60],	  which	  have	  both	  exhibited	  in	  vivo	  sustained-­‐release	  profiles	  and	  enhanced	  
drug	  retention	  by	  lymph	  nodes	  in	  locally	  aggressive	  metastatic	  tumor	  models	  of	  
head	  and	  neck	  squamous	  cell	  cariconma	  and	  breast	  cancer.	  Consequently,	  
intralymphatic	  delivery	  of	  HA-­‐cisplatin	  and	  HA-­‐doxorubicin	  significantly	  inhibited	  
	   22	  
tumor	  progression	  and	  led	  to	  the	  increased	  survival	  rates	  when	  compared	  with	  the	  
conventional	  chemotherapy.	  
	  
3.2.2	  Synthetic	  polymeric	  nanoparticles	  
In	  aqueous	  solution,	  biodegradable	  amphiphilic	  block	  copolymers	  such	  as	  
PEG-­‐PCL	  or	  PEG-­‐poly	  (aminio	  acid)	  self-­‐assemble	  into	  a	  core-­‐shell	  structured	  
polymeric	  micelle	  with	  a	  size	  of	  20	  to	  100	  nm,	  as	  shown	  in	  Figure	  5.	  The	  description	  
and	  characterization	  of	  polymeric	  micelles	  and	  the	  recent	  developments	  in	  
functional	  biodegradable	  micelles	  for	  safe	  and	  efficient	  cancer	  chemotherapy	  have	  
been	  extensively	  reviewed	  by	  Croy	  et	  at	  [157]	  and	  Deng	  et	  al	  [158].	  In	  the	  past	  
decade,	  polymeric	  micelles	  have	  generated	  great	  interest	  for	  sustained	  delivery	  of	  
poorly	  water-­‐soluble	  anticancer	  drugs	  attributed	  to	  their	  inherent	  physiochemical	  
features.	  For	  example,	  a	  core	  formed	  from	  poly	  (3-­‐caprolactone)	  or	  poly	  (amino	  acid)	  
provides	  a	  hydrophobic	  environment	  for	  accommodating	  lipophilic	  drug	  molecules,	  
while	  the	  presence	  of	  PEG	  in	  the	  hydrophilic	  shell	  spares	  micelles	  from	  aggregation	  
and	  also	  reduces	  the	  fast	  clearance	  of	  the	  micelles	  by	  RES.	  	  







Figure	  5.	  Self-­‐assembly	  of	  polymeric	  micelles	  encapsulated	  with	  poorly	  water-­‐
soluble	  anticancer	  drugs.	  	  
+ 
Self Assembly 
Poorly water-soluble drug 
Amphiphilic polymer 
	   24	  
	   Drug-­‐loaded	  polymeric	  micelles	  generally	  enter	  the	  primary	  tumor	  via	  
passive	  diffusion	  through	  blood	  capillaries	  after	  IV	  administration.	  Surface-­‐
modification	  of	  the	  polymeric	  micelles	  with	  targeting	  ligands	  can	  enhance	  their	  
binding	  with	  tumor	  lymphatic	  vessels	  through	  a	  receptor-­‐mediated	  interaction	  to	  
achieve	  active	  lymphatic	  targeting.	  LyP-­‐1	  peptide,	  as	  mentioned	  in	  section	  1.3.1,	  has	  
been	  identified	  as	  a	  ligand	  for	  p32/gC1qR,	  which	  is	  overexpressed	  in	  highly	  
metastatic	  tumor	  cells	  and	  tumor	  lymphatics	  [148].	  Wang	  et	  al	  [117]	  developed	  a	  
LyP-­‐1	  peptide-­‐conjugated	  PEG-­‐PCL	  micelles	  (LyP-­‐1-­‐PM)	  with	  a	  size	  of	  around	  30	  nm.	  
The	  specific	  binding	  of	  the	  LyP-­‐1-­‐PM	  with	  highly	  metastatic	  tumor	  cells	  (MDA-­‐MB-­‐
435S)	  and	  lymphatic	  endothelial	  cells	  was	  first	  observed	  by	  flow	  cytometry	  and	  
laser	  confocal	  microscopy,	  leading	  to	  an	  in	  vivo	  investigation	  of	  its	  lymphatic	  
targeting	  in	  a	  breast	  tumor	  model.	  After	  IV	  injection	  of	  the	  fluorescein-­‐loaded	  LyP-­‐1-­‐
PM	  into	  the	  breast	  tumor-­‐bearing	  mice,	  in	  vivo	  fluorescent	  imaging	  only	  showed	  
good	  co-­‐localization	  of	  the	  LyP-­‐1-­‐1PM	  with	  the	  lymph	  vessel	  marker	  (LYVE-­‐1)	  but	  
not	  with	  the	  blood	  vessel	  marker	  (CD31).	  In	  addition,	  targeted	  delivery	  of	  
artemisinin-­‐encapsulated	  LyP-­‐1-­‐PM	  remarkably	  enhanced	  the	  antitumor	  efficacy	  
and	  reduced	  the	  systemic	  toxicity,	  indicating	  the	  potential	  of	  LyP-­‐1-­‐targeting	  
polymeric	  micelles	  as	  specific	  drug	  carriers	  for	  lymphatic	  delivery.	  	  
	   Poly	  (lactide-­‐co-­‐glycolide)	  (PLGA)	  -­‐based	  drug	  carriers	  have	  also	  been	  used	  
for	  lymphatic	  targeting.	  This	  biocompatible	  and	  biodegradable	  polymer	  has	  been	  
approved	  by	  the	  FDA	  for	  use	  in	  humans	  as	  a	  therapeutic	  device	  and	  it	  has	  been	  
extensively	  studied	  as	  a	  sustained	  release	  system	  to	  deliver	  chemotherapeutic	  
agents	  [120,	  121,	  126,	  153].	  Drug-­‐incorporated	  PLGA	  microspheres	  or	  sub-­‐100	  nm	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nanoparticles	  can	  be	  readily	  prepared	  by	  emulsification-­‐solvent	  evaporation	  
methods	  [159-­‐163],	  and	  it	  has	  been	  reported	  that	  surface-­‐coating	  with	  poloxamer	  
or	  poloxamine	  block	  co-­‐polymers	  can	  remarkably	  enhance	  the	  maximal	  lymphatic	  
uptake	  from	  6%	  to	  17%	  after	  SC	  injection	  [124].	  Paclitaxel-­‐loaded	  PLGA	  (PTX-­‐PLGA)	  
microspheres	  have	  been	  demonstrated	  to	  effectively	  inhibit	  tumor	  growth	  in	  animal	  
models	  bearing	  intraperitoneal	  carcinomatosis	  [125]	  and	  subcutaneous	  carcinoma	  
[127].	  Liu	  et	  al	  [128]	  further	  incorporated	  PTX-­‐PLGA	  into	  a	  biodegradable	  gelatin	  
sponge	  that	  enabled	  a	  continuous	  release	  of	  PTX	  into	  the	  lymphatics	  with	  
subsequent	  accumulation	  in	  the	  regional	  lymph	  nodes.	  The	  PTX-­‐PLGA	  sponge	  was	  
implanted	  into	  the	  pleural	  space	  of	  rats,	  and	  its	  retention	  in	  mediastinal	  lymph	  
nodes	  was	  compared	  with	  that	  of	  the	  IV	  PTX	  solution.	  During	  the	  given	  28-­‐d	  
experimental	  time,	  an	  over	  400-­‐fold	  increase	  in	  PTX	  exposure	  at	  the	  ipsilateral	  
mediastinal	  lymph	  nodes	  and	  approximately	  a	  100-­‐fold	  increase	  at	  the	  contralateral	  
side	  were	  observed	  in	  the	  group	  treated	  with	  IP	  PTX-­‐PLGA	  sponge.	  Attributed	  to	  the	  
improved	  drug	  distribution	  into	  the	  lymphatic	  system,	  the	  PTX-­‐PLGA	  sponge	  also	  
exhibited	  the	  enhanced	  antitumor	  efficacy	  in	  an	  orthotopic	  lung	  tumor-­‐bearing	  rat	  
model,	  which	  resulted	  in	  an	  80%	  inhibition	  of	  lymphatic	  metastasis.	  
	  
4	  Conclusions	  
The	  theranostic	  agent	  integrates	  the	  advantages	  of	  non-­‐invasive	  in	  vivo	  
diagnosis,	  evaluation	  of	  therapeutic	  response	  and	  administration	  of	  
chemotherapeutic	  agents	  within	  a	  single	  nanoparticles	  for	  biomedical	  applications.	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The	  unique	  physiochemical	  properties	  possessed	  by	  magnetic	  nanoparticles,	  
quantum	  dots,	  carbon	  nanotubes	  and	  gold	  nanoparticles	  enable	  them	  to	  serve	  as	  
efficient	  contrast	  agents	  for	  a	  variety	  of	  imaging	  modalities	  for	  cancer	  diagnosis,	  
including	  MRI,	  CT	  and	  photoacoustics	  imaging.	  In	  addition,	  magnetic	  nanoparticles	  
can	  also	  mediate	  local	  hyperthermia	  in	  response	  to	  an	  external	  alternating	  magnetic	  
field	  to	  disrupt	  tumor	  tissues,	  while	  quantum	  dots	  photosensitize	  upon	  activation	  by	  
light	  and	  then	  transfer	  energy	  to	  surrounding	  oxygen	  molecules	  to	  damage	  cancer	  
cells.	  As	  sufficient	  accumulation	  of	  the	  theranostic	  agents	  in	  diseased	  regions	  is	  
required,	  formulations	  such	  as	  liposomes	  or	  polymer-­‐based	  nanocarriers	  have	  been	  
under	  extensive	  investigation	  as	  platforms	  to	  selectively	  deliver	  cargos	  to	  tumors	  
with	  reduced	  systemic	  toxicity.	  In	  summary,	  nanoparticle-­‐based	  cancer	  theranostic	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1.	  Introduction	  
Noninvasive	  imaging	  techniques	  are	  necessary	  for	  early	  cancer	  detection	  and	  
evaluation	  of	  the	  chemotherapeutic	  effect	  on	  tumors.	  Current	  diagnostic	  imaging	  
techniques	  generally	  include	  γ	  -­‐scintigraphy,	  magnetic	  resonance	  imaging,	  computed	  
tomography,	  and	  ultrasonography;	  however,	  these	  techniques	  only	  give	  morphological	  
information	  on	  the	  tumor.	  These	  techniques	  do	  not	  report	  the	  biochemical	  response	  of	  the	  
tumor	  to	  treatment	  and	  physical	  changes	  in	  the	  tumor	  in	  response	  to	  treatment	  may	  take	  
days	  to	  weeks	  to	  fully	  manifest.	  Positron	  emission	  topography	  and	  SPECT	  can	  indirectly	  
detect	  tumor	  response	  to	  treatment	  due	  to	  changes	  in	  metabolic	  activity	  and	  blood	  
perfusion,	  respectively.	  However,	  no	  clinical	  imaging	  technique	  can	  directly	  detect	  the	  
biochemical	  response,	  e.g.,	  apoptosis,	  of	  tumors	  to	  treatment.	  Typically	  anti-­‐cancer	  agents	  
act	  on	  cancer	  cells	  to	  induce	  apoptosis,	  so	  apoptosis	  is	  a	  rapid	  and	  definite	  indicator	  of	  
tumor	  response.	  Since	  apoptosis	  often	  occurs	  within	  in	  the	  first	  18	  to	  36	  h	  after	  treatment,	  
direct	  imaging	  of	  apoptosis	  would	  rapidly	  indicate	  if	  there	  is	  a	  response	  in	  the	  tumor	  to	  
chemotherapy.	  	  
Apoptosis	  is	  the	  process	  of	  programmed	  cell	  death	  by	  which	  multicellular	  organisms	  
regulate	  cell	  number	  and	  maintain	  homeostasis.	  Within	  the	  series	  of	  biochemical	  events	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involved	  in	  apoptosis,	  the	  activation	  of	  caspase	  family	  of	  cysteine	  proteases	  has	  been	  
recognized	  as	  a	  critical	  marker.	  Apoptosis	  can	  be	  triggered	  by	  extrinsic	  or	  intrinsic	  signals	  
such	  as	  physiological	  activators	  (TNF	  family,	  neurotransmitters,	  calcium,	  glucocorticoids),	  
damage-­‐related	  inducers	  (heat	  shock,	  viral	  infection,	  tumor	  suppressors	  p53,	  oxidants,	  free	  
radicals),	  therapy-­‐associated	  agents	  (chemotherapeutic	  agents,	  gamma	  radiation	  and	  UV	  
radiation)	  and	  toxins	  (ethanol,	  β	  -­‐	  amyloid	  peptide)	  [1-­‐5].	  Defective	  apoptosis	  processes	  
can	  lead	  to	  severe	  pathological	  disorders,	  for	  example,	  down-­‐regulated	  apoptosis	  is	  
involved	  in	  autoimmune	  diseases,	  cancer	  and	  viral	  infections	  [6,	  7];	  abnormal	  upregulation	  
of	  apoptosis	  is	  associated	  with	  AIDS,	  neurodegenerative	  disorders	  and	  ischemic	  injury	  [7,	  
8].	  Therefore,	  the	  development	  of	  caspase	  inhibitors	  could	  be	  novel	  treatments	  for	  a	  variety	  
apoptosis	  associated	  diseases.	  
A	  number	  of	  peptidyl	  caspase	  inhibitors	  have	  been	  developed	  including	  peptidyl	  
chloromethyl	  ketones,	  peptidyl	  fluoromethyl	  ketones	  and	  peptidyl	  aldehydes.	  The	  
chloromethyl	  ketones	  have	  strong	  electrophilicity	  and	  are	  not	  stable	  to	  high	  concentrations	  
of	  thiol,	  which	  limits	  their	  use	  in	  vivo	  [9].	  The	  aldehyde	  based	  inhibitors	  are	  poorly	  cell	  
permeable	  and	  are	  not	  effective	  caspase	  inhibitors	  under	  concentrations	  of	  1	  μ	  M	  [10].	  The	  
fluoromethyl	  ketone	  (FMK)	  inhibitors,	  which	  are	  more	  stable	  in	  vivo	  and	  cell	  permeable	  
[10,	  11],	  act	  as	  broad-­‐spectrum,	  irreversible	  caspase	  inhibitors	  [12]	  with	  no	  added	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cytotoxic	  effects.	  Inhibitors	  synthesized	  with	  a	  benzyloxycarbonyl	  group	  (such	  as	  Boc-­‐	  or	  Z-­‐
)	  at	  the	  N-­‐terminus	  and	  O-­‐methyl	  side	  chains	  such	  as	  Z-­‐Val-­‐Ala-­‐Asp	  (OMe)-­‐FMK	  display	  
improved	  cellular	  permeability	  facilitating	  their	  use	  in	  both	  in	  vitro	  cell	  culture	  and	  in	  vivo	  
animal	  studies	  [13,	  14].	  
Photoacoustic	  imaging	  (PAI)	  overcomes	  the	  spatial	  and	  resolution	  limitations	  of	  
conventional	  imaging	  techniques	  at	  a	  relatively	  low	  cost	  [15,	  16],	  and	  it	  has	  shown	  its	  
potential	  to	  monitor	  the	  growth	  of	  melanoma	  brain	  tumors	  [17]	  and	  melanoma	  metastasis	  
in	  sentinel	  lymph	  nodes	  [18].	  However,	  ascribed	  to	  the	  fact	  that	  PAI	  utilizes	  the	  optical	  
absorption	  of	  tissues	  for	  contrast,	  it	  cannot	  differentiate	  normal	  from	  cancerous	  cells	  
unless	  the	  cells	  are	  overexpressing	  chromomeric	  marker	  (e.g.,	  melanomas)	  or	  labeled	  by	  
reporter	  moieties	  as	  contrast	  agent	  to	  enhance	  the	  contrast	  between	  normal	  and	  
pathological	  tissues.	  In	  this	  case,	  contrast	  agents	  such	  as	  fluorochromes	  with	  absorption	  
and	  emission	  maxima	  wavelengths	  between	  650	  and	  900	  nm	  (within	  the	  near-­‐infrared	  
range)	  are	  ideally	  suited	  for	  imaging	  in	  tissue	  due	  to	  the	  minimal	  optical	  absorption	  from	  
hemoglobin,	  water,	  and	  lipids	  over	  this	  range	  [19-­‐21].	  These	  fluorochromes	  are	  expected	  to	  
facilitate	  both	  the	  visualization	  of	  head	  and	  neck	  squamous	  cell	  carcinoma	  (HNSCC)	  cancer	  
cells	  and	  their	  response	  to	  treatment	  in	  vivo	  by	  PAI	  with	  a	  significant	  benefit	  over	  current	  
commercial	  cell	  caspase	  imaging	  agents,	  such	  as	  FLIVO™,	  which	  use	  fluorophores	  
	   51	  
wavelengths	  less	  than	  600	  nm,	  e.g.	  fluorescein	  and	  rhodamine,	  where	  there	  is	  significantly	  
more	  tissue	  autofluorescence	  and	  optical	  attenuation.	  	  
We	  reported	  herein	  an	  imaging	  agent	  containing	  a	  near-­‐infrared	  (NIR)	  
fluorochrome	  IR780	  with	  high	  quantum	  yield	  and	  a	  cell	  permeable	  fluoromethyl	  ketone	  of	  
the	  tripeptides	  valine,	  alanine,	  and	  O-­‐methyleglutamic	  acid	  [Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK],	  
which	  specifically	  and	  irreversibly	  binds	  to	  the	  cysteine	  residue	  at	  the	  active	  site	  of	  
caspase-­‐9	  [12].	  In	  this	  study,	  we	  first	  demonstrated	  the	  sensitivity	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐
Glu	  (OMe)-­‐FMK	  imaging	  probe	  for	  cell	  apoptosis	  via	  in	  vitro	  cell-­‐imaging	  with	  prostate	  
cancer	  DU	  145	  cells,	  followed	  by	  evaluating	  the	  application	  of	  the	  imaging	  probe	  for	  PAI	  to	  
detect	  procaspase-­‐9	  activation	  caused	  by	  anticancer	  drug	  treatment	  in	  living	  nude	  mice	  
bearing	  HNSCC	  tumors.	  
	  
2	  Materials	  and	  Methods	  
2.1	  Materials	  
All	  chemicals	  were	  obtained	  from	  Sigma-­‐Aldrich	  (St.	  Louis,	  MO,	  USA)	  and	  used	  as	  
received	  unless	  stated	  otherwise.	  Solvents	  were	  distilled	  under	  argon	  immediately	  before	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use.	  Dichloromethane	  (DCM),	  N,Ndimethylformamide	  (DMF)	  and	  triethylamine	  (TEA)	  were	  
freshly	  distilled	  from	  CaH2,	  and	  tetrahydrafuran	  (THF)	  was	  freshly	  distilled	  from	  sodium	  
benzophenone.	  Camptothecin	  was	  purchased	  from	  Natland	  International	  Corporation	  
(Morrisville,	  NC,	  USA).	  Human	  prostate	  cancer	  cell	  line	  DU145	  was	  kindly	  provided	  by	  Dr.	  
Benyi	  Li,	  The	  University	  of	  Kansas	  Medical	  Center	  (Kansas	  City,	  Kansas,	  USA).	  The	  human	  
oral	  squamous	  carcinoma	  cell	  line,	  MDA-­‐1986,	  was	  a	  gift	  from	  Dr.	  Jeffrey	  Myers	  (University	  
of	  Texas,	  M.D.	  Anderson	  Cancer	  Center;	  Houston,	  TX).	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  
and	  trypsin-­‐EDTA	  were	  purchased	  from	  Life	  Technologies	  (Grand	  Island,	  NY,	  USA).	  Fetal	  
bovine	  serum	  (U.S.D.A	  Origin)	  was	  purchased	  from	  Biowest	  LLC	  (Kansas	  City,	  MO,	  USA).	  
Double	  distilled	  water	  was	  used	  in	  syntheses,	  characterization	  and	  cell-­‐culture	  (sterilized	  
by	  autoclaving).	  	  
	  
2.2	  Methods	  
2.2.1	  Synthesis	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  
The	  NIR	  fluorescent	  imaging	  agent	  4′	  C-­‐[4-­‐[2-­‐(fluoromethylketone-­‐Ala-­‐Val-­‐
NH)carbonyl]ethyl]carbonyl]amino]butyl]amino-­‐IR780	  [IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐
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FMK]	  (compound	  10)	  was	  synthesized	  in	  11	  steps	  shown	  in	  Scheme	  1.	  Reactions	  were	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Scheme	  1.	  Synthetic	  scheme	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  imaging	  agent	  
Reagents:	  	  a)	  i,	  Swern	  oxidation;	  ii,	  methyl	  4-­‐nitrobutyrate,	  TEA;	  b)	  10%	  Pd/C,	  H2,	  in	  
MeOH;	  c)	  TEA,	  HBTU,	  DMF;	  d)	  10%	  Pd/C,	  H2,	  in	  THF;	  e)	  EDCI,	  DMAP,	  THF;	  	  f)	  Dess-­‐Martin	  
periodinane,	  in	  DCM;	  	  g)	  4M	  HCl/EtOAc;	  	  h)	  1,4-­‐dioxan,	  DMAP,	  reflux;	  	  i)	  EDCI,	  HOBt,	  DMAP,	  
THF;	  	  j)	  i,	  4M	  HCl/EtOAc;	  ii,	  IR	  780,	  TEA,	  DMF.	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6-­‐Fluoro-­‐5-­‐hydroxy-­‐4-­‐nitrohexanoic	  acid	  methyl	  ester	  (compound	  1)	  
Anhydrous	  DMSO	  (1.4	  mL,	  19	  mmol)	  was	  added	  dropwise	  to	  the	  solution	  of	  oxalyl	  
chloride	  (0.9	  mL,	  9.6	  mmol)	  in	  DCM	  (5	  mL)	  at	  −78°C.	  To	  this	  solution	  was	  added	  2-­‐
fluoroethanol	  (0.44	  mL,	  7.5	  mmol)	  in	  DCM	  (2	  mL).	  Fifteen	  minutes	  later,	  the	  reaction	  
mixture	  was	  diluted	  with	  DCM	  (60	  mL),	  followed	  by	  addition	  of	  TEA	  (4.4	  mL,	  31	  mmol).	  
The	  mixture	  was	  allowed	  to	  warm	  up	  to	  0°C	  and	  stirred	  for	  2	  h	  followed	  by	  the	  addition	  of	  
methyl	  4-­‐nitrobutyrate	  (0.93	  g,	  6.3	  mmol)	  in	  DCM	  (5	  mL).	  The	  mixture	  was	  stirred	  at	  0°C	  
for	  3	  h	  and	  then	  ambient	  temperature	  (ca.	  20°C)	  overnight	  (23).	  The	  solution	  was	  
concentrated	  and	  washed	  with	  ethyl	  acetate	  (EtOAc).	  Removal	  of	  the	  solvent	  followed	  by	  
purification	  by	  silica	  gel	  column	  (hexanes:	  EtOAc	  =	  5:1)	  gave	  the	  desired	  compound	  (1.0	  g,	  
76%)	  as	  yellow	  viscous	  oil.	  	  
4-­‐Amino-­‐6-­‐fluoro-­‐5-­‐hydroxyhexanoic	  acid	  methyl	  ester	  (compound	  2)	  A	  
solution	  of	  6-­‐fluoro-­‐5-­‐hydroxy-­‐4-­‐nitrohexanoic	  acid	  methyl	  ester	  (compound	  1,	  1.15	  g,	  5.5	  
mmol)	  in	  methanol	  (20	  mL)	  and	  acetic	  acid	  (0.5	  mL)	  was	  hydrogenated	  with	  H2	  (40-­‐45	  psi)	  
at	  ambient	  temperature	  for	  5	  h	  using	  10%	  Pd/C	  (0.5	  g)	  catalyst.	  The	  Pd/C	  was	  filtered	  off	  
and	  the	  solvent	  was	  evaporated	  under	  reduced	  pressure.	  The	  desired	  compound	  was	  
obtained	  as	  colorless	  viscous	  oil	  (0.92	  g,	  yield	  87%),	  which	  was	  used	  for	  the	  next	  step	  
without	  further	  purification.	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   Boc-­‐Val-­‐Ala-­‐OBn	  (compound	  3)	  Boc-­‐Val	  (3.0	  g,	  13.8	  mmol),	  alanine	  benzyl	  ester	  
hydrochloride	  salt	  (3.3	  g,	  15.3	  mmol)	  and	  O-­‐benzotriazole-­‐N,	  N,	  N’,	  N’-­‐tetramethyl-­‐
uronium-­‐hexafluoro-­‐phosphate	  (HBTU,	  5.76	  g,	  15.3	  mmol)	  were	  dissolved	  in	  DMF	  (100	  
mL)	  followed	  by	  addition	  of	  TEA	  (4.3	  mL).	  The	  reaction	  was	  stirred	  at	  ambient	  temperature	  
for	  24	  h	  and	  then	  diluted	  with	  saturated	  citric	  acid	  (100	  mL).	  Then	  the	  mixture	  was	  washed	  
with	  EtOAc	  (100	  mL	  ×	  2),	  and	  the	  combined	  organic	  layers	  were	  washed	  with	  brine,	  
saturated	  NaHCO3	  and	  brine,	  respectively,	  and	  then	  dried	  over	  Na2SO4.	  Removal	  of	  the	  
solvent	  under	  reduced	  pressure	  followed	  by	  purification	  on	  silica	  gel	  (EtOAc:	  hexanes	  =	  
1:3)	  gave	  the	  desired	  compound	  (4.48	  g,	  86%)	  as	  a	  white	  solid.	  	  
Boc-­‐Val-­‐Ala-­‐COOH	  (compound	  4)	  Boc-­‐Val-­‐Ala-­‐OBn	  (Compound	  3,	  5.0	  g,	  12.7	  
mmol)	  was	  dissolved	  in	  THF	  (100	  mL),	  and	  the	  solution	  was	  hydrogenated	  with	  H2	  (1	  atm)	  
using	  10%	  Pd/C	  catalyst	  (0.50	  g)	  for	  24	  h.	  The	  solid	  Pd/C	  was	  removed	  by	  filtration,	  and	  
the	  solvent	  was	  evaporated	  under	  reduced	  pressure.	  The	  desired	  compound	  was	  obtained	  
as	  a	  white	  solid	  (3.4	  g,	  82%).	  	  
4-­‐(Boc-­‐Val-­‐Ala-­‐amido)-­‐6-­‐fluoro-­‐5-­‐hydroxylhexa-­‐noic	  acid	  methyl	  ester	  
(compound	  5)	  Boc-­‐Val-­‐Ala-­‐COOH	  (compound	  4,	  1.0	  g,	  3.5	  mmol),	  4-­‐dimethyla-­‐
minopyridine	  (DMAP,	  0.25	  g,	  1.9	  mmol),	  and	  N	  -­‐(3-­‐dimethylaminopropyl)-­‐N	  -­‐
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ethylcarbodiimide	  hydrochloride	  (EDAC,	  0.74	  g,	  3.9	  mmol)	  were	  dissolved	  in	  anhydrous	  
THF	  (10	  mL)	  at	  ambient	  temperature.	  After	  10	  min	  a	  solution	  of	  4-­‐amino-­‐6-­‐fluoro-­‐5-­‐
hydroxyhexanoic	  acid	  methyl	  ester	  (compound	  2,	  0.69	  g,	  3.9	  mmol)	  in	  anhydrous	  THF	  (10	  
mL)	  was	  added	  directly	  to	  the	  above	  solution,	  and	  the	  reaction	  was	  stirred	  at	  ambient	  
temperature	  overnight.	  The	  solvent	  was	  removed	  under	  reduced	  pressure,	  and	  the	  residue	  
was	  dissolved	  in	  EtOAc,	  washed	  with	  saturated	  NaHCO3,	  brine,	  and	  citric	  acid,	  respectively.	  
The	  organic	  layer	  was	  dried	  with	  Na2SO4,	  and	  the	  product	  was	  purified	  over	  silica	  gel	  
(EtOAc:	  hexanes	  =	  3:1)	  to	  give	  the	  desired	  compound	  as	  a	  white	  solid	  (0.5	  g,	  32%).	  	  
4-­‐(Boc-­‐Val-­‐Ala-­‐amido)-­‐6-­‐fluoro-­‐5-­‐oxohexanoic	  acid	  methyl	  ester	  (compound	  
6)	  A	  solution	  of	  compound	  5	  (0.898	  g,	  2.0	  mmol)	  in	  DCM	  (20	  mL)	  was	  treated	  with	  Dess	  -­‐	  
Martin	  periodinane	  solution	  (20	  mL,	  0.3	  M	  in	  DCM).	  The	  reaction	  mixture	  was	  stirred	  at	  
ambient	  temperature	  for	  12	  h.	  The	  solvent	  was	  removed	  under	  reduced	  pressure,	  and	  the	  
crude	  product	  was	  purified	  by	  silica	  gel	  chromatography	  (EtOAc:	  hexanes	  =	  1:1)	  to	  give	  the	  
desired	  compound	  as	  a	  white	  solid	  (0.749	  g,	  81%).	  	  
4-­‐(Val-­‐Ala-­‐amido)-­‐6-­‐fluoro-­‐5-­‐oxohexanoic	  acid	  methyl	  ester	  [Val-­‐Ala-­‐
Glu(OMe)]	  (compound	  7)	  A	  solution	  of	  4-­‐M	  HCl	  in	  anhydrous	  EtOAc	  (20	  mL)	  was	  cooled	  
to	  0°C,	  4-­‐(Boc-­‐Val-­‐Alaamido)-­‐6-­‐fluoro-­‐5-­‐oxohexanoic	  acid	  methyl	  ester	  (compound	  6,	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0.749	  g,	  1.62	  mmol)	  was	  added,	  and	  the	  mixture	  was	  stirred	  at	  ambient	  temperature	  
overnight.	  Collection	  of	  the	  precipitated	  solid	  followed	  by	  washing	  with	  EtOAc	  (50	  mL)	  
gave	  a	  pale	  yellow	  solid	  (0.564	  g,	  quantitative	  yield),	  which	  was	  directly	  used	  for	  the	  next	  
step	  without	  further	  purification.	  	  
4-­‐(4-­‐(Tert-­‐butoxycarbonyl)ethylamino)-­‐4-­‐oxobutanoic	  acid	  (Boc-­‐linker,	  
compound	  8)	  Mono-­‐Boc-­‐protected	  butane-­‐1,	  4-­‐diamine	  (2.82	  g,	  15	  mmol;	  prepared	  
according	  to	  previous	  reports	  [22,	  23])	  in	  10	  mL	  of	  dioxane	  was	  added	  slowly	  to	  a	  solution	  
of	  succinic	  anhydride	  (1.5	  g,	  15	  mmol)	  in	  10	  mL	  of	  dioxane	  and	  then	  stirred	  at	  80°C	  for	  3	  h.	  
Removal	  of	  the	  solvent	  followed	  by	  purification	  of	  the	  residue	  through	  silica	  gel	  
chromatography	  (EtOAc:	  hexanes:acetic	  acid	  =	  50:5:1)	  gave	  the	  desired	  compound	  as	  a	  
white	  solid	  (2.64	  g,	  63%).	  	  
Boc-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK	  (compound	  9)	  To	  a	  solution	  of	  compound	  8	  
(1.44	  g,	  5.0	  mmol)	  in	  THF	  (30	  mL)	  was	  added	  N	  -­‐	  (3-­‐dimethylaminopropyl)-­‐N-­‐
ethylcarbodiimide	  hydrochloride	  (EDCI,	  0.96	  g,	  5.0	  mmol),	  1-­‐hydroxybenzotriazole	  (HOBt;	  
0.68	  g,	  5.0	  mmol),	  and	  4-­‐dimethylaminopyridine	  (DMAP)	  (0.31	  g,	  2.5	  mmol).	  The	  mixture	  
was	  stirred	  for	  10	  min	  at	  ambient	  temperature	  followed	  by	  the	  addition	  of	  compound	  7	  
(2.24	  g,	  5.0	  mmol)	  in	  THF	  (15	  mL).	  The	  mixture	  was	  stirred	  at	  ambient	  temperature	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overnight.	  After	  removing	  the	  solvent	  under	  reduced	  pressure,	  the	  residue	  was	  diluted	  
with	  EtOAc	  (100	  mL)	  and	  washed	  with	  brine	  (50	  mL).	  The	  organic	  layer	  was	  dried	  over	  
sodium	  sulfate	  the	  solvent	  was	  removed	  under	  reduced	  pressure.	  Purification	  of	  the	  
residue	  by	  silica	  gel	  chromatography	  (EtOAc:	  MeOH	  =	  20:1)	  gave	  the	  desired	  compound	  as	  
a	  yellow	  solid	  (1.17	  g,	  38%).	  	  
IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  (compound	  10)	  To	  a	  solution	  of	  Boc-­‐
linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  (compound	  9,	  0.46	  g,	  0.75	  mmol)	  in	  dry	  DMF	  (5	  mL)	  was	  
added	  a	  solution	  of	  4-­‐M	  HCl/EtOAc	  (10	  mL)	  at	  0°C.	  The	  mixture	  was	  stirred	  for	  12	  h	  at	  
ambient	  temperature,	  followed	  by	  the	  addition	  of	  TEA	  (55	  μL,	  0.75	  mmol)	  and	  IR780	  iodide	  
(0.1	  g,	  0.15	  mmol)	  in	  dry	  DMF	  (5	  mL)	  [24,	  25].	  The	  mixture	  was	  then	  heated	  to	  85°C	  and	  
stirred	  continuously	  for	  24	  h	  in	  the	  dark.	  Removal	  of	  the	  solvent	  followed	  by	  purification	  of	  
the	  obtained	  residue	  through	  silica	  gel	  chromatography	  (CHCl3:	  MeOH	  =	  50:1)	  gave	  the	  
desired	  compound	  as	  a	  blue	  solid	  (0.038	  g,	  25%).	  	  
	  
2.2.2	  Spectral	  properties	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  
The	  fluorescent	  spectrum	  of	  a	  1-­‐μM	  solution	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK	  
in	  DMSO	  was	  recorded	  using	  a	  Shimadzu	  RF-­‐5301	  PC	  spectrofluorophotometer.	  The	  Stokes	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shift	  was	  determined	  by	  the	  difference	  in	  wavelength	  between	  excitation	  and	  emission	  
maxima.	  The	  quantum	  yield	  was	  measured	  according	  to	  a	  reported	  protocol	  [26,	  27]	  using	  
cresyl	  violet	  as	  a	  reference.	  
	  
2.2.3	  TUNEL	  assay	  
DU145	  cells	  were	  treated	  with	  1	  μ	  M	  of	  camptothecin	  as	  described	  for	  24	  h	  and	  then	  
were	  fixed	  in	  freshly	  prepared	  4%	  paraformaldehyde	  in	  PBS,	  pH	  7.4,	  for	  1	  h	  at	  ambient	  
temperature.	  After	  washing	  with	  PBS,	  cells	  were	  permeabilized	  with	  0.1%	  Triton	  X-­‐100	  in	  
0.1%	  sodium	  citrate	  for	  2	  min	  on	  ice.	  Cells	  were	  incubated	  with	  TUNEL	  reaction	  mixture	  
(Roche	  Diagnostics,	  Indianapolis,	  IN,	  USA)	  at	  37°C	  in	  a	  humidified	  atmosphere	  for	  1	  h.	  
Samples	  were	  directly	  imaged	  under	  a	  Nikon	  Eclipse	  80i	  microscope	  coupled	  with	  a	  
Hamamatsu	  ORCA-­‐ER	  digital	  camera	  at	  465-­‐495	  nm	  excitation	  and	  515	  -­‐	  555	  nm	  emission.	  
	  
2.2.4	  Western	  blotting	  
DU145	  cells	  were	  treated	  with	  1	  μ	  M	  of	  camptothecin	  as	  described	  in	  the	  previous	  
section,	  and	  cell	  lysates	  were	  prepared	  with	  a	  solution	  of	  1%	  Nonidet	  P-­‐40,	  50-­‐mM	  Tris,	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150-­‐mM	  NaCl,	  APL	  protease	  inhibitors,	  and	  PMSF	  adjusted	  to	  pH	  7.4.	  After	  treatment,	  
floating	  cells	  were	  collected	  by	  aspiration,	  and	  attached	  cells	  were	  collected	  by	  
trypsinization	  followed	  by	  centrifugation	  at	  350	  ×	  g	  for	  5	  min.	  Cell	  pellets	  were	  incubated	  
with	  lysis	  buffer	  on	  ice	  for	  20	  min	  and	  then	  centrifuged	  at	  3,000	  ×	  g	  for	  20	  min	  at	  4°C.	  The	  
protein	  concentration	  was	  determined	  by	  BCA	  assay.	  Samples	  (40	  μ	  g	  of	  protein/sample)	  
were	  separated	  by	  10%	  polyacrylaminde	  gel	  and	  then	  transferred	  onto	  0.45-­‐μ	  m	  
nitrocellulose	  membrane,	  which	  was	  then	  blocked	  with	  5%	  (w/v)	  non-­‐fat	  milk	  in	  TBS	  and	  
0.1%	  Tween	  20	  (TBS/T).	  After	  washing	  with	  TBS/T,	  the	  nitrocellulose	  membrane	  was	  
incubated	  with	  the	  anti-­‐caspase-­‐9	  polyclonal	  antibody	  (diluted	  1:1,000,	  Cell	  Signaling	  
Technology	  #9502,	  Danvers,	  MA,	  USA)	  overnight	  at	  4°C,	  followed	  by	  horseradish	  
peroxidase-­‐conjugated	  secondary	  antibody	  (diluted	  1:2,000,	  Santa	  Cruz	  Biotechnology	  #sc-­‐
2004,	  Santa	  Cruz,	  CA,	  USA)	  for	  1	  h	  at	  ambient	  temperature.	  Proteins	  were	  visualized	  with	  
the	  Western	  Lightening®	  ECL	  detection	  system	  from	  Perkin	  Elmer.	  
	  
2.2.5	  Cell	  imaging	  for	  apoptosis	  
The	  DU145	  cell	  line	  was	  cultured	  in	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  
supplemented	  with	  10%	  fetal	  bovine	  serum	  and	  1%	  L-­‐glutamine.	  Cells	  were	  seeded	  into	  an	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8-­‐chamber	  culture	  slide	  at	  a	  density	  of	  40,000	  per	  well,	  and	  after	  overnight	  incubation,	  they	  
were	  treated	  with	  or	  without	  1	  μM	  of	  camptothecin.	  After	  24	  h,	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  
(OMe)-­‐FMK	  (compound	  10)	  or	  IR780	  iodide	  at	  different	  concentrations	  (0.1,	  0.2,	  0.5	  and	  
1.0	  μM)	  was	  applied,	  and	  the	  cells	  were	  incubated	  at	  37°C	  for	  30	  min.	  Fresh	  MEM	  medium	  
was	  exchanged	  once	  every	  hour	  for	  3	  h.	  The	  cells	  were	  washed	  once	  with	  sterile	  phosphate	  
buffered	  saline	  (PBS)	  for	  fluorescent	  imaging	  using	  a	  Nikon	  Eclipse	  80i	  microscope	  coupled	  
with	  a	  Hamamatsu	  ORCA-­‐ER	  digital	  camera.	  The	  fluorescent	  images	  were	  analyzed	  using	  
the	  MetaMorph	  software.	  	  
For	  the	  nuclear	  counterstain,	  DU145	  cells	  were	  seeded	  onto	  a	  12-­‐mm	  coverslip	  in	  6-­‐
well	  plate	  at	  a	  density	  of	  1.5	  ×	  105	  cells	  per	  well	  for	  overnight.	  After	  cells	  were	  treated	  with	  
or	  without	  1	  μ	  M	  of	  camptothecin	  for	  24	  h,	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  at	  
concentrations	  of	  0.1	  or	  0.5	  μ	  M	  was	  incubated	  with	  cells	  for	  30	  min	  at	  37°C.	  Then	  the	  cells	  
were	  washed	  twice	  with	  sterile	  PBS	  and	  subsequently	  incubated	  with	  5-­‐μ	  g/mL	  DAPI	  in	  
MEM	  for	  at	  37°C	  for	  5	  min.	  Finally,	  the	  cells	  were	  washed	  with	  sterile	  PBS	  twice	  and	  imaged	  
using	  the	  system	  described	  above.	  
The	  acute	  toxicity	  of	  the	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  in	  cell	  culture	  was	  
determined	  by	  incubating	  the	  cells	  with	  the	  imaging	  agent	  for	  30	  min	  and	  then	  measuring	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the	  ratio	  of	  dead	  to	  live	  (attached	  cells).	  DU145	  cells	  had	  been	  seeded	  at	  1.5	  ×	  105	  cells/well	  
in	  a	  6-­‐well	  plate	  and	  allowed	  to	  attach	  overnight	  before	  addition	  of	  the	  imaging	  agent.	  
	  
2.2.6	  Tumor	  model	  
Female	  Nu/Nu	  mice	  used	  in	  the	  experiments	  were	  maintained	  under	  the	  
supervision	  and	  guidelines	  of	  the	  University	  of	  Kansas	  Institutional	  Animal	  Care	  and	  Use	  
Committee.	  Animals	  were	  fed	  on	  a	  diet	  of	  low	  chlorophyll	  feed	  for	  at	  least	  two	  weeks	  before	  
imaging.	  Human	  HNSCC	  cells,	  MDA1986,	  were	  prepared	  in	  1	  ×	  PBS	  solution	  at	  a	  cell	  
concentration	  of	  2	  ×	  107	  cells/mL.	  Nude	  mice	  were	  anesthetized	  with	  1.5%	  isoflurane	  in	  
oxygen-­‐air	  mixture	  (50:50).	  Fifty	  microliters	  of	  cell	  suspension	  was	  injected	  into	  the	  sub-­‐
mucosa	  of	  a	  mouse	  using	  a	  30-­‐ga	  needle.	  Primary	  HNSCC	  tumors	  were	  observed	  on	  the	  
cheek	  of	  the	  animals	  two	  weeks	  after	  implantation	  with	  a	  size	  range	  of	  5	  to	  150	  mm3	  
[tumor	  volume	  =	  0.52	  ×	  (width)	  2	  ×	  (length)].	  Animals	  were	  euthanized	  at	  the	  completion	  
of	  the	  study.	  
	  
2.2.7	  Treatments	  and	  fluorescent	  imaging	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Female	  nude	  mice	  bearing	  head	  and	  neck	  tumors	  were	  randomly	  divided	  into	  two	  
groups,	  including	  cisplatin	  treatment	  and	  control	  groups.	  One	  dose	  of	  10.0-­‐mg/kg	  cisplatin	  
(LC	  Laboratories)	  was	  intravenously	  administered	  via	  the	  tail	  vein	  to	  the	  animals	  in	  the	  
treatment	  group	  once	  the	  tumor	  size	  was	  between	  40	  to	  50mm3.	  The	  control	  group	  
received	  no	  treatment.	  NIR-­‐FMK	  (25	  nmol	  in	  100-­‐μL	  of	  saline)	  was	  intravenously	  injected	  
via	  the	  tail	  vein	  into	  a	  tumor-­‐negative	  mouse,	  and	  systemic	  clearance	  of	  the	  dye	  was	  
evaluated	  by	  fluorescent	  imaging	  (CRI	  Maestro	  Flex,	  CRI	  Inc.,	  Woburn,	  Massachusetts)	  
throughout	  5	  min	  to	  24	  h.	  A	  575	  to	  605-­‐nm	  filtered	  halogen	  excitation	  light	  and	  a	  645-­‐nm	  
long	  pass	  emission	  filter	  were	  applied.	  Fluorescence	  intensity	  in	  the	  abdominal	  area	  was	  
measured	  using	  a	  cooled	  chargecoupled-­‐	  device	  (CCD)	  camera	  with	  auto	  exposure.	  The	  
unscaled	  images	  were	  normalized	  to	  the	  same	  exposure	  and	  the	  brightness	  and	  constrast	  
were	  adjusted	  for	  print.	  
	  
2.2.8	  In	  vivo	  photoacoustic	  imaging	  	  
Figure	  1	  illustrates	  the	  schematic	  of	  the	  PAI	  system.	  The	  mechanism	  of	  the	  PAI	  
system	  was	  previously	  described[16,	  17]	  and	  is	  identical	  to	  the	  system	  presented	  by	  Song	  
et	  al	  [15].	  A	  tunable	  OPO	  laser	  (Surelite	  OPO	  PLUS;	  Continuum,	  Santa	  Clara,	  California)	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pumped	  by	  a	  Q-­‐switchedNd:YAGlaser	  (Surelite;	  Continuum,	  Santa	  Clara,	  California)	  is	  used	  
to	  generate	  the	  laser	  pulse	  with	  a	  repetition	  rate	  of	  10	  Hz	  and	  a	  laser	  wavelength	  of	  680	  
nm.	  The	  laser	  light,	  directed	  by	  a	  prism	  group,	  forms	  a	  ring-­‐shaped	  illumination	  on	  an	  
optical	  condenser	  and	  is	  then	  refocused	  by	  a	  conical	  lens	  on	  the	  targeted	  area.	  The	  
produced	  photoacoustic	  signals	  are	  collected	  by	  a	  5-­‐MHz	  single-­‐element	  focused	  ultrasonic	  
transducer	  (SU-­‐108-­‐013,	  Sonic	  Concepts,	  Bothell,	  Washington),	  amplified	  by	  a	  pre-­‐
amplifier	  (5072PR,	  Olympus-­‐NDT,	  Waltham,	  Massachusetts),	  and	  finally	  collected	  by	  a	  
personal	  computer	  through	  an	  A/D	  Scope	  Card	  (CS21G8	  -­‐	  256MS,	  Gage,	  Lockport,	  Illinois)	  
with	  a	  125-­‐MHz	  sampling	  rate	  to	  reconstruct	  2-­‐D	  images.	  The	  5-­‐MHz	  ultrasonic	  transducer	  
(fractional	  bandwidth	  of	  60%,	  35-­‐mm	  focal	  length,	  and	  33-­‐mm	  aperture	  size)	  is	  mounted	  in	  
the	  center	  of	  the	  condenser	  and	  driven	  by	  a	  step	  motor	  to	  scan	  over	  the	  targeted	  region.	  It	  
takes	  ca.	  20	  min	  to	  scan	  a	  20	  mm	  ×	  20	  mm	  area.	  Previous	  work	  [16,	  17]	  on	  this	  system	  has	  
shown	  that	  it	  has	  a	  lateral	  resolution	  of	  270	  μm	  and	  an	  axial	  resolution	  of	  220	  μm.	  
	  
	  




Figure	  1.	  Schematic	  of	  Photoacoustic	  Imaging	  system	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Twenty-­‐four	  hours	  post-­‐treatment	  with	  cisplatin,	  mice	  were	  positioned	  as	  shown	  in	  
Figure	  2	  and	  anesthetized	  by	  inhalation	  of	  a	  mixture	  of	  1%	  isoflurane	  and	  pure	  oxygen	  at	  1-­‐
L/min	  flow	  rate.	  The	  initial	  background	  photoacoustic	  (PA)	  images	  were	  obtained	  around	  
the	  tumor	  region	  on	  the	  cheek	  of	  the	  mouse	  and	  then	  NIR-­‐FMK	  (25	  nmol	  in	  100	  μL	  of	  
saline)	  was	  intravenously	  injected	  via	  the	  tail	  vein.	  PA	  images	  were	  acquired	  at	  2,	  4,	  6,	  and	  
8	  h.	  A	  laser	  wavelength	  of	  680	  nm	  was	  used	  during	  the	  imaging,	  and	  the	  imaging	  depth	  was	  
2	  to	  3	  mm.	  Signal	  intensity	  was	  analyzed	  using	  Fiji/ImageJA	  software	  (ver.	  20110307,	  
http://pacific.mpicbg.de/wiki/index.php/Fiji).	  
	  
2.2.9	  Immunostaining	  for	  apoptosis	  
The	  HNSCC	  tumor	  was	  excised	  within	  several	  hours	  after	  PAI.	  Subsequently,	  it	  was	  
embedded	  into	  tissue	  freezing	  medium	  (Triangle	  Biomedical	  Sciences,	  Durham,	  North	  
Carolina)	  and	  sectioned	  using	  a	  cryostat	  (Thermo	  Shandon	  Limited,	  Kalamazoo,	  Michigan).	  
Fourteen-­‐micron	  (thickness)	  sections	  of	  the	  tumor	  tissue	  were	  stained	  with	  a	  goat	  primary	  
polyclonal	  antibody	  for	  cleaved	  caspase-­‐3	  p11	  subunit	  (Asp-­‐175-­‐Ser-­‐176)	  and	  a	  donkey	  
anti-­‐goat	  secondary	  antibody	  with	  a	  fluorescein	  isothiocyanate	  (FITC)	  fluorophore	  (Santa	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Cruz	  Biotechnology	  Inc.,	  Santa	  Cruz,	  California).	  Cell	  nuclei	  were	  stained	  with	  4,6-­‐
diamidino-­‐2-­‐phenylindole	  (DAPI).	  
	  
3.	  Results	  and	  Discussion	  
3.1	  Synthesis	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  
We	  successfully	  synthesized	  the	  NIR	  fluorescent	  imaging	  agent	  [IR780-­‐linker-­‐Val-­‐
Ala-­‐Glu	  (OMe)-­‐FMK]	  in	  11	  steps	  with	  an	  overall	  yield	  0.75%.	  The	  structure	  of	  each	  
compound	  was	  determined	  by	  1	  H-­‐NMR	  or	  together	  with	  APCI-­‐MS	  (ESI-­‐MS).	  NMR	  spectra	  
were	  taken	  on	  a	  400-­‐MHz	  Bruker	  with	  the	  TMS	  peak	  as	  internal	  reference.	  Mass	  spectra	  
were	  run	  in	  the	  electrospray	  ionization	  mass	  spectrometry	  (ESI-­‐MS)	  mode	  or	  atmospheric	  
pressure	  chemical	  ionization	  (APCI-­‐MS)	  mode.	  Optically	  pure	  starting	  materials	  were	  used	  
in	  the	  synthesis;	  however,	  isomers	  may	  have	  been	  introduced	  during	  the	  synthesis	  at	  the	  
three	  chiral	  centers.	  During	  the	  purification	  of	  compound	  5,	  only	  the	  major	  compound	  was	  
collected,	  a	  pair	  of	  enantiomers,	  which	  resulted	  in	  the	  low	  yield	  of	  32%.	  The	  enantiomers	  
were	  not	  separated	  further	  before	  proceeding.	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Compound	  1:	  1H-­‐NMR	  (400	  MHz,	  CDCl3):	  2.40	  -­‐	  2.45	  (m,	  4H),	  3.69	  (s,	  3H),	  4.20	  (brs)	  
and	  4.25	  (brs,	  1H),	  4.40	  -­‐	  4.80	  (m,	  3H),	  5.02	  (brs)	  and	  5.19	  (brs,	  1H).	  
Compound	  2:	  1H-­‐NMR	  (400	  MHz,	  MeOD):	  1.65-­‐2.00	  (m,	  2H),	  2.90-­‐3.42	  (m,	  2H),	  3.65	  
(s,	  3H),	  3.66-­‐3.3.95	  (m,	  2H),	  4.41	  -­‐	  4.55	  (m,	  2H).	  
Compound	  3:	  1H-­‐NMR	  (400	  MHz,	  CDCl3):	  0.93	  (d,	  J	  =	  7.0	  Hz,	  3H),	  0.97	  (d,	  J	  =	  6.8	  Hz,	  
3H),	  1.44	  (d,	  J	  =	  7.2	  Hz,	  3H),	  1.46	  (s,	  9H),	  2.08-­‐2.20	  (m,	  1H),	  3.94	  (t,	  J	  =	  7.6	  Hz,	  1H),	  4.62-­‐
4.69	  (m,	  1H),	  5.08	  (d,	  J	  =	  8.8,	  1H),	  5.19	  (dd,	  J	  =	  12.3,	  8.2	  Hz,	  2H),	  6.44	  (d,	  J	  =	  5.8	  Hz,	  1H),	  
7.32-­‐7.44	  (m,	  5H).	  
Compound	  4:	  1H-­‐NMR	  (400	  MHz,	  CDCl3):	  0.92	  (d,	  J	  	  =	  6.7	  Hz,	  3H),	  0.96	  (d,	  J	  	  =	  6.7	  Hz,	  
3H),	  1.42-­‐1.47	  (m,	  12H,	  overlap),	  2.00-­‐2.11	  (m,	  1H),	  4.01	  (t,	  J	  	  =	  8.0	  Hz,	  1H),	  4.57	  (t,	  J	  	  =	  7.0	  
Hz,	  1H),	  5.51	  (brs,	  1H),	  7.04	  (brs,	  1H),	  9.66	  (brs,	  1H).	  
Compound	  5:	  APCI	  -­‐MS:	  [M	  +	  1]	  =	  450.3,	  [M	  +	  1-­‐C4H8]	  =	  394.2,	  [M-­‐Boc]	  =	  350.2.	  1H-­‐
NMR	  (400	  MHz,	  CDCl3):	  0.95	  (d,	  J	  	  =	  7.0	  Hz,	  3H),	  0.98	  (d,	  J	  	  =	  6.6	  Hz,	  3H),	  1.40	  (d,	  J	  	  =	  7.6	  Hz,	  
3H),	  1.45	  (s,	  9H),	  1.85-­‐1.97	  (m,	  2H),	  2.08-­‐2.18	  (m,	  1H),	  2.41	  (t,	  J	  	  =	  7.2	  Hz,	  2H),	  3.69	  (s,	  3H),	  
3.83-­‐3.95	  (m,	  1H),	  3.96-­‐4.10	  (m,	  1H),	  4.29-­‐4.55	  (m,	  3H),	  6.54	  (brs,	  1H),	  6.58	  (brs,	  1H).	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Compound	  6:	  APCI-­‐MS:	  [M	  +	  1]	  =	  448.3,	  [M	  +	  1-­‐C4H8	  ]	  =	  392.2,	  [M-­‐Boc]	  =	  348.2.	  1H-­‐
NMR	  (400	  MHz,	  CDCl3):	  0.95	  (d,	  J	  	  =	  7.0	  Hz,	  3H),	  0.99	  (d,	  J	  	  =	  6.6	  Hz,	  3H),	  1.40	  (d,	  J	  	  =	  7.6	  Hz,	  
3H),	  1.45	  (s,	  9H),	  1.88-­‐1.96	  (m,	  2H),	  2.12-­‐2.22	  (m,	  1H),	  2.43	  (t,	  J	  	  =	  7.2	  Hz,	  2H),	  3.68	  (s,	  3H),	  
3.87-­‐3.99	  (m,	  1H),	  4.46-­‐4.59	  (m,	  1H),	  5.09-­‐5.21	  (m,	  2H),	  6.76	  (brs,	  1H),	  7.37	  (brs,	  1H).	  
Compound	  8:	  1H-­‐NMR	  (400	  MHz,	  MeOD):	  1.46	  (s,	  9H),	  1.46-­‐1.57	  (m,	  4H),	  2.39-­‐2.50	  
(m,	  2H),	  2.55-­‐2.67	  (m,	  2H),	  3.06	  (t,	  J	  =	  4.6	  Hz,	  2H),	  3.19	  (t,	  J	  =	  6.5	  Hz,	  2H),	  6.53	  (brs,	  1H),	  
7.90	  (brs,	  1H),	  12.10	  (brs,	  1H).	  
Compound	  9:	  APCI-­‐MS:	  [M	  +	  1]	  =	  618.7,	  [M-­‐Boc]	  =	  518.5.	  1H-­‐NMR	  (400	  MHz,	  
CDCl3):	  0.95	  (d,	  J	  =	  7.0	  Hz,	  3H),	  0.99	  (d,	  J	  =	  6.6	  Hz,	  3H),	  1.40	  (d,	  J	  =	  7.6	  Hz,	  3H),	  1.46	  (s,	  9H),	  
1.47-­‐1.55	  (m,	  4H),	  1.67-­‐1.78	  (m,	  2H),	  2.14-­‐2.26	  (m,	  1H),	  2.39-­‐2.50	  (m,	  4H),	  2.55-­‐2.68	  (m,	  
2H),	  3.07	  (t,	  J	  =	  4.7	  Hz,	  2H),	  3.20	  (t,	  J	  =	  6.4,	  2H),	  3.68	  (s,	  3H),	  4.08-­‐4.20	  (m,	  1H),	  4.45-­‐4.58	  
(m,	  1H),	  4.48-­‐4.59	  (m,	  1H),	  4.99-­‐5.30	  (m,	  2H),	  6.19	  (brs,	  1H),	  6.50	  (brs,	  1H),	  7.45	  (brs,	  1H),	  
7.53	  (brs,	  1H),	  7.56	  (brs,	  1H).	  
Compound	  10:	  ESI-­‐MS:	  [M+	  1]	  =	  1022.3.	  1H-­‐NMR	  (400	  MHz,	  DMSO-­‐d6):	  0.95	  (d,	  J	  =	  
7.0	  Hz,	  3H),	  0.98	  (d,	  J	  =	  6.6	  Hz,	  3H),	  1.03-­‐1.07	  (m,	  6H),	  1.32-­‐1.41	  (m,	  2H),	  1.42-­‐1.51	  (m,	  5H),	  
1.52-­‐1.57	  (m,	  4H),	  1.59-­‐1.70	  (m,	  15H),	  1.71-­‐1.76	  (m,	  4H),	  2.07-­‐2.15	  (m,	  2H),	  2.18-­‐2.27	  (m,	  
1H),	  2.34	  (t,	  J	  =	  7.2	  Hz,	  2H),	  2.49	  (t,	  J	  =	  6.8	  Hz,	  2H),	  2.57	  (t,	  J	  =	  6.8	  Hz,	  2H),	  2.83	  (t,	  J	  =	  7.5	  Hz,	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4H),	  2.89	  (t,	  J	  =	  6.8	  Hz,	  2H),	  3.05	  (t,	  J	  =	  6.8	  Hz,	  2H),	  3.64	  (s,	  3H),	  3.79	  (t,	  J	  =	  6.8,	  2H),	  3.94	  (t,	  J	  
=	  7.2	  Hz,	  2H),	  4.10-­‐4.20	  (m,	  1H),	  4.26-­‐4.37(m,	  1H),	  4.48-­‐4.56	  (m,	  1H),	  5.13-­‐5.25	  (m,	  2H),	  
5.86	  (d,	  J	  =	  13.0	  Hz,	  2H),	  7.06-­‐7.15	  (m,	  4H),	  7.29-­‐7.36	  (m,	  1H),	  7.62-­‐7.71	  (m,	  1H),	  7.77	  (d,	  J	  =	  
13.0	  Hz,	  2H),	  8.13-­‐8.25	  (m,	  2H).	  
	  
3.2	  Absorption	  and	  emission	  spectrum	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  
The	  structure	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  consists	  of	  three	  parts:	  the	  
IR780	  fluorophore,	  the	  linker,	  and	  the	  fluoromethyl	  ketone	  of	  the	  tripeptides	  valine,	  
alanine,	  and	  Omethyle-­‐glutamic	  acid	  [Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK]	  as	  the	  reactive	  part	  to	  the	  
caspase-­‐9.	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  had	  a	  maximum	  excitation	  at	  650	  nm	  
(Figure	  2)	  and	  emission	  at	  729	  nm	  respectively.	  By	  contrast,	  the	  λmax	  of	  unconjugated	  
IR780	  dye	  was	  at	  685	  and	  760	  nm	  for	  excitation	  and	  emission,	  respectively.	  The	  
fluorescence	  quantum	  yield	  (Φ)	  was	  calculated	  as	  0.75,	  which	  was	  determined	  in	  methanol	  
with	  reference	  compound	  cresyl	  violet	  (Φ	  =	  0.54	  in	  methanol	  [28]).	  The	  quantum	  yield	  is	  
high	  enough	  to	  be	  employed	  as	  a	  fluorescent	  label	  in	  cell	  imaging	  studies.	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3.3	  Camptothecin	  induces	  apoptosis	  via	  activation	  of	  caspases-­‐9	  
The	  caspase	  proteases	  can	  be	  activate	  either	  though	  the	  death	  signal-­‐induced	  or	  
stress-­‐induced	  pathways.	  Caspase-­‐9	  is	  an	  activator	  of	  apoptosis	  in	  the	  mitochondrion-­‐
mediated	  or	  stress-­‐induced	  pathway,	  wherein	  it	  subsequently	  activates	  caspases-­‐3/6/7.	  
Caspase-­‐9	  can	  be	  bypassed	  in	  the	  death	  signal-­‐induced	  pathway	  when	  death	  receptors	  (e.g.	  
TNF	  receptor)	  activate	  caspases-­‐3/6/7	  directly	  via	  caspase-­‐10	  [29].	  Camptothecin	  inhibits	  
DNA	  synthesis	  and	  was	  expected	  to	  induce	  apoptosis	  via	  the	  caspase-­‐9	  pathway.	  	  After	  
treatment	  with	  camptothecin,	  TUNEL	  assay	  indicated	  DNA	  fragmentation	  characteristic	  of	  
apoptosis	  (Figure	  3)	  and	  immunoblotting	  found	  cleaved	  caspase-­‐9	  fragments	  (Figure	  4),	  
which	  are	  the	  target	  of	  the	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  imaging	  agent.	  	  
	  
	  





Figure	  3.	  TUNEL	  assay.	  Apoptotic	  DU145	  cells	  that	  have	  been	  treated	  with	  1	  μM	  
camptothecin	  for	  24	  h	  were	  labeled	  by	  TUNEL	  staining	  of	  the	  DNA	  fragments.	  In	  
comparison,	  untreated	  cells	  did	  not	  undergo	  apoptosis.	  
	  






Figure	  4.	  Western	  blot	  analysis	  of	  caspase-­‐9	  cleavage	  in	  untreated	  DU145	  cells,	  or	  cells	  
treated	  with	  1-­‐μM	  camptothecin	  for	  24	  h.	  (a)	  full	  length;	  (b)	  cleaved	  caspase-­‐9	  (37	  kDa);	  (c)	  
cleaved	  caspase-­‐9	  (35	  kDa
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The	  normal	  DU145	  cells	  had	  no	  uptake	  of	  IR780	  dye	  in	  the	  tested	  concentration	  
range	  (0.1-­‐1	  μM).	  The	  unconjugated	  IR780	  dye	  is	  highly	  polar	  and	  impregnable	  to	  cell	  
membrane,	  and	  we	  did	  not	  observe	  nonspecific	  uptake	  of	  the	  unconjugated	  IR780	  dye	  in	  
normal	  or	  apoptotic	  DU145	  cells	  (images	  not	  shown).	  DU145	  cells	  undergoing	  apoptosis	  
showed	  fluorescent	  signals,	  because	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  bound	  to	  the	  
cleaved	  caspase-­‐9	  induced	  by	  camptothecin,	  which	  caused	  it	  to	  be	  retained	  within	  the	  cells	  
(Figures	  5D,	  E,	  and	  F).	  Furthermore,	  counter-­‐staining	  of	  the	  cells	  with	  DAPI	  confirmed	  that	  
the	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  was	  confined	  to	  the	  cytoplasm	  (Figure	  6).	  The	  
inhibition	  and	  binding	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  to	  cleaved	  caspase-­‐9	  is	  a	  
result	  of	  the	  peptide	  sequence	  recognition	  and	  the	  nucleophilic	  substitution	  of	  the	  fluoro-­‐
group	  by	  a	  sulfhydryl	  group	  of	  the	  cysteine	  protease	  [30].	  By	  contrast,	  after	  untreated	  
DU145	  cells	  (~	  90%	  cell	  confluence)	  were	  incubated	  with	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐
FMK,	  there	  was	  no	  accumulation	  of	  fluorescence	  either	  on	  the	  cell	  membrane	  or	  inside	  the	  
cells	  at	  0.1-­‐	  or	  0.2-­‐μM	  IR780-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  concentrations	  (Figures	  5A	  and	  5B).	  
However,	  there	  was	  a	  small	  amount	  of	  fluorescence	  detected	  when	  the	  cells	  were	  incubated	  
with	  0.5-­‐μM	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu	  (OMe)-­‐FMK	  (Figure	  5C).	  This	  was	  probably	  due	  to	  
the	  high	  cell	  confluence	  (~	  90%)	  used	  for	  the	  imaging,	  as	  this	  non-­‐specific	  binding	  was	  not	  
observed	  in	  the	  cells	  at	  60%	  confluency	  used	  for	  the	  DAPI	  counterstaining	  (Figure	  6),	  and	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the	  imaging	  agent	  alone	  was	  not	  toxic.	  When	  the	  cells	  were	  incubated	  with	  the	  imaging	  
agent	  for	  30	  min,	  there	  were	  no	  statistically	  significant	  differences	  in	  cell	  death	  between	  0,	  
0.1	  and	  0.5	  μM	  of	  agent,	  which	  resulted	  in	  3.17	  ±	  0.85,	  3.01	  ±	  1.17,	  and	  3.34	  ±	  1.01%	  dead	  
cells,	  respectively.
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Figure	  5.	  DU145	  cell	  imaging	  after	  treatment	  with	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK	  at	  
concentrations	  of:	  A)	  0.1	  μM;	  B)	  0.2	  μM;	  C)	  0.5	  μM;	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK	  
with	  1	  μM	  of	  camptothecin	  at	  concentrations	  of:	  D)	  0.1	  μM;	  E)	  0.2	  μM;	  F)	  0.5	  μM.
	  




Figure	  6.	  Fluorescent	  microscopic	  images	  of	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK-­‐stained	  
DU145	  cells;	  DAPI	  counter	  stain.	  The	  IR780-­‐linker-­‐Val-­‐Ala-­‐Glu(OMe)-­‐FMK	  fluorescent	  label	  
(red)	  is	  distributed	  within	  the	  cytoplasm	  of	  the	  cells.
	  
	   80	  
3.4	  In	  vivo	  fluorescent	  imaging	  of	  tumor-­‐free	  mice	  treated	  with	  IR780-­‐linker-­‐Val-­‐Ala-­‐
Glu	  (OMe)-­‐FMK	  
Systemic	  clearance	  of	  the	  imaging	  agent	  from	  a	  tumor-­‐free	  mouse	  was	  evaluated	  by	  
injecting	  animals	  with	  25	  nmol	  of	  NIR-­‐FMK	  via	  their	  tail	  vein	  and	  fluorescently	  imaging	  
animals	  from	  5	  min	  to	  24	  h.	  Fluorescence	  signals	  in	  the	  abdominal	  area	  shown	  in	  Figure	  7	  
indicated	  that	  NIR-­‐FMK	  was	  retained	  by	  the	  liver	  within	  the	  first	  5	  min	  after	  injection,	  with	  
later	  distribution	  to	  the	  small	  intestines	  and	  spleen.	  Organ	  fluorescence	  decreased	  to	  
background	  or	  auto-­‐fluorescence	  levels	  after	  eight	  hours,	  indicating	  that	  the	  agent	  had	  
been	  completely	  cleared	  from	  the	  body.	  The	  kinetics	  of	  clearance	  of	  NIR-­‐FMK	  served	  to	  
assist	  with	  determining	  the	  time	  course	  of	  PA	  imaging	  on	  tumor-­‐positive	  mice.	  Within	  the	  
first	  hour,	  the	  liver	  had	  cleared	  the	  imaging	  agent	  from	  the	  systemic	  circulation,	  offering	  a	  
favorable	  time	  frame	  for	  PA	  imaging	  to	  differentiate	  the	  imaging	  agents	  bound	  to	  the	  tumor	  
tissue	  from	  the	  free	  agent	  distributed	  in	  the	  tissue	  space.	  In	  addition,	  considering	  the	  
imaging	  resolution	  and	  patients’	  comfort	  in	  future	  clinical	  applications,	  we	  performed	  the	  
PA	  imaging	  at	  2,	  4,	  6,	  and	  8	  h	  after	  intravenous	  injection.	  
	  





Figure	  7.	  Fluorescent	  images	  of	  the	  systemic	  clearance	  of	  NIR-­‐FMK	  constrast	  agent.	  Animal	  
was	  fluorescently	  imaged	  after	  tail	  vein	  injection	  of	  25	  nmol	  of	  NIR-­‐FMK.	  Agent	  was	  rapidly	  
cleared	  from	  the	  systemic	  circulation	  and	  was	  concentrated	  in	  the	  liver	  from	  5	  to	  30	  min	  
and	  in	  the	  intestines	  from	  1	  to	  6	  h.	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3.5	  In	  vivo	  photoacoustic	  imaging	  of	  chemotherapy-­‐induced	  apoptosis	  in	  squamous	  
cell	  carcinoma	  
Maximum	  amplitude	  projection	  images	  obtained	  from	  the	  PAI	  of	  the	  HNSCC	  tumor	  
region	  shown	  in	  Figure	  8	  were	  converted	  to	  grayscale	  images.	  The	  grayscale	  images	  at	  
various	  time	  points	  were	  linearly	  aligned	  using	  the	  scale-­‐invariant	  feature	  transform	  
function	  of	  Fiji/ImageJA	  software	  (ver.	  20110307,	  http://pacific.mpi-­‐
cbg.de/wiki/index.php/Fiji)	  (Figure	  9).	  Quantification	  of	  PA	  signal	  intensity	  within	  the	  
tumor	  region	  was	  performed	  in	  triplet	  for	  each	  image	  by	  measuring	  the	  mean	  gray	  value	  
(units:	  gray/pixel)	  of	  the	  circled	  tumor	  region.	  The	  extent	  of	  signal	  enhancement	  was	  
calculated	  by	  normalizing	  the	  tumor	  signal	  against	  a	  background	  reading	  taken	  
immediately	  before	  injection	  of	  the	  imaging	  agent	  (Figure	  8),	  and	  the	  process	  can	  be	  
indicated	  with	  the	  following	  equation:	  
Increase	  in	  PA	  signal	  =	  [(intensity	  of	  each	  time	  point−intensity	  of	  background	  
image)/intensity	  of	  background	  imaging]	  ×	  100%.	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Figure	  8.	  Increase	  in	  PA	  amplitude	  within	  the	  HNSCC	  tumor	  after	  intravenous	  injection	  of	  
imaging	  agent	  via	  the	  tail	  vein.	  The	  treated	  animals	  (n	  =	  2)	  were	  intravenously	  given	  10	  
mg/kg	  of	  cisplatin	  24	  h	  prior	  to	  administration	  of	  the	  imaging	  agent.	  PAI	  images	  were	  
centered	  on	  the	  tumor	  (circle,	  bottom).	  Images	  of	  the	  control	  animal	  (n	  =	  1)	  at	  the	  optimal	  
imaging	  depth	  were	  chosen	  for	  data	  analysis.	  






























Figure	  9.	  PA	  images	  of	  HNSCC	  tumor	  apoptosis	  after	  contrast	  treatment.	  Animals	  were	  
administered	  25	  nmol	  of	  NIR-­‐FMK	  via	  the	  tail	  vein.	  Intravenous	  cisplatin	  (10	  mg/kg)	  was	  
administered	  24	  h	  prior	  to	  imaging	  in	  the	  treatment	  group.
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The	  signal	  intensity	  within	  the	  tumor	  region	  of	  each	  frame	  (denoted	  by	  a	  white	  
circle	  in	  Figure	  	  9)	  was	  compared	  with	  other	  frames	  in	  the	  same	  time	  series	  between	  the	  
treated	  and	  control	  groups.	  The	  same	  scaling	  was	  used	  for	  all	  images	  within	  the	  series.	  The	  
triangle-­‐shaped	  white	  region	  in	  the	  lower	  left	  corner	  of	  the	  control	  group	  images	  in	  Figure	  
10	  is	  noise	  from	  a	  piece	  of	  paper	  used	  to	  cover	  the	  right	  eye,	  which	  is	  outside	  of	  the	  HNSCC	  
tumor	  region.	  The	  signal	  of	  the	  mouse	  in	  the	  control	  group	  reached	  the	  maximum	  intensity	  
at	  2	  h	  and	  after	  that	  it	  began	  to	  drop.	  This	  indicated	  that	  the	  imaging	  probe	  was	  
nonspecifically	  distributed	  to	  the	  tumor	  tissues	  after	  injection,	  and	  the	  agent	  then	  cleared	  
with	  the	  systemic	  circulation	  as	  observed	  in	  the	  fluorescence	  studies	  (Figure	  7).	  By	  
comparison,	  PA	  images	  of	  the	  treatment	  group	  demonstrated	  enhanced	  signal	  intensity	  
during	  the	  same	  time	  course.	  The	  significant	  difference	  between	  control	  and	  cisplatin	  
treatment	  groups	  could	  be	  explained	  by	  the	  specific	  and	  irreversible	  binding	  between	  NIR-­‐
FMK	  and	  caspase	  9	  in	  the	  tumor	  tissue.	  In	  cisplatin	  treated	  mice,	  apoptosis	  of	  HNSCC	  
cancer	  cells	  resulted	  in	  the	  activation	  of	  caspase	  9	  around	  the	  tumor,	  serving	  as	  binding	  
sites	  for	  the	  imaging	  probe	  and	  allowing	  the	  probe	  to	  accumulate.7	  Since	  the	  control	  group	  
did	  not	  receive	  the	  chemotherapy	  treatment,	  caspase	  9	  was	  not	  activated	  due	  to	  the	  lack	  of	  
the	  cell	  apoptosis	  process	  and	  the	  imaging	  probe	  was	  rapidly	  cleared	  from	  the	  tumor.	  
	   86	  
Diffuse	  contrast	  on	  the	  peripheral	  of	  the	  tumor	  region	  in	  the	  treated	  group	  is	  likely	  due	  to	  
apoptosis	  of	  metastatic	  cells	  on	  the	  margins	  of	  the	  solid	  primary	  tumor	  mass.	  
	  
3.6	  Immunostaining	  of	  sliced	  tumor	  for	  apoptosis	  
Apoptosis	  in	  the	  tumor	  tissues	  was	  independently	  verified	  by	  immunohistochemical	  
staining	  for	  caspase	  3,	  a	  downstream	  indicator	  of	  apoptosome-­‐activated	  caspase-­‐mediated	  
apoptosis	  that	  would	  not	  cross-­‐react	  with	  the	  caspase-­‐9	  PA	  probe.	  Figure	  10(a)	  represents	  
a	  control	  section	  stained	  with	  the	  secondary	  antibody	  alone	  (autofluorescence	  of	  the	  tissue	  
without	  apparent	  staining);	  while,	  Figure	  10	  (b)	  shows	  the	  immunostaining	  of	  the	  caspase-­‐
3	  p11	  subunit	  (green)	  and	  the	  DAPI	  staining	  of	  cell	  nuclei.	  The	  intense	  green	  fluorescence	  
in	  these	  sections	  suggests	  the	  wide	  spread	  apoptosis	  of	  cells	  in	  the	  tumor	  tissues	  after	  
intravenous	  administration	  of	  high-­‐dose	  cisplatin.	  In	  addition,	  cells	  on	  the	  peripheral	  of	  the	  
tumor	  stained	  more	  strongly	  for	  caspase	  3	  (green	  fluorescence)	  compared	  to	  cells	  at	  the	  
tumor	  interior.	  This	  was	  consistent	  with	  the	  PA	  imaging	  of	  apoptosis	  that	  showed	  strong	  
apoptosis	  at	  the	  tumor	  peripheral,	  suggesting	  chemotherapeutics	  had	  penetrated	  the	  outer	  
layers	  of	  the	  tumor	  and	  induced	  apoptosis.	  
	  






Figure	  10.	  Immunostaining	  for	  apoptosis	  in	  tumor.	  (A)	  	  representative	  control	  section	  
stained	  with	  secondary	  antibody	  alone,	  and	  (B)	  tissue	  section	  of	  the	  HNSCC	  tumor	  stained	  
for	  caspase-­‐3	  p11	  subunit	  after	  cisplatin	  treatment.	  Green	  FITC	  fluorescence	  indicates	  the	  
presence	  of	  apoptotic	  cells,	  and	  blue	  DAPI	  indicates	  the	  cell	  nuclei.
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4.	  Conclusions	  
In	  conclusion,	  the	  synthesis	  of	  a	  new	  NIR	  fluorescent	  imaging	  agent	  [IR780-­‐Val-­‐Ala-­‐
Glu	  (OMe)-­‐FMK]	  for	  caspase-­‐9	  was	  successfully	  accomplished	  in	  11	  steps	  (0.75%	  overall	  
yield),	  which	  has	  a	  maxima	  excitation	  at	  650	  nm	  and	  emission	  at	  729	  nm.	  The	  in	  vitro	  cell	  
imaging	  has	  demonstrated	  the	  sensitivity	  of	  this	  imaging	  agent	  for	  caspase-­‐9-­‐mediated	  cell	  
apoptosis.	  At	  high	  confluences	  and	  dye	  concentrations,	  the	  dye	  uptake	  lost	  specificity.	  In	  
addition,	  the	  cell-­‐permeable	  imaging	  probe	  can	  be	  utilized	  to	  monitor	  cancer	  cell	  apoptosis	  
in	  living	  mice	  by	  photoacoustic	  imaging	  with	  improved	  contrast.	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1.	  Introduction	  
Engineered	  superparamagnetic	  iron	  oxide	  nanoparticles	  (SPINOs),	  including	  
magnetite	  Fe3O4	  and	  γ-­‐	  Fe2O3,	  with	  elaborately	  tailored	  particle	  sizes	  and	  surface	  
chemistry	  have	  been	  extensively	  studied	  as	  probes	  for	  magnetic	  resonance	  imaging	  
(MRI)	  and	  magnetic	  hyperthermia	  treatment	  (MFH)	  due	  to	  their	  biocompatibility,	  
ease	  in	  synthesis,	  and	  their	  FDA-­‐approval	  for	  clinical	  usage.	  With	  recent	  advances	  in	  
materials	  science	  and	  nanotechnology,	  the	  composition,	  crystallinity	  and	  magnetism	  
of	  SPIONs	  can	  be	  modified	  to	  markedly	  enhance	  magnetic	  saturation	  [1,	  2].	  
Therefore,	  SPIONs	  represents	  a	  powerful	  tool	  in	  the	  field	  of	  cancer	  theranostics	  that	  
combines	  magnetic	  resonance	  imaging	  (MRI)	  and	  magnetic	  hyperthermia	  treatment	  
(MHT)	  under	  extra	  alternating	  current	  magnetic	  fields[3-­‐9].	  However,	  a	  major	  
challenge	  in	  the	  biomedical	  application	  of	  SPIONs	  for	  MHT	  is	  its	  moderate	  heating	  
efficiency	  and	  lack	  of	  precise	  control	  of	  in	  vivo	  temperature	  evolution	  during	  the	  
treatment	  [10].	  	  
In	  order	  to	  achieve	  strong	  MRI	  contrast	  sensitivity	  and	  sufficient	  heating	  
efficacy	  for	  MHT,	  high	  magnetization	  is	  a	  prerequisite,	  which	  has	  led	  to	  the	  
exploration	  of	  magnetic	  alloy	  nanoparticles	  including	  FePt	  [11,	  12],	  FeCo[13,	  14]	  
and	  FePd	  [15]as	  new	  theranostics	  probes.	  The	  magnetic	  alloy	  nanoparticles	  have	  
demonstrated	  enhanced	  magnetic	  properties,	  and	  compared	  to	  FeCo	  MNPs,	  FePt	  
MNPs	  are	  more	  chemically	  stable	  against	  rapid	  oxidation	  in	  biological	  solutions[16].	  
Novel	  bi-­‐magnetic	  core/shell	  nanostructures	  that	  incorporate	  magnetically	  soft	  
materials	  (e.g.	  iron	  oxide,	  FeCo)	  and	  magnetically	  hard	  magnetic	  alloy	  nanoparticles	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(MNPs)	  (e.g.	  FePt,	  FePd)	  take	  advantage	  of	  the	  intrinsic	  magnetic	  properties	  at	  both	  
ends	  of	  the	  spectrum.	  These	  core/shell	  MNPs	  combine	  high	  magnetocrystalline	  
anisotropy	  and	  saturated	  magnetization	  via	  the	  effective	  interfacial	  exchange	  
coupling	  interaction	  between	  the	  two	  phases,	  affording	  cooperative	  magnetic	  
switching	  and	  tunable	  magnetic	  properties	  [17,	  18].	  	  The	  enhanced	  magnetism	  can	  
be	  further	  translated	  into	  a	  high	  thermal	  energy	  transfer	  capability,	  which	  is	  crucial	  
for	  generating	  the	  high	  local	  temperatures	  needed	  for	  thermal	  abduction	  of	  tumor	  
tissues	  [19]	  during	  the	  magnetically	  mediated	  hyperthermia.	  Compared	  with	  a	  
clinically	  approved	  Fe3O4	  MNPs	  formulation,	  Feridex®,	  a	  significant	  enhancement	  of	  
magnetic	  heat	  induction	  has	  been	  reported	  in	  exchange-­‐coupled	  CoFe2O4	  
@MnFe2O4,	  which	  were	  intradumorally	  injected	  and	  led	  to	  the	  complete	  tumor	  
eradication	  after	  local	  hyperthermia	  [20].	  Although	  high	  concentration	  of	  MNPs	  
within	  the	  tumor	  region	  can	  be	  achieved	  by	  local	  administration,	  direct	  injection	  is	  
invasive	  and	  not	  amenable	  to	  suppress	  small	  metastatic	  tumor	  growth,	  presenting	  a	  
severe	  practical	  challenge.	  For	  example,	  tumor	  overheating	  has	  been	  found	  to	  cause	  
plaque	  formation	  over	  a	  period	  of	  7	  days	  following	  the	  hyperthermia	  after	  the	  local	  
injection	  of	  MNPs	  [20].	  In	  contrast,	  intravenous	  (i.v.)	  administration	  is	  far	  less	  
invasive	  and	  could	  offer	  better	  coverage	  for	  the	  metastatic	  tumor	  regions.	  
The	  aim	  of	  this	  study	  was	  to	  develop	  novel	  MNPs	  of	  core/shell	  structures	  
with	  mutual	  coupling	  of	  magnetically	  hard	  and	  soft	  components	  to	  simultaneously	  
achieve	  high	  saturated	  magnetization	  and	  coercivity,	  which	  could	  be	  used	  as	  an	  
anticancer	  theranostic	  agent	  for	  imaging	  and	  treatment.	  In	  addition,	  an	  efficient	  
surface	  coating	  strategy	  was	  applied	  to	  the	  as-­‐synthesized	  core/shell	  MNPs	  to	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increase	  their	  biocompatibility,	  aqueous-­‐dispersity	  and	  colloidal	  stability.	  Surface-­‐
coating	  materials	  typically	  include	  inorganic	  materials	  such	  as	  gold	  [21,	  22]	  and	  
silica	  [23,	  24],	  and	  biodegradable	  polymers	  such	  as	  dextran	  [25,	  26],	  chitosan	  [27-­‐
29],	  poly	  (lactide	  acid)	  [30,	  31]	  and	  polyethylene	  glycol	  (PEG)	  [32,	  33].	  	  Amongst	  
these	  surface	  modification	  methods,	  PEG	  coating	  is	  one	  of	  the	  most	  efficient	  
approaches	  for	  preventing	  aggregation	  of	  MNPs	  in	  physiological	  conditions	  due	  to	  
the	  steric	  expulsion	  between	  the	  hydrophilic	  chains,	  which	  extends	  the	  in	  vivo	  
circulation	  and	  subsequently	  enhances	  the	  accumulation	  of	  MNPs	  in	  tumors	  due	  to	  
its	  capability	  to	  resist	  reticuloendothelial	  system	  clearance	  [34-­‐38].	  	  
The	  potential	  of	  our	  PEGylated	  core/shell	  FePt@Fe3O4	  MNPs	  (PEG-­‐MNPs)	  as	  
a	  robust	  probe	  for	  cancer	  theranostics	  was	  investigated	  in	  a	  mouse	  model	  of	  4T1.2	  
Neu	  breast	  tumor.	  The	  i.v.	  injected	  PEG-­‐	  MNPs	  were	  activated	  by	  an	  alternating	  
magnetic	  field	  to	  generate	  high	  magnetic	  heating.	  Combined	  with	  the	  deep-­‐tissue	  
penetration	  capacity	  of	  the	  magnetic	  field,	  the	  PEG-­‐MNPs-­‐mediated	  hyperthermia	  
exhibited	  significant	  antitumor	  efficacy.	  In	  addition,	  the	  enhanced	  in	  vivo	  T2-­‐
weighted	  spin-­‐echo	  MRI	  sensitivity	  within	  the	  tumor	  region	  demonstrated	  the	  
potential	  of	  using	  the	  PEG-­‐MNPs	  for	  integrated	  diagnostics.	  
	  
2.	  Materials	  and	  Methods	  
2.1	  Materials	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All	  chemicals	  were	  used	  as	  received	  without	  further	  purification	  unless	  
otherwise	  noted.	  Platinum	  acetylacetonate	  (Pt(acac)2)	  (97%),	  iron	  pentacarbonyl	  
(Fe(CO)5)	  (>99.99%	  trace	  metal	  basis),	  iron	  (III)	  acetylacetonate	  (Fe(acac)3),	  1,2-­‐
hexadecanediol	  (Technical	  grade	  90%),	  dioctylether	  (99%),	  oleylamine	  (technical	  
grade	  70%),	  oleic	  acid	  (technical	  grade	  90%),	  anhydrous	  hexane	  (95%),	  acetone	  
(≥99.5%)	  and	  triethylamine	  (≥99.5%)	  were	  purchased	  from	  Sigma-­‐Aldrich	  Co	  (St.	  
Louis,	  MO,	  USA).	  Methanol	  (≥99.9%)	  and	  phenyl	  ether	  (99%)	  were	  obtained	  from	  
Fisher	  Scientific	  (Pittsburgh,	  PA,	  USA).	  Ethanol	  (200	  proof)	  was	  purchased	  from	  
Decon	  Labs,	  Inc	  (King	  of	  Prussia,	  PA,	  USA).	  Double	  distilled	  water	  was	  used	  in	  
syntheses,	  characterization,	  cell	  culture,	  and	  animal	  experiments	  (sterilized	  by	  
autoclaving).	  Metastatic	  murine	  breast	  cancer	  cell	  line	  4T1.2-­‐Neu	  was	  a	  kind	  gift	  
from	  Dr.	  Zhaoyang	  You,	  University	  of	  Pittsburgh	  (Pittsburgh,	  PA,	  USA).	  Cell	  culture	  
medium,	  Dulbecco's	  Modified	  Eagle	  Medium	  (DMEM),	  and	  Fetal	  Bovine	  Serum	  (FBS)	  
were	  purchased	  from	  Life	  Technologies	  (Grand	  Island,	  NY,	  USA).	  	  
	  
2.2	  Methods	  
2.2.1	  FePt@Fe3O4	  MNPs	  synthesis	  
The	  core/shell	  FePt@Fe3O4	  MNPs	  synthetic	  procedure	  consists	  of	  two	  steps,	  
including	  FePt	  core	  synthesis	  and	  Fe3O4	  coating.	  Under	  an	  argon	  atmosphere,	  
platinum	  acetylacetonate	  (Pt(acac)2,	  0.5	  mmol)	  and	  1,2-­‐hexadecanediol	  (2	  mmol)	  
were	  dissolved	  in	  20	  mL	  of	  dioctylether,	  degased/refilled	  three	  cycles,	  and	  heated	  to	  
100oC.	  Iron	  pentacarbonyl	  (Fe(CO)5,	  1	  mmol),	  oleylamine	  (0.17	  mL)	  and	  oleic	  acid	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(0.16	  mL)	  were	  injected,	  degased/refilled	  one	  cycle	  under	  argon,	  and	  then	  the	  
solution	  was	  heated	  to	  295	  oC	  for	  30	  min.	  After	  cooling	  to	  room	  temperature,	  the	  
FePt	  MNPs	  were	  precipitated	  using	  methanol/hexane	  (5:1	  v/v)	  and	  washed	  three	  
times.	  The	  black	  FePt	  MNPs	  were	  collected	  and	  annealed	  at	  450	  oC	  for	  2	  h	  in	  a	  N2/H2	  
annealing	  atmosphere.	  The	  FePt	  MNPs	  were	  dispersed	  in	  hexane	  and	  stored	  under	  
N2.	  FePt	  MNPs	  (25mg)	  in	  hexane,	  iron	  (III)	  acetylacetonate	  (Fe(acac)3,	  1	  mmol),	  
oleylamine	  (1	  mmol),	  oleic	  acid	  (1	  mmol),	  and	  1,2-­‐hexadecanediol	  (5	  mmol)	  were	  
mixed	  in	  phenyl	  ether	  (20	  mL)	  in	  a	  flask	  equipped	  with	  a	  condenser	  and	  
degased/refilled	  with	  N2	  for	  three	  cycles.	  The	  mixture	  was	  heated	  to	  100	  oC	  and	  
purged	  under	  N2	  for	  10	  min	  to	  remove	  the	  hexane.	  The	  remaining	  solution	  was	  
heated	  to	  265	  oC	  for	  30	  min.	  After	  cooling	  to	  room	  temperature,	  the	  MNP	  were	  
precipitated	  using	  methanol/hexane	  (5:1	  v/v)	  and	  washed	  three	  times.	  The	  final	  
black	  FePt@Fe3O4	  MNPs	  were	  dispersed	  in	  hexane	  and	  stored	  in	  the	  N2	  glovebox.	  
	  
2.2.2	  Specific	  absorption	  rate	  (SAR)	  measurements	  of	  the	  FePt@Fe3O4	  
MNPs	  
A	  series	  of	  MNPs	  sample	  solutions	  with	  different	  MNP	  sizes	  were	  prepared,	  
and	  their	  heating	  properties	  were	  measured	  using	  an	  inductive	  magnetic	  filed	  
generator.	  Briefly,	  a	  2	  mL	  MNPs	  sample	  solution	  was	  placed	  in	  a	  glass	  vial	  and	  held	  
within	  the	  induction	  heater	  coil	  using	  a	  Teflon	  holder.	  The	  Teflon	  holder	  acted	  as	  an	  
insulator	  and	  prevented	  residual	  heating	  of	  the	  sample	  from	  the	  coil.	  The	  
temperature	  change	  of	  the	  colloidal	  solution	  was	  measured	  using	  a	  fiber	  optic	  probe	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(Neoptix	  Inc,	  Québec,	  QC,	  Canada)	  and	  the	  temperature	  rise	  of	  the	  sample	  solutions	  
as	  a	  function	  of	  time	  was	  recoded	  with	  a	  computer.	  In	  order	  to	  reduce	  errors	  due	  to	  
heat	  loss	  to	  the	  environment,	  the	  initial	  slope	  of	  the	  time	  dependent	  temperature	  
curve	  (∆T/∆t)	  was	  taken	  for	  the	  calculation	  of	  SAR.	  The	  SAR	  value	  was	  calculated	  
with	  the	  following	  equation,	  SAR=(C/mNP)(∆T/∆t),	  where	  C	  is	  the	  heat	  capacity	  of	  
the	  solution	  and	  mNP	  is	  the	  mass	  of	  the	  nanoparticles.	  	  
	  
2.2.3	  Nuclear	  Magnetic	  Resonance	  (NMR)	  relaxivity	  measurement	  of	  
MNPs	  solution	  
Longitudinal	  (T1)	  and/or	  Transverse	  (T2)	  relaxation	  rate	  constants	  were	  
measured	  as	  a	  function	  of	  MNPs	  concentration	  using	  the	  inversion	  recovery	  and	  
spin	  echo	  pulse	  sequences	  on	  a	  400	  MHz	  Bruker	  AV	  spectrometer	  [39].	  
	  
2.2.4	  Surface	  PEGylation	  of	  FePt@Fe3O4	  MNPs	  
Core/shell	  FePt@Fe3O4	  MNPs	  were	  modified	  with	  2-­‐methoxy	  
polyethyleneoxy	  propyltrimethoxysilane	  (silane-­‐PEG)	  through	  a	  ligand	  exchange	  
reaction	  according	  to	  the	  method	  of	  Larsen	  et.	  al.	  [35,	  40].	  Briefly,	  300	  μL	  of	  as-­‐
synthesized	  nanoparticles	  in	  hexane	  (30	  mg/mL)	  were	  washed	  with	  10	  mL	  of	  
methanol/acetone	  (1:1)	  and	  centrifuged	  at	  2,000×g	  for	  30	  min.	  	  After	  the	  
supernatant	  was	  discarded,	  precipitated	  nanoparticles	  were	  re-­‐suspended	  in	  300	  μL	  
of	  hexane.	  The	  washing	  step	  was	  repeated	  three	  times	  and	  the	  precipitated	  
nanoparticles	  were	  then	  dried	  under	  an	  argon	  flow	  to	  remove	  residual	  solvents.	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The	  dried	  nanoparticles	  were	  dispersed	  in	  6	  mL	  of	  toluene,	  followed	  by	  addition	  of	  
600	  μL	  of	  silane-­‐PEG	  (1	  mg/mL),	  3	  mL	  of	  triethylamine,	  and	  60	  μL	  of	  double	  
distilled	  water.	  The	  mixture	  was	  stirred	  at	  60°	  C	  overnight,	  after	  which	  the	  
nanoparticles	  were	  precipitated	  with	  25	  mL	  of	  hexane/ethanol	  (3:1).	  The	  particle	  
suspension	  was	  precipitated	  by	  centrifugation	  (2,000×g	  for	  10	  min)	  and	  re-­‐
suspended	  in	  2	  mL	  of	  toluene.	  The	  washing	  cycle	  was	  repeated	  three	  times.	  The	  
washed	  PEGylated	  FePt@Fe3O4	  MNPs	  (PEG-­‐MNPs)	  were	  dried	  at	  35	  °C	  overnight	  
with	  a	  centrifugal	  evaporator.	  
	  
2.2.5	  Fourier	  Transform	  Infrared	  Spectroscopy	  (FTIR)	  
FTIR	  spectra	  of	  approximately	  2	  mg	  of	  dried	  MNPs	  were	  recorded	  using	  an	  
IRAffinity-­‐1	  FTIR	  (Shimadzu	  Scientific	  Instruments,	  KS,	  USA).	  For	  each	  spectrum,	  45	  
scans	  were	  collected	  between	  4000	  and	  400	  cm-­‐1	  at	  a	  resolution	  of	  1	  cm-­‐1.	  
	  
2.2.6	  Hydrodynamic	  Diameters	  Measurements	  	  
PEG-­‐MNPs	  were	  dispersed	  at	  1	  mg/mL	  in	  PBS,	  and	  Dynamic	  light	  scattering	  
(DLS)	  measurements	  of	  the	  hydrodynamic	  diameters	  of	  PEG-­‐MNP	  dispersions	  were	  
performed	  at	  25	  °C	  using	  a	  ZetaPlus	  Particle	  Size	  Analyzer	  (Brookshaven	  
Instrument,	  NY,	  USA),	  and	  all	  measurements	  were	  repeated	  five	  times.	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2.2.7	  Thermal	  Gravimetric	  Analysis	  (TGA)	  
TGA	  was	  performed	  on	  a	  Q50	  TGA	  thermal	  analyzer	  (TA	  instruments,	  PA,	  
USA).	  Approximately	  8	  mg	  of	  dried	  PEG-­‐MNPs	  were	  heated	  from	  room	  temperature	  
to	  900	  °C	  at	  10	  °/min.	  
	  
2.2.8	  Stability	  of	  the	  PEG-­‐MNPs	  in	  physiological	  media	  
PEG-­‐MNPs	  dispersed	  at	  1	  mg/mL	  in	  PBS,	  DMEM,	  and	  10%	  FBS	  were	  stored	  at	  
room	  temperature	  (r.t.)	  or	  2-­‐5	  °C	  for	  up	  to	  one	  week.	  Stability	  of	  PEG-­‐MNPs	  in	  the	  
physiological	  media	  was	  assessed	  by	  observing	  aggregates	  and	  measuring	  
hydrodynamic	  diameters	  by	  DLS.	  All	  measurements	  were	  repeated	  five	  times.	   	  
	  
2.2.9	  In	  vitro	  cytotoxicity	  
Metastatic	  murine	  breast	  cancer	  cell	  line	  4T1.2-­‐Neu	  was	  cultured	  in	  DMEM	  
supplemented	  with	  10%	  (v/v)	  FBS	  and	  1%	  L-­‐glutamine.	  Cells	  were	  trypsinized	  and	  
seeded	  into	  96-­‐well	  plates	  at	  3,000	  cells/well	  (n=3	  plates,	  12	  wells/concentration)	  
and	  incubated	  overnight.	  PEG-­‐MNPs	  dispersed	  in	  PBS	  were	  added	  to	  each	  well	  with	  
final	  concentrations	  of	  4	  μg/mL	  to	  4	  mg/mL.	  PBS	  and	  10%	  trichloroacetic	  acid	  
(TCA)	  were	  used	  as	  negative	  and	  positive	  controls,	  respectively.	  A	  resazurin-­‐based	  
colorimetric	  assay	  was	  used	  to	  measure	  viability	  of	  cell	  cultures	  [41],	  and	  the	  IC50	  
was	  determined	  as	  the	  midpoint	  between	  control	  groups	  of	  positive	  and	  negative	  
using	  GraphPad	  Prism	  6	  software	  (GraphPad	  Software	  Inc.,	  La	  Jolla,	  CA).	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2.2.10	  Cellular	  uptake	  
To	  investigate	  the	  intracellular	  uptake	  of	  PEG-­‐MNPs,	  4T1.2-­‐Neu	  cells	  were	  
seeded	  in	  12-­‐well	  plates	  at	  3×105	  cells/well	  and	  then	  incubated	  with	  PEG-­‐MNP	  
suspensions	  in	  PBS	  at	  0.3	  mg/mL	  for	  24	  h.	  The	  same	  volume	  of	  the	  PBS	  without	  
PEG-­‐MNPs	  was	  added	  to	  cell	  cultures	  at	  the	  same	  cell	  density	  as	  a	  negative	  control.	  
After	  three	  washes	  with	  PBS,	  the	  cells	  were	  detached	  with	  trypsin	  and	  then	  re-­‐
suspended	  in	  DMEM	  for	  cell	  counting	  using	  a	  hemocytometer.	  To	  measure	  the	  
intracellular	  uptake	  of	  PEG-­‐MNPs,	  the	  cell	  suspensions	  were	  centrifuged	  at	  8,000×g	  
for	  10	  min,	  and	  cell	  pellets	  were	  digested	  in	  30%	  HCl	  at	  70	  °C	  for	  1h	  [42].	  	  PEG-­‐
MNPs	  in	  cells	  were	  quantified	  on	  an	  inductively	  coupled	  plasma	  mass	  spectrometer	  
(ICP-­‐MS)	  (7500a,	  Agilent	  Technologies,	  CA,	  USA)	  for	  iron	  content,	  and	  samples	  
collected	  from	  untreated	  cells	  were	  used	  as	  a	  negative	  control.	  All	  measurements	  
were	  repeated	  four	  times.	  	  
	  
2.2.11	  Tumoral	  uptake	  of	  PEG-­‐MNPs	  
The	  animal	  study	  was	  approved	  by	  the	  Institutional	  Animal	  Care	  and	  Use	  
Committee	  of	  the	  University	  of	  Kansas.	  To	  determine	  the	  dosage	  of	  PEG-­‐MNPs	  used	  
for	  the	  tumoral	  uptake,	  antitumor	  efficacy	  and	  MRI	  experiments,	  PEG-­‐MNPs	  
suspended	  in	  sterile	  saline	  were	  injected	  into	  tumor-­‐free	  female	  Balb/c	  mice	  via	  the	  
tail	  vein	  at	  three	  different	  dosages,	  100,	  50	  and	  20	  mg/kg.	  Body	  weights	  of	  the	  mice	  
were	  recorded	  every	  other	  day,	  and	  the	  animals	  were	  monitored	  for	  toxic	  reactions	  
for	  ten	  days	  after	  the	  injection.	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Female	  Balb/c	  mice	  were	  anesthetized	  with	  2%	  isoflurane	  in	  O2,	  and	  3×106	  
4T1.2-­‐Neu	  breast	  cancer	  cells	  in	  PBS	  were	  injected	  into	  the	  right	  mammary	  fat	  pad	  
under	  the	  second	  nipple	  along	  the	  lateral	  line.	  Tumor	  sizes	  were	  measured	  three	  to	  
four	  times	  weekly	  with	  a	  digital	  caliper	  in	  two	  perpendicular	  dimensions,	  and	  the	  
tumor	  volume	  was	  calculated	  as:	  tumor	  volume	  =	  0.52	  ×	  (width)	  2	  ×	  (length).	  Once	  
tumor	  volumes	  reached	  150	  mm3,	  100	  mg/kg	  of	  PEG-­‐MNPs	  suspended	  in	  sterile	  
saline	  was	  injected	  intravenously	  via	  the	  tail	  vein.	  Animals	  were	  euthanized	  at	  0.5,	  4,	  
24,	  48,	  72	  and	  96	  h	  post	  injection	  (n=3	  per	  time	  point),	  and	  tumors	  were	  excised	  
and	  blood	  samples	  were	  drawn	  into	  EDTA-­‐treated	  vials	  through	  cardiac	  puncture	  
followed	  by	  centrifugation	  for	  5	  minutes	  at	  2,000×g	  to	  collect	  plasma.	  	  Biological	  
samples	  were	  digested	  using	  aqua	  regia	  at	  130	  °C	  for	  1	  h	  and	  diluted	  with	  1%	  HNO3	  
prior	  to	  platinum	  analysis	  by	  ICP-­‐MS.	  	  
	  
2.2.12	  Therapeutic	  efficacy	  
Female	  Balb/c	  mice	  bearing	  4T1.2-­‐Neu	  breast	  tumors	  were	  randomly	  
divided	  into	  four	  groups	  (n=3	  to	  5	  per	  group),	  including	  PEG-­‐MNPs	  plus	  inductive	  
field,	  inductive	  magnetic	  field	  only,	  PEG-­‐MNPs	  only	  and	  untreated	  controls.	  When	  
tumors	  reached	  150	  mm3	  in	  size,	  100	  mg/kg	  of	  PEG-­‐MNPs	  dispersed	  in	  sterile	  saline	  
was	  injected	  via	  the	  tail	  vein.	  After	  24	  h,	  the	  mice	  were	  placed	  under	  anesthesia	  in	  a	  
water-­‐cooled	  magnetic	  induction	  coil	  with	  the	  tumor	  region	  positioned	  in	  the	  
central	  part	  of	  the	  coil.	  An	  inductive	  magnetic	  field	  of	  400	  kHz	  at	  25.6	  kAm-­‐1	  was	  
applied	  for	  5	  min	  for	  two	  consecutive	  days	  using	  a	  SI-­‐7KWHF	  induction	  heater	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(Superior	  Induction	  Company,	  CA,	  USA)	  and	  a	  2.5-­‐cm	  copper	  coil.	  Following	  the	  
inductive	  heating	  treatment,	  tumor	  growth	  was	  monitored	  until	  it	  reached	  an	  
endpoint	  of	  1,500	  mm3.	  
	  
2.2.13	  Magnetic	  Resonance	  Imaging	  (MRI)	  
In	  vivo	  MRI	  was	  performed	  using	  a	  9.4-­‐Tesla	  horizontal	  MR	  system	  (Agilent	  
Technologies,	  Santa	  Clara,	  CA),	  in	  the	  Hoglund	  Brain	  Imaging	  Center	  at	  the	  
University	  of	  Kansas	  Medical	  Center.	  Tumor	  bearing	  mice	  were	  injected	  
intravenously	  with	  PEG-­‐MNPs	  as	  stated	  in	  section	  6.	  T2-­‐weighted	  MR	  images	  (echo	  
times:	  9.3,	  14,	  20,	  30	  and	  40	  ms)	  of	  mouse	  whole	  bodies	  were	  obtained	  at	  
predetermined	  time	  points	  after	  injection.	  MR	  images	  acquired	  from	  animals	  
without	  any	  injections	  were	  used	  as	  controls.	  MR	  images	  were	  processed	  using	  the	  
Stimulate	  software	  [43].	  A	  mono-­‐exponential	  model	  of	  signal	  decay	  was	  applied	  to	  
calculate	  T2	  values	  within	  the	  tumor	  region	  on	  a	  pixel-­‐by-­‐pixel	  basis.	  	  
	  
	   2.3	  Statistical	  analyses	  
Tumor	  size	  ratio	  for	  the	  four	  experimental	  groups	  were	  analyzed	  and	  
expressed	  at	  mean	  ±	  standard	  deviation.	  Statistical	  significance	  was	  determined	  by	  
the	  unpaired	  t-­‐test	  with	  P<	  0.05	  using	  the	  GraphPad	  Prism	  6	  software.	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3.	  Results	  and	  Discussion	  
3.1	  Synthesis	  and	  characterization	  of	  core/shell	  FePt@Fe3O4	  MNPs	  
Co-­‐reduction	  of	  Pt(acac)2	  and	  Fe(CO)5	  ,	  followed	  by	  annealing	  at	  450	  °C	  for	  2	  
hr	  formed	  the	  hard	  FePt	  core.	  Then	  the	  soft	  Fe3O4	  shell	  was	  controllably	  hybridized	  
via	  thermal	  decomposition	  from	  Fe(acac)3	  in	  the	  presence	  of	  oleylamine,	  oleic	  acid	  
and	  1,2-­‐hexadecanediol	  in	  phenyl	  ether.	  	  Transmission	  electron	  microscopy	  (TEM)	  
images	  of	  the	  core/shell	  FePt@Fe3O4	  MNPs	  (Figure	  1A)	  clearly	  revealed	  the	  
spherical	  shape	  of	  the	  core/shell	  MNPs,	  and	  the	  detailed	  structure	  of	  the	  core/shell	  
structure	  was	  characterized	  by	  the	  high-­‐resolution	  TEM	  (HRTEM)	  in	  the	  inset	  that	  
shows	  the	  coating	  of	  5-­‐nm	  Fe3O4	  (lighter	  ring)	  on	  the	  initial	  12-­‐nm	  FePt	  core	  (darker	  
region)	  to	  render	  a	  homogenous	  22-­‐nm	  core/shell	  structure.	  The	  highly	  uniform	  
size	  distribution	  of	  the	  core/shell	  MNPs	  in	  Figure	  1A	  confirmed	  that	  the	  MNPs	  
formed	  is	  solely	  the	  core/shell	  FePt@Fe3O4	  and	  not	  a	  mixture	  of	  FePt	  and	  Fe3O4	  
MNPs	  with	  much	  smaller	  sizes.	  	  
The	  exchange-­‐coupled	  behavior	  of	  the	  FePt@Fe3O4	  MNPs	  was	  compared	  
with	  two	  different	  MNPs	  coupling	  schemes,	  including	  randomly	  mixed	  hard	  and	  soft	  
MNPs	  and	  aggregated	  hard	  and	  soft	  MNPs.	  In	  comparison,	  the	  aggregated	  FePt	  and	  
Fe3O4	  MNPs	  were	  prepared	  by	  removing	  the	  oleic	  acid	  used	  to	  isolate	  and	  stabilize	  
the	  MNPs	  during	  the	  synthesis.	  The	  M-­‐H	  hysteresis	  measurement	  of	  the	  MNPs	  
conducted	  with	  a	  superconducting	  quantum	  interference	  device	  (Figure	  1B)	  shows	  
that	  the	  coercivity	  values	  (Hc)	  for	  Fe3O4	  and	  FePt	  MNPs	  are	  50	  Oe	  and	  800	  Oe	  at	  
ambient	  temperature,	  respectively.	  Several	  research	  groups	  have	  investigated	  the	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influence	  of	  annealing	  temperature	  on	  the	  microstructures	  and	  magnetic	  properties	  
of	  the	  FePt	  MNPs	  [44-­‐47].	  It	  has	  been	  shown	  that	  higher	  annealing	  temperature	  
could	  provide	  increased	  magnetic	  coercivities.	  For	  example,	  conversion	  of	  the	  soft	  
face	  center	  cubic	  (fcc)	  phase	  FePt	  with	  a	  single	  SiO2	  [44]	  or	  a	  TaOx	  [45]	  capping	  layer	  
to	  the	  hard	  face	  center	  tetragonal	  (fct)	  phase	  have	  been	  found	  after	  annealing	  at	  400	  
°C,	  and	  a	  highest	  coercivity	  (4.2	  kOe)of	  FePt/TaOx	  was	  reached	  as	  the	  annealing	  
temperature	  increased	  to	  550	  °C	  [45].	  However,	  further	  increases	  in	  annealing	  
temperature	  above	  580	  -­‐	  600	  °C	  could	  cause	  severe	  MNPs	  aggregation,	  increasing	  
the	  particles	  size	  and	  size	  distribution	  [45,	  47].	  In	  this	  study,	  annealing	  was	  
performed	  at	  450	  °	  and	  a	  partial	  conversion	  from	  chemically	  disordered	  face-­‐
centered	  cubic	  (fcc)	  into	  the	  ordered	  face-­‐centered	  tetragonal	  (fct)	  structure	  was	  
achieved.	  The	  coercivity	  of	  our	  FePt	  MNPs	  is	  800	  Oe,	  which	  is	  consistent	  with	  the	  
data	  reported	  by	  Kang	  et	  al	  [48].	  Comparatively,	  the	  core/shell	  FePt@Fe3O4	  MNPs	  
have	  an	  Hc	  of	  600	  Oe	  with	  a	  single-­‐phase-­‐like	  loop	  due	  to	  the	  smooth	  magnetization	  
transition,	  indicating	  the	  adjacent	  moments	  effectively	  aligning	  with	  each	  other	  due	  
to	  the	  magnetic	  exchange	  coupling	  at	  the	  interface.	  In	  addition,	  a	  uniform	  size	  
dispersion	  of	  the	  core/shell	  MNPs	  without	  any	  particle	  aggregation	  was	  illustrated	  
in	  Figure	  1A.	  






Figure	  1.	  Nanostructures	  and	  magnetic	  characteristics	  of	  exchange	  coupled	  MNPs.	  
(A)	  FePt@Fe3O4	  (core/shell)	  MNPs;	  (B)	  The	  magnetic	  hysteresis	  loop	  of	  hard,	  soft	  
and	  core/shell	  magnetic	  MNPs.	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The	  effectiveness	  of	  hybrid	  FePt@Fe3O4	  magnetically	  coupled	  nanoparticles	  
as	  an	  MRI	  contrast	  agent	  was	  examined	  by	  measuring	  the	  dependence	  of	  the	  
longitudinal	  (1/T1	  =	  R1)	  and	  transverse	  (1/T2	  =	  R2)	  relaxation	  rate	  constant	  of	  
FePt@Fe3O4	  MNPs	  solution.	  First,	  we	  measured	  R1	  and	  R2	  of	  the	  soft	  Fe3O4	  MNPs,	  
hard	  FePt	  MNPs,	  1:1	  mixture	  and	  core/shell	  FePt@Fe3O4	  MNPs	  as	  a	  function	  of	  MNP	  
concentration	  using	  the	  inversion	  recovery	  and	  spin	  echo	  pulse	  sequences,	  
respectively,	  on	  a	  9.4	  T	  nuclear	  magnetic	  resonance	  (NMR)	  spectrometer	  [39]	  
(Figure	  2A	  and	  B).	  	  The	  relaxivities	  (r1	  (or	  2))	  were	  determined	  from	  the	  slope	  of	  the	  
plot	  of	  R1	  and	  R2	  versus	  MNP	  concentration.	  	  The	  values	  for	  r1	  equals	  2.0,	  0.2	  and	  1.2	  
Hz	  ml	  mg-­‐1	  for	  Fe3O4	  MNPs,	  FePt	  MNPs	  and	  a	  1:1	  mixture	  MNPs,	  respectively,	  and	  
the	  values	  for	  r2	  equals	  20.1,	  3.6	  and	  17.4	  Hz	  ml	  mg-­‐1	  for	  Fe3O4	  MNPs,	  FePt	  MNPs	  
and	  the	  1:1	  mixture	  MNPs,	  respectively.	  	  For	  FePt@Fe3O4,	  r1	  equals	  4.4	  Hz	  ml	  mg-­‐1	  
and	  r2	  equals	  99.2	  Hz	  ml	  mg-­‐1.	  The	  larger	  relaxivity	  of	  the	  FePt@Fe3O4	  MNPs	  relative	  
to	  Fe3O4	  and	  FePt	  MNPs	  is	  hypothesized	  to	  stem	  from	  the	  favorable	  combination	  of	  
coercively	  and	  saturation	  magnetization	  of	  the	  Fe3O4	  shell	  and	  the	  FePt	  core	  
structure.	  Comparing	  R1	  and	  R2	  of	  Fe3O4	  MNPs,	  FePt	  MNPs,	  the	  1:1	  mixture	  of	  Fe3O4:	  
FePt	  MNPs,	  a	  1:	  1	  mixture	  prepared	  by	  ligand	  exchange	  and	  core/shell	  FePt@Fe3O4	  
MNPs	  at	  1	  mg/ml,	  the	  FePt@Fe3O4	  MNPs	  have	  the	  largest	  effect	  upon	  the	  relaxation	  
rate	  constant	  (Figure	  2C	  and	  D),	  indicating	  their	  enhanced	  efficiency	  as	  contrast	  
agents	  for	  either	  T1-­‐weighted	  or	  T2-­‐weighted	  MRI	  to	  promote	  spin-­‐lattice	  relaxation.	  
Therefore,	  the	  core/shell	  FePt@Fe3O4	  MNPs	  were	  beneficial	  in	  both	  high	  oxidation	  
resistance	  and	  maximum	  magnetic	  coupling	  to	  surrounding	  spins.	  





Figure	  2.	  MNP	  relaxivity	  in	  hexane.	  (A)	  R1	  versus	  MNPs	  concentration.	  	  (B)	  R2	  
versus	  MNPs	  concentration.	  	  Filled	  circles	  are	  data	  points	  for	  Fe3O4	  (green),	  FePt	  
(purple),	  1:1	  mixture	  of	  Fe3O4	  and	  FePt	  (blue)	  and	  Core/shell	  (red).	  	  Lines	  are	  linear	  
fits	  of	  data	  to	  determine	  relaxivity.	  	  (C)	  R1	  and	  (D)	  R2	  at	  1	  mg/ml	  for	  Fe3O4	  (green),	  
FePt	  (purple),	  1:1	  mixture	  of	  Fe3O4:FePt	  (blue),	  1:1	  mixture	  of	  Fe3O4:FePt	  with	  
ligands	  exchanged	  by	  the	  addition	  of	  hexanoic	  acid	  (dark	  blue)	  and	  Core/shell	  (red).	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During	  a	  local	  hyperthermia	  treatment,	  the	  MNPs	  dispersed	  in	  the	  biological	  
fluids	  or	  tumor	  tissues	  are	  subjected	  to	  a	  magnetic	  alternating	  current	  field	  and	  then	  
induce	  a	  gradual	  alignment	  of	  the	  magnetic	  moments	  towards	  the	  external	  field.	  	  
When	  the	  magnetic	  moments	  of	  MNPs	  relax	  to	  their	  equilibrium	  orientation	  states,	  
the	  magnetic	  energy	  is	  dissipated	  and	  converted	  into	  heating	  effects	  that	  are	  related	  
to	  the	  maximum	  power	  loss	  during	  the	  magnetization	  reversal	  process.	  Specific	  
absorption	  rate	  (SAR)	  is	  a	  key	  parameter	  to	  describe	  the	  energy	  amount	  converted	  
into	  thermal	  energy	  material	  per	  gram	  [49].	  In	  order	  to	  achieve	  efficient	  magnetic	  
hyperthermia,	  the	  MNPs	  should	  heat	  rapidly	  within	  a	  short	  period	  of	  treatment	  
time.	  Therefore,	  a	  maximized	  SAR	  is	  required	  as	  MNPs	  possessing	  the	  high	  SAR	  
value	  enable	  a	  smaller	  injection	  dose	  due	  to	  their	  excellent	  heat-­‐generation	  
capability,	  thus	  reducing	  the	  toxic	  effects.	  
The	  SAR	  values	  of	  core–shell	  nanoparticles	  were	  compared	  with	  single-­‐
component	  magnetic	  MNPs,	  randomly	  mixed	  MNPs	  and	  aggregated	  MNPs	  (Figure	  
3A).	  While	  the	  SARs	  of	  single-­‐component	  MNPs	  range	  from	  20	  (FePt	  MNPs)	  to	  300	  
Wg1	  (Fe3O4	  MNPs),	  the	  SAR	  of	  core–shell	  MNPs	  was	  of	  550	  Wg-­‐1.	  The	  significantly	  
increased	  SAR	  value	  results	  from	  the	  mutual	  coupling	  between	  the	  magnetically	  
hard	  (FePt)	  and	  soft	  (Fe3O4)	  materials,	  which	  enhances	  the	  efficiency	  of	  magnetic	  
thermal	  induction	  and	  reduces	  the	  required	  dose	  of	  MNPs	  for	  hyperthermia.	  The	  
heating	  effect	  depends	  on	  the	  particle	  geometry	  as	  well	  as	  the	  anisotropy.	  The	  SAR	  
of	  core–shell	  nanoparticles	  can	  be	  precisely	  tuned	  by	  varying	  the	  combination	  of	  the	  
differently	  sized	  core	  and	  shell	  components.	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Using	  an	  adopted	  theoretical	  model,	  we	  then	  calculated	  SAR	  values	  as	  a	  
function	  of	  particle	  size	  at	  varying	  polydispersity	  indices	  (σ).	  During	  the	  calculation,	  
the	  values	  of	  the	  magnetic	  anisotropy	  constant	  and	  the	  saturation	  magnetization	  of	  
FePt	  MNPs	  (Md=1140	  kA/m,	  K=206	  kJ/m3)	  and	  Fe3O4	  MNPs	  (Md=446	  kA/m,	  K=9	  
kJ/m3)	  were	  taken	  from	  the	  published	  data	  [50].	  The	  K	  values	  have	  been	  reported	  to	  
vary	  from	  206	  to	  7000	  kJ/m3	  for	  FePt	  MNPs	  with	  the	  fcc	  structure	  and	  fct	  structure	  
after	  annealing	  at	  500	  °C	  for	  5	  h	  [51].	  As	  our	  FePt	  MNPs	  were	  annealed	  at	  a	  lower	  
temperature	  and	  a	  shorter	  time,	  the	  un-­‐annealed	  value	  was	  used	  in	  the	  theoretical	  
calculation.	  The	  calculated	  SAR	  of	  both	  MNP	  types	  increased	  with	  particle	  sizes	  up	  
to	  a	  maximum	  of	  183	  W/g	  for	  16.2-­‐nm	  FePt	  MNPs	  and	  132	  W/g	  for	  18.3-­‐nm	  Fe3O4	  
MNPs.	  Single-­‐domain	  superparamagnetic	  nanoparticles	  primarily	  generate	  heat	  in	  
an	  alternating	  field	  by	  a	  relaxation	  losses	  mechanism,	  which	  is	  collectively	  ruled	  by	  
two	  distinct	  modes,	  Néel	  relaxation	  and	  Brownian	  relaxation	  [19,	  52].	  Néel	  
relaxation	  refers	  to	  an	  internal	  magnetic	  moment	  vector	  rotation	  along	  the	  crystal	  
easy	  axis,	  and	  the	  power	  loss	  corresponding	  to	  this	  process	  is	  exponentially	  
proportional	  to	  the	  magnetic	  anisotropy	  constant	  and	  the	  MNPs	  volume.	  In	  the	  
Brownian	  mode,	  however,	  MNPs	  undergo	  oscillation	  as	  a	  whole	  towards	  the	  
external	  field,	  and	  the	  corresponding	  power	  loss	  correlates	  linearly	  with	  the	  
hydrodynamic	  volume	  of	  the	  MNPs.	  Due	  to	  the	  exponential	  correlation	  between	  the	  
relaxation	  time	  versus	  the	  product	  of	  the	  magnetic	  anisotropy	  constant	  and	  the	  
particle	  size	  in	  the	  Néel	  mode,	  the	  Néel	  relaxation	  typically	  dominates	  the	  effective	  
relaxation	  process	  for	  the	  MNPs	  with	  smaller	  size[19].	  In	  our	  study,	  the	  optimal	  size	  
is	  16.2	  nm	  for	  FePt	  MNPs	  and18.3	  nm	  for	  Fe3O4	  MNPs	  (Figure	  3B).	  Beyond	  this	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point,	  the	  dominant	  relaxation	  process	  changed	  to	  the	  Brownian	  relaxation,	  which	  is	  
independent	  of	  the	  magnetic	  anisotropy	  and	  only	  relies	  on	  the	  particle	  size.	  Size	  
distribution	  of	  the	  MNPs	  also	  appeared	  to	  play	  a	  critical	  role	  to	  achieve	  high	  SAR.	  As	  
shown	  in	  Figure	  2B,	  when	  the	  polydispersity	  index	  (σ)	  increased	  from	  zero	  to	  40%,	  
the	  SAR	  values	  decreased	  accordingly	  by	  32.74	  %	  for	  FePt	  MNPs	  and	  62.17%	  for	  
Fe3O4	  MNPs.	  We	  have	  also	  observed	  that	  the	  measured	  SAR	  value	  of	  FePt	  MNPs	  is	  
much	  lower	  than	  the	  calculated	  value	  using	  the	  theoretical	  model,	  probably	  due	  to	  
the	  achieved	  partial	  fct	  sturcture	  using	  the	  relatively	  lower	  annealing	  temperatures	  
during	  the	  synthesis.




Figure	  3.	  Hyperthermia	  characteristics	  of	  exchange	  coupled	  MNPs;	  (A)	  Magnetic	  
field	  dependence	  of	  Specific	  Absorption	  Rate	  (SAR)	  for	  FePt	  hard	  MNPs,	  Fe3O4	  soft	  
magnetic	  MNPs,	  1:1	  mixed	  FePt	  and	  Fe3O4	  MNPs	  before	  ligand	  exchange,	  1:1	  mixed	  
FePt	  and	  Fe3O4	  MNPs	  after	  ligand	  exchange	  and	  core/shell	  FePt@Fe3O4	  MNPs;	  (B)	  
Calculated	  FePt	  and	  Fe3O4	  MNP	  diameter	  dependence	  of	  SAR	  (field	  amplitude:	  5000	  
Am-­‐1;	  frequency:	  366	  kHz).	  The	  σ	  corresponds	  to	  the	  particle	  distribution	  parameter	  
in	  the	  lognormal	  distribution	  used	  in	  the	  calculation	  to	  simulate	  the	  effect	  of	  
polydispersity	  of	  the	  sample.	  The	  arrows	  in	  the	  Figure	  2(B)	  indicate	  that	  σ	  values	  




















































	   114	  
3.2	  Surface	  PEGylation	  and	  characterization	  of	  core/shell	  FePt@Fe3O4	  MNPs	  	  
Colloidal	  stability	  and	  biocompatibility	  are	  two	  essential	  requirements	  for	  
clinical	  application	  of	  exchange-­‐coupled	  magnetic	  nanoparticles.	  The	  core/shell	  
FePt@Fe3O4	  MNPs	  synthesized	  in	  organic	  solvent	  and	  coated	  with	  oleic	  acid	  are	  not	  
easily	  dispersed	  in	  water.	  These	  as-­‐made	  MNPs	  are	  hydrophobic	  and	  they	  are	  
subject	  to	  rapid	  elimination	  from	  the	  blood	  circulation	  before	  reaching	  tumor	  sites	  
by	  macrophages	  of	  the	  mononuclear	  phagocyte	  system.	  Modification	  of	  the	  
core/shell	  FePt@Fe3O4	  MNPs	  was	  achieved	  by	  exchanging	  oleic	  acid	  with	  
hydrophilic	  PEG	  molecules	  using	  silane-­‐PEG,	  and	  the	  success	  of	  PEGylation	  was	  
confirmed	  by	  FTIR.	  The	  three	  FTIR	  peaks	  resolved	  between	  840	  and	  1040	  cm-­‐1	  in	  
the	  purified	  PEG-­‐MNPs	  dry	  power	  (Figure	  4)	  were	  assigned	  to	  the	  Si-­‐O-­‐Fe	  
stretching.	  The	  peaks	  at	  1100	  cm-­‐1	  and	  1360	  cm-­‐1	  corresponded	  to	  the	  ether	  group	  
C-­‐O-­‐C	  stretch	  band	  and	  the	  vibration	  band,	  respectively.	  Detection	  of	  these	  
characteristic	  peaks	  confirmed	  the	  presence	  of	  a	  silane-­‐PEG	  coating	  on	  the	  surface	  
of	  magnetic	  nanoparticles.	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The	  weight	  percentage	  of	  silane-­‐PEG	  was	  estimated	  to	  be	  21.34%	  using	  
thermal	  gravimetric	  analysis	  (TGA)	  (Figure	  5),	  based	  on	  a	  21.34%	  mass	  loss	  from	  
17.28	  to	  455.01	  °C.	  In	  addition,	  the	  longitudinal	  relaxivity	  value	  for	  PEG-­‐MNPs	  was	  
determined	  to	  be	  0.2084	  mL	  (s-­‐1)(mg-­‐1)	  with	  a	  good	  linear	  correlation	  (R2	  =	  0.99629)	  
(Figure	  6).	  





Figure	  5.	  Thermogravimetric	  analysis	  of	  the	  PEG-­‐MNPs









Figure	  6.	  1/T1	  values	  measured	  by	  NMR	  as	  a	  function	  of	  the	  PEG-­‐MNPs	  
concentrations	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PEGylated	  FePt@Fe3O4	  MNPs	  were	  well	  dispersed	  in	  aqueous	  solutions	  with	  
a	  hydrodynamic	  diameter	  of	  25.9	  ±	  2.8	  nm	  and	  a	  narrow	  colloid	  size	  distribution	  
(Figure	  7).	  	  






Figure	  7.	  DLS	  of	  the	  freshly	  prepared	  PEG-­‐MNPs	  in	  PBS	  at	  25o	  C	  (size	  distribution	  in	  
number).	  Hydrodynamic	  diameter=	  25.9	  ±	  2.8	  nm.	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The	  stability	  of	  monodisperse	  PEG-­‐MNPs	  was	  investigated	  in	  PBS,	  DMEM	  
with	  10%	  (v/v)	  FBS	  and	  PBS	  with	  10%	  (v/v)	  FBS,	  at	  both	  room	  temperature	  and	  
refrigerated	  temperature	  for	  a	  week.	  Although	  hydrodynamic	  diameters	  of	  all	  six	  of	  
the	  PEG-­‐MNPs	  dispersions	  increased	  (Table1),	  from	  9.26	  %	  in	  PBS	  at	  4	  °C	  to	  29.7%	  
in	  DMEM	  at	  room	  temperature,	  no	  agglomeration	  was	  observed	  during	  this	  period	  
of	  time	  (Figure	  8),	  indicating	  high	  colloidal	  stability	  due	  to	  the	  steric	  repulsion	  
between	  the	  PEG	  chains.	  






Table	  1.	  DLS	  measurements	  of	  PEG-­‐MNP	  dispersion	  stored	  in	  physiological	  media	  
for	  one	  week	  (Size	  of	  freshly	  prepared	  PEG-­‐MNPs:	  25.9	  ±	  2.8	  nm).	  
	   2-­‐5	  °C,	  nm	   r.t.,	  nm	  
PBS	   28.3	  ±	  3.2	   31.2	  ±	  3.3	  
DMEM	   30.3	  ±	  3.0	   33.6	  ±	  3.2	  
10%	  FBS	   29.9	  ±	  3.3	   31.3	  ±	  3.2	  
	  









Figure	  8.	  PEG-­‐MNP	  dispersion	  (1	  mg/mL)	  in	  PBS,	  DMEM,	  and	  10%	  FBS	  stored	  for	  
one	  week	  at	  room	  temperature	  (left)	  and	  4	  o	  C	  (right)	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3.3	  Intracellular	  uptake	  and	  in	  vitro	  cytotoxicity	  of	  PEG-­‐MNPs	  
The	  PEG-­‐MNPs	  had	  low	  toxicity	  and	  high	  uptake	  in	  cells.	  The	  IC50	  of	  silane-­‐
PEG-­‐coated	  was	  determined	  as	  0.487	  ±	  0.073	  mg/mL	  in	  murine	  breast	  cancer	  4T1.2	  
Neu	  cells,	  and	  the	  cells	  were	  approximately	  85%	  to	  100%	  viable	  at	  the	  
concentrations	  of	  4	  μg/mL	  to	  100	  μg/mL	  after	  incubation	  for	  72	  h	  (Figure	  9A).	  The	  
ICP-­‐MS	  iron	  analysis	  of	  digested	  cell	  pellets	  after	  a	  24-­‐h	  PEG-­‐MNPs	  treatment	  
demonstrated	  significant	  intracellular	  uptake	  of	  PEG-­‐MNPs	  with	  0.95	  ±	  0.21	  pg/cell	  
(Figure	  9B),	  which	  is	  probably	  due	  to	  the	  enhanced	  nanoparticles	  internalization	  of	  
the	  particles	  provided	  by	  the	  PEG	  chain	  [53].	  	  






Figure	  9.	  (A)	  Effect	  of	  the	  PEG-­‐MNPs	  on	  the	  proliferation	  of	  murine	  breast	  cancer	  
4T1.2-­‐Neu	  cells.	  After	  72-­‐h	  incubation,	  the	  relative	  number	  of	  the	  viable	  cells	  was	  
determined	  by	  a	  resazurin	  assay.	  IC50=0.487	  ±	  0.073	  mg/mL;	  (B)	  Intracellular	  
uptake	  of	  the	  PEG-­‐MNPs	  by	  4T1.2-­‐Neu	  cells	  after	  24-­‐h	  incubation	  at	  the	  IC50	  
concentration.	  (Iron	  analysis	  by	  ICP-­‐MS:	  detection	  limits=3.79	  ppb;	  R2=0.9982)	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3.4	  Tumor	  accumulation	  of	  PEG-­‐MNPs	  
Healthy	  Balb/c	  mice	  were	  dose	  escalated	  by	  i.v.	  administration	  of	  PEG-­‐MNPs	  
and	  monitored	  for	  toxic	  reactions	  for	  up	  to	  ten	  days.	  All	  of	  the	  mice	  remained	  in	  
good	  condition,	  with	  body	  scores	  above	  2.5	  and	  body	  weight	  losses	  less	  than	  20%	  
(Figure	  10).	  No	  toxic	  reactions	  including	  lethargy,	  paralysis,	  orrespiratory	  
depression	  were	  observed	  during	  the	  study.	  Therefore,	  a	  dosage	  of	  100	  mg/kg	  was	  
chosen	  for	  subsequent	  animal	  experiments.	  	  







Figure	  10.	  Balb/c	  mice	  were	  intravenously	  injected	  with	  100,	  50	  and	  20	  mg/kg	  of	  
PEG-­‐MNPs	  via	  the	  tail	  vein.	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It	  has	  been	  reported	  that	  nano-­‐sized	  bare	  SPIONs	  are	  susceptible	  to	  
opsonization	  by	  plasma	  proteins,	  followed	  by	  rapid	  clearance	  from	  systemic	  
circulation	  by	  macrophages	  of	  the	  reticuloendothelial	  system[54]	  .	  For	  example,	  the	  
plasma	  half-­‐life	  of	  SPIONs	  sized	  at	  40	  nm	  was	  less	  than	  10	  min	  after	  intravenous	  
injection,	  and	  approximately	  90%	  of	  the	  injected	  particles	  accumulated	  in	  
mononuclear	  phagocyte	  system	  organs	  including	  the	  liver,	  spleen	  and	  bone	  marrow	  
[55].	  Therefore,	  the	  amount	  of	  MNPs	  that	  reached	  the	  target	  tissues	  was	  
substantially	  reduced,	  limiting	  their	  biomedical	  applications.	  In	  this	  study,	  the	  
surface	  of	  as-­‐synthesized	  core/shell	  MNPs	  was	  grafted	  with	  hydrophilic	  and	  steric	  
PEG	  chains	  to	  minimize	  their	  clearance	  by	  macrophages	  [40]	  and	  thus	  prolong	  their	  
retention	  time.	  Figure	  11	  shows	  that	  PEG-­‐MNPs	  exhibited	  a	  half-­‐life	  of	  1.35	  h	  
(Figure	  11A)	  after	  intravenous	  injection	  into	  tumor-­‐bearing	  Balb/c	  mice.	  
Pharmacokinetic	  analysis	  of	  PEG-­‐MNPs	  was	  performed	  by	  fitting	  data	  (0	  to	  24	  h)	  to	  
a	  two-­‐compartment	  model	  (Table	  2).	  The	  plasma	  PEG-­‐MNPs	  concentration	  
decreased	  by	  98.24	  ±	  0.33	  %	  in	  the	  first	  4	  h	  as	  PEG-­‐MNPs	  distributed	  from	  the	  
central	  compartment	  to	  peripheral	  compartments,	  followed	  by	  slow	  clearance	  in	  the	  
beta	  phase.	  Long-­‐circulating	  PEG-­‐MNPs	  gradually	  accumulated	  in	  the	  leaky	  
vasculature	  of	  the	  breast	  tumor	  region	  from	  4	  h	  to	  96	  h	  (Figure	  11B,	  Table	  3)	  due	  
the	  enhanced	  permeability	  and	  retention	  effect,	  achieving	  enhanced	  tumor	  delivery.	  




Figure	  11.	  After	  intravenous	  administration,	  PEG-­‐MNPs	  were	  (A)	  cleared	  from	  the	  
systemic	  circulation,	  and	  (B)	  accumulated	  in	  the	  4T1.2-­‐Neu	  breast	  tumors.	  N=3	  per	  
time	  point.	  (Platinum	  analysis	  by	  ICP-­‐MS:	  detection	  limits=10.01	  ppt;	  r2=0.9998)	  

















































Table	  2.	  Pharmacokinetics	  of	  2.5-­‐mg	  i.v.	  PEG-­‐MNPs	  in	  Balb/c	  mice	  with	  4T1.2-­‐Neu	  











Parameters	  (unit)	   PEG-­‐MNPs	  i.v.	  
Vd	  (mL)	   0.768	  ±	  0.489	  
Cp0	  (mg	  mL-­‐1)	   131.609	  ±	  51.074	  
AUC	  0-­‐24	  h	  (mg	  h	  mL-­‐1)	   154.467	  ±	  31.428	  
Cl	  (ml	  h-­‐1)	   0.017	  ±	  0.003	  
k	  (h-­‐1)	  (β)	   0.033	  ±	  0.026	  












Parameters	  (unit)	   PEG-­‐MNPs	  i.v.	  
AUC	  0-­‐96	  h	  (mg	  h	  mL-­‐1)	   58.870	  ±	  12.953	  
Cmax	  (μg	  mg-­‐1)	   0.932	  ±	  0.279	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3.5	  PEG-­‐MNPs-­‐mediated	  hyperthermia	  and	  MR	  imaging	  
Hyperthermia	  may	  cause	  the	  shrinkage	  or	  sometimes	  a	  complete	  eradication	  
of	  tumors	  by	  killing	  cancer	  cells	  and	  damaging	  proteins	  within	  the	  cancer	  cells	  [20].	  
The	  effectiveness	  of	  hyperthermia	  treatment	  mainly	  depends	  on	  the	  degree	  of	  
temperature	  increase	  during	  a	  defined	  length	  of	  treatment.	  The	  excellent	  thermal	  
energy	  transfer	  capability	  of	  the	  PEG-­‐MNPs	  was	  demonstrated	  in	  a	  phantom	  test	  
using	  PEG-­‐MNPs	  in	  saline	  solution	  (25	  mg/mL).	  After	  applying	  an	  inductive	  
magnetic	  field	  for	  5	  min,	  the	  temperature	  of	  the	  PEG-­‐MNP	  solution	  increased	  from	  
22.5	  °C	  to	  64.5	  °C.	  For	  the	  animals	  that	  received	  PEG-­‐MNPs	  plus	  inductive	  magnetic	  
field,	  the	  tumor	  size	  increased	  2.32	  fold	  two	  weeks	  after	  the	  treatment	  (Figure	  12).	  
In	  comparison,	  for	  the	  animals	  in	  the	  saline	  group,	  PEG-­‐MNPs	  only	  group,	  and	  
inductive	  magnetic	  field	  only	  group,	  the	  tumor	  size	  increased	  8.66,	  12.96	  and	  8.05	  
fold,	  respectively	  in	  the	  same	  time	  period.	  PEG-­‐MNPs-­‐mediated	  hyperthermia	  
demonstrated	  a	  significantly	  enhanced	  inhibition	  of	  the	  tumor	  progression,	  which	  is	  
likely	  due	  to	  the	  fact	  that	  PEG-­‐MNPs	  in	  the	  tumor	  region	  induced	  efficient	  magnetic-­‐
heat	  energy	  transfer	  to	  albate	  the	  cancer	  cells,	  achieving	  improved	  local	  tumor	  
control.	  	  	  





Figure	  12.	  Tumor	  Volume	  (V/V	  initial)	  after	  treatment,	  3	  ≤	  N	  ≤	  5.	  PEG-­‐MNPs	  were	  
injected	  intravenously	  once	  tumors	  reached	  approximately	  150	  mm3,	  and	  an	  
inductive	  magnetic	  field	  of	  400	  kHz	  at	  25.6	  kAm-­‐1	  was	  applied	  for	  5	  min	  in	  the	  
following	  two	  days.	  	  Tumor	  inhibition	  was	  observed	  in	  the	  mice	  treated	  with	  PEG-­‐
MNPs	  hyperthermia.	  	  (*	  p<0.05,	  **	  p<0.01,	  and	  ***	  p<0.001).	  Inset	  shows	  a	  mouse	  
with	  a	  150	  mm3-­‐sized	  breast	  tumor	  (red	  circle)	  in	  a	  water-­‐cooled	  coil	  receiving	  
hyperthermia	  treatment.	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The	  potential	  application	  of	  PEG-­‐MNPs	  as	  an	  MRI	  contrast	  agent	  for	  cancer	  
diagnosis	  was	  evaluated	  by	  T2	  –weighted	  MRI	  on	  Balb/c	  mice	  implanted	  with	  4T1.2-­‐
Neu	  breast	  tumors.	  Mice	  injected	  with	  the	  i.v.	  PEG-­‐MNPs	  were	  randomly	  divided	  
into	  three	  groups:	  	  MRI	  at	  24	  h	  post-­‐injection	  (n=3),	  48	  h	  post-­‐injection	  (n=2),	  and	  
48	  h	  post-­‐injection	  with	  hyperthermia	  at	  24	  h	  post-­‐injection	  (n=3).	  T2-­‐weighted	  MR	  
images	  of	  animals	  in	  all	  three	  of	  the	  PEG-­‐MNP	  injected	  groups	  showed	  significant	  
signal	  reduction	  within	  the	  tumor	  region	  when	  compared	  to	  the	  untreated	  animals	  
(Figure	  13).	  	  Region	  of	  interest	  analysis	  showed	  T2	  values	  in	  the	  tumor	  were	  
remarkably	  lower	  (Table	  4)	  in	  animals	  with	  PEG-­‐MNPs	  injection	  compared	  with	  
controls.	  	  







Figure	  13.	  Representative	  axial	  T2-­‐weighted	  spin-­‐echo	  MR	  images	  of	  Balb/c	  mice	  
with	  4T1.2-­‐Neu	  breast	  tumors	  (circled)	  without	  PEG-­‐MNPs	  injection,	  and	  at	  24	  and	  
48	  h	  after	  PEG-­‐MNPs	  injection	  (i.v.).	  Significant	  signal	  decrease	  was	  observed	  in	  the	  
tumor	  region	  at	  24	  h	  and	  48	  h	  post-­‐injection.











Untreated	   37.07	   13.97	  
24	  h	  post-­‐injection	   20.77	   0.34	  
48	  h	  post-­‐injection	   26.65	   1.28	  
48	  h	  post-­‐injection	  with	  
hyperthermia	  
31.21	   2.61	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4.	  Conclusions	  
In	  conclusion,	  we	  developed	  formulations	  of	  biocompatible	  core/shell	  
exchanged-­‐coupled	  magnetic	  nanoparticles	  as	  a	  novel	  theranostics	  agent	  through	  
surface-­‐PEGylation.	  PEG-­‐MNPs-­‐induced	  hyperthermia	  in	  a	  breast	  orthotopic	  tumor	  
model	  in	  immune-­‐competent	  animals	  demonstrated	  the	  enhanced	  anti-­‐tumor	  
effectiveness	  due	  to	  the	  high	  magnetic-­‐thermal	  energy	  transfer	  capability	  of	  PEG-­‐
MNPs.	  In	  addition,	  augmented	  MRI	  contrast	  in	  the	  tumor	  region	  suggested	  
application	  potential	  of	  PEG-­‐MNPs	  for	  cancer	  diagnosis.	  Our	  further	  studies	  will	  
focus	  on	  developing	  targeted	  core/shell	  PEG-­‐MNPs	  to	  expand	  the	  scope	  of	  their	  bio-­‐
application	  in	  theranostics.	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1.	  Introduction	  
Receptor	  tyrosine	  kinases	  (RTKs)	  are	  a	  family	  of	  transmembrane	  cell	  surface	  
receptors	  for	  diverse	  cell-­‐signaling	  molecules	  such	  as	  cytokines,	  growth	  factors,	  and	  
hormones.	  Functionally,	  RTKs	  regulate	  many	  critical	  cellular	  processes,	  including	  
cell	  growth,	  differentiation	  and	  angiogenesis.	  Dysregulation	  of	  RTK	  activity	  is	  
associated	  with	  several	  tumorigenic	  pathways,	  including	  the	  stimulation	  of	  
malignant	  transformation,	  angiogenesis	  and	  tumor	  growth.	  RTK	  overexpression	  has	  
been	  observed	  in	  a	  wide	  variety	  of	  highly	  invasive	  human	  tumors,	  including	  head	  
and	  neck	  squamous	  cell	  carcinomas	  [1],	  medullary	  thyroid	  cancer	  (MTC)	  [2-­‐5],	  
glioblastoma	  multiforme	  (GBM)	  [6-­‐8]	  and	  non	  small	  cell	  lung	  cancer	  (NSCLC)	  [9,	  
10].	  	  
Dysregulation	  of	  RTKs	  can	  be	  activated	  via	  multiple	  mechanisms	  such	  as	  
gene	  mutations,	  overexpression	  of	  ligands,	  and	  receptor	  overexpression.	  Aberrant	  
activation	  of	  mesenchymal-­‐epithelial	  transition	  factor	  (MET)	  [11-­‐15]	  and	  vascular	  
endothelial	  growth	  factor	  receptor	  2	  (VEGFR-­‐2)	  [16-­‐18]	  signaling	  pathways	  are	  two	  
main	  contributors	  to	  tumor	  angiogenesis,	  pathogenesis,	  and	  progression.	  These	  
pathways	  also	  promote	  tumor	  malignancy	  and	  invasion	  with	  poor	  prognostic	  
parameters	  and	  poor	  survival	  [19,	  20].	  In	  light	  of	  the	  strong	  correlation	  of	  
MET/VEGFR-­‐2	  overexpression	  with	  tumor	  malignancies,	  inhibiting	  the	  signaling	  
pathways	  influenced	  by	  MET	  or	  VEGFR-­‐2	  has	  been	  suggested	  as	  an	  important	  
therapeutic	  strategy	  for	  attenuating	  tumor	  growth	  [21-­‐24].	  Indeed,	  several	  FDA-­‐
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approved	  VEGF	  pathway	  inhibitors,	  such	  as	  sunitinib	  [25],	  sorafenib	  [26,	  27]	  and	  
VEGFR2-­‐targeting	  antibody	  bevacizumab	  [22,	  28],	  have	  shown	  temporary	  
antitumor	  effects	  that	  can	  last	  from	  weeks	  to	  approximately	  two	  years	  in	  patients.	  
Despite	  their	  effectiveness,	  drug	  resistance	  can	  develop	  in	  these	  tumor	  cells	  via	  
adaptation	  to	  hypoxia,	  which	  strongly	  implicates	  MET	  expression	  [29-­‐31].	  Such	  
resistance	  from	  the	  VEGF	  pathway-­‐targeted	  inhibition	  has	  led	  to	  aggressive	  tumor	  
invasion	  and	  metastasis	  in	  murine	  models	  of	  pancreatic	  cancer	  [27,	  32],	  
glioblastoma	  [32]	  and	  breast	  cancer	  [33].	  Given	  their	  interdependence	  and	  
connection,	  simultaneous	  inhibition	  of	  MET	  and	  VEGFR2	  pathways	  may	  achieve	  
enhanced	  efficacy	  over	  the	  VEGFR2	  inhibition	  alone,	  leading	  to	  the	  development	  of	  
broad-­‐spectrum	  RTK	  inhibitors	  such	  as	  Cabozantinib.	  	  
Cabozantinib	  is	  a	  potent	  pan-­‐tyrosine	  kinase	  inhibitor	  targeting	  MET,	  
VEGFR2	  and	  a	  variety	  of	  other	  RTKs	  that	  have	  been	  associated	  with	  tumor	  
pathobiology	  [21],	  such	  as	  RET,	  mast/stem	  cell	  growth	  factor	  receptor,	  endothelial-­‐
specific	  receptor	  and	  FMS-­‐like	  tyrosine	  kinase	  3	  [34-­‐36].	  It	  has	  been	  reported	  that	  in	  
vitro	  and	  in	  vivo	  cancer	  cell	  invasion	  were	  significantly	  reduced	  through	  inhibition	  of	  
MET/VEGFR2	  phophorylation	  following	  cabozantinib	  treatment.	  In	  addition,	  
antitumor	  efficacy	  studies	  demonstrated	  that	  cabozantinib	  disrupts	  tumor	  
vasculature,	  decreases	  tumor	  and	  endothelial	  cell	  proliferation,	  and	  inhibits	  tumor	  
growth	  in	  mouse	  models	  of	  breast	  cancers,	  lung	  cancers,	  and	  glioblastomas	  [37].	  In	  
2012,	  cabozantinib	  was	  approved	  by	  the	  US	  Food	  and	  Drug	  administration	  as	  the	  
second	  targeted	  therapeutic	  (following	  vandetanib)	  for	  the	  treatment	  of	  medullary	  
thyroid	  cancer.	  Currently	  it	  is	  being	  tested	  in	  clinical	  trials	  in	  numerous	  cancers,	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including	  non-­‐small	  cell	  lung	  cancer,	  ovarian	  cancer,	  hepatocellular	  carcinoma,	  
glioblastoma,	  melanoma,	  colorectal	  cancer,	  and	  prostate	  cancer	  [38,	  39].	  
Cabozantinib	  is	  reasonably	  well	  tolerated	  by	  patients	  with	  a	  side	  effect	  profile	  
(mainly	  gastrointestinal	  and	  skin	  effects)	  similar	  to	  other	  TKIs	  in	  the	  clinic.	  Early	  
clinical	  efficacy	  results	  in	  MTC	  demonstrate	  a	  small	  percentage	  of	  patients	  with	  
partial	  responses	  similar	  to	  vandetanib	  [37,	  39].	  	  
Cabozantinib	  however	  is	  hydrophobic	  and	  is	  practically	  insoluble	  in	  water,	  so	  
it	  has	  been	  administered	  mainly	  via	  the	  oral	  route	  in	  a	  powder	  or	  capsule	  
formulation	  in	  both	  preclinical	  and	  clinical	  trials.	  Daily	  dosing	  was	  calculated	  to	  
maintain	  the	  targeted	  drug	  plasma	  concentration.	  To	  improve	  the	  solubility	  of	  
Cabozantinib,	  some	  animal	  studies	  added	  hydrochloric	  acid	  (10	  mM)	  in	  saline	  to	  
formulate	  cabozantinib	  in	  an	  aqueous	  solution	  [37].	  Alternatively,	  cabozantinib	  was	  
formulated	  in	  a	  vehicle	  mixture	  of	  ethanol/polyethylene	  glycol	  (PEG)	  /reverse	  
osmosis	  water	  (5:45:50)	  in	  some	  toxicity	  and	  toxicokinetic	  studies	  in	  rats	  [40].	  
Assessed	  by	  a	  mass	  balance	  study,	  the	  bioavailability	  of	  the	  clinical	  formulation	  of	  
cabozantinib	  is	  at	  least	  27%	  [41].	  However,	  the	  poor	  solubility	  of	  cabozantinib	  may	  
present	  a	  challenge	  for	  its	  parental	  formulation.	  	  
Polymeric	  micelles	  systems	  have	  been	  extensively	  evaluated	  for	  the	  delivery	  
of	  poorly	  soluble	  chemotherapeutic	  agents,	  due	  to	  their	  attractive	  bio-­‐
physicochemical	  and	  structural	  properties	  [42-­‐45].	  In	  aqueous	  solution,	  amphiphilic	  
polymers,	  such	  as	  1,2-­‐distearoyl-­‐sn-­‐glycero-­‐3-­‐phosphoethanolamine-­‐N-­‐	  [methoxy	  
(polyethylene	  glycol)-­‐2000]	  (DSPE-­‐PEG2000),	  poly	  (ethylene	  glycol)-­‐poly	  (ɛ-­‐	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caprolactone	  (PEG-­‐PCL)	  or	  poly	  (ethylene	  glycol)	  -­‐poly	  (amino	  acid),	  self-­‐assemble	  
into	  core-­‐shell	  structured	  nanoparticles	  with	  sizes	  from	  10	  to	  100	  nm.	  In	  particular,	  
PEG-­‐phospholipid-­‐	  based	  micelles	  have	  generated	  significant	  interest	  for	  their	  
sustained	  delivery	  of	  anticancer	  drugs	  and	  excellent	  biocompatibility	  [46-­‐49].	  In	  
such	  micelles	  the	  hydrophobic	  environment	  formed	  by	  the	  long	  fatty	  acyl	  chains	  can	  
accommodate	  lipophilic	  drug	  molecules	  to	  efficiently	  solubilize	  these	  poorly	  water-­‐
soluble	  drugs	  and	  restrict	  the	  mobility	  of	  the	  incorporated	  drugs	  at	  the	  same	  time,	  
leading	  to	  a	  sustained	  drug	  release.	  Furthermore,	  the	  PEG	  moiety	  on	  the	  hydrophilic	  
shell	  creates	  steric	  hindrance	  that	  stabilizes	  micelles	  from	  aggregation,	  reduces	  the	  
clearance	  rate	  by	  the	  reticuloendothelial	  system	  (RES),	  prolongs	  the	  circulation	  time	  
of	  the	  drug-­‐loaded	  micelles	  [50,	  51]	  and	  in	  turn	  facilitates	  the	  tumor	  accumulation	  
of	  drug-­‐loaded	  micelles	  due	  to	  the	  compromised	  leaky	  vasculature	  [52]	  found	  in	  
many	  solid	  tumors.	  	  
In	  this	  study,	  we	  have	  developed	  a	  stable	  cabozantinib-­‐encapsulated	  DSPE-­‐
PEG2000	  micelles	  formulation,	  with	  sustained	  release	  and	  enhanced	  delivery	  into	  
cancer	  cells.	  The	  micellar	  formulation	  showed	  enhanced	  cytotoxicity	  and	  
comparable	  cellular	  uptake	  of	  cabozantinib	  by	  human	  glioblastoma	  cancer	  cells	  and	  
non-­‐small	  lung	  cancer	  cells.	  The	  micellar	  formulation	  could	  be	  stored	  in	  the	  
lyophilized	  form	  for	  an	  extended	  period	  of	  time	  with	  96	  %	  drug	  recovery,	  making	  
the	  micelle	  formulation	  a	  potential	  candidate	  for	  cancer	  therapy.	  	  
	  
2.	  Materials	  and	  Methods	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2.1.	  Materials	  
N-­‐(Carbonyl-­‐methoxypolyethyleneglycol	  2000)-­‐1,2-­‐distearoyl-­‐sn-­‐glycero-­‐3-­‐
phosphoethanolamine	  (DSPE-­‐PEG	  2000	  sodium	  salt)	  was	  purchased	  from	  NOF	  
AMERICA	  CORPORATION	  (White	  Plains,	  NY,	  USA).	  Cabozantinib	  was	  obtained	  from	  
Chemietek®	  (Indianapolis,	  IN,	  USA).	  HEPES	  (BioPerformance	  Certified,	  ≥99.5%)	  and	  
penicillin/streptomycin	  (in	  0.9%	  NaCl,	  sterile-­‐filtered,	  BioReagent)	  were	  purchased	  
from	  Sigma-­‐Aldrich	  Co	  (St.	  Louis,	  MO,	  USA).	  Ammonium	  acetate	  (≥97	  %	  HPLC),	  
acetonitrile	  (≥99.9%)	  and	  methanol	  (≥99.9%)	  were	  obtained	  from	  Fisher	  Scientific	  
(Pittsburgh,	  PA,	  USA).	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  and	  trypsin-­‐EDTA	  were	  
purchased	  from	  Life	  Technologies	  (Grand	  Island,	  NY,	  USA).	  Fetal	  bovine	  serum	  
(U.S.D.A	  Origin)	  was	  purchased	  from	  Biowest	  LLC	  (Kansas	  City,	  MO,	  USA).	  Human	  
malignant	  glioblastoma	  cell	  lines	  U87	  and	  U251	  were	  kindly	  provided	  by	  Jann	  
Sakaria,	  (Mayo	  Clinic,	  Rochester,	  MN).	  	  Human	  lung	  adenocarcinoma	  epithelial	  cell	  
line	  A549	  was	  kindly	  provided	  by	  Dr.	  Cory	  Berkland,	  University	  of	  Kansas	  
(Lawrence,	  KS,	  USA).	  Double	  distilled	  water	  (ddH2O)	  was	  used	  in	  syntheses,	  
characterization	  and	  cell-­‐culture	  (sterilized	  by	  autoclaving).	  
	  
2.2	  Micelles	  formation	  and	  drug	  loading	  
2.2.1	  Preparation	  of	  cabozantinib	  encapsulated	  DSPE-­‐PEG2000	  micelles	  
DSPE-­‐PEG2000	  micelles	  were	  prepared	  by	  the	  lipid	  film	  rehydration	  method	  
described	  elsewhere	  [53]	  with	  modifications.	  Briefly,	  20	  mg	  of	  DSPE-­‐PEG2000	  and	  1.5	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mg	  of	  cabozantinib	  were	  weighed	  in	  a	  15-­‐mL	  round	  bottom	  flask	  and	  dissolved	  with	  
methanol,	  followed	  by	  bath	  sonication	  for	  1	  min.	  A	  thin	  film	  of	  drug-­‐polymer	  was	  
formed	  after	  the	  organic	  solvent	  was	  removed	  under	  reduced	  pressure	  by	  rotary	  
evaporator.	  Residual	  methanol	  was	  removed	  by	  placing	  the	  flask	  on	  a	  high	  vacuum	  
pump	  (<	  0.2	  mbar)	  overnight	  to	  thoroughly	  dry	  the	  thin	  film.	  The	  resulting	  dry	  film	  
was	  then	  rehydrated	  using	  2	  mL	  of	  10-­‐mM	  HEPES-­‐buffered	  saline	  (HBS)	  (pH	  7.4).	  
The	  flask	  with	  the	  cabozantinib	  loaded	  DSPE-­‐PEG2000	  micelles	  was	  sonicated	  for	  5	  
min,	  placed	  in	  a	  50°C	  incubator	  for	  1	  h	  and	  then	  cooled	  to	  room	  temperature,	  
followed	  by	  passing	  through	  a	  0.22-­‐μm	  Nylon	  syringe	  filter.	  The	  un-­‐encapsulated	  
cabozantinib	  was	  removed	  by	  ultracentrifugation	  (MWCO:	  3KDa)	  at	  3000	  rpm	  for	  
10	  min.	  Freshly	  prepared	  cabozantinib	  loaded	  DSPE-­‐PEG2000	  micelles	  were	  stored	  at	  
-­‐20	  °C	  overnight	  and	  then	  transferred	  to	  -­‐80°C	  for	  2	  h,	  followed	  by	  lyophilization	  
below	  0.01mbar.	  	  
	  
2.2.2	  Gel-­‐permeation	  chromatography	  
The	  DSPE-­‐PEG2000	  micelles	  encapsulating	  cabozantinib	  were	  characterized	  
by	  gel-­‐permeation	  chromatography	  (GPC)	  on	  a	  Shimadzu	  2010CHT	  HPLC	  with	  an	  
evaporative	  light	  scattering	  detector	  (ELSD-­‐LTII,	  Shimadzu	  Scientific	  Instruments,	  
Inc.,	  Columbia,	  MA,	  USA).	  GPC	  was	  performed	  with	  a	  Shodex	  OHpak	  SB-­‐803	  HQ	  
column	  (Showa	  Denko	  America,	  Inc.,	  New	  York,	  NY)	  using	  ddH2O	  as	  the	  mobile	  
phase	  at	  a	  flow	  rate	  of	  0.8	  mL/min.	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   2.2.3	  1H	  Nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy	  
The	  cabozantinib	  loaded	  DSPE-­‐PEG2000	  micelles	  solution	  was	  freshly	  
prepared	  with	  ddH2O	  and	  then	  frozen	  at	  -­‐80	  °C	  for	  4	  h,	  followed	  by	  lyophilization	  
overnight.	  The	  1H	  NMR	  spectra	  of	  the	  cabozantinib	  in	  CDCl3,	  DSPE-­‐PEG2000	  in	  D2O	  
and	  reconstituted	  dry	  cabozantinib	  loaded	  micelles	  in	  D2O	  or	  CDCl3	  were	  collected	  
on	  a	  Bruker	  Avance	  400	  MHz	  NMR	  Spectrometer	  (Bruker	  Corporation,	  MA,	  USA).	  
	  
2.2.4	  Quantification	  of	  cabozantinib	  amount	  in	  the	  micelles	  
The	  amount	  of	  cabozantinib	  incorporated	  into	  the	  DSPE-­‐PEG2000	  micelles	  was	  
quantified	  by	  gradient	  reverse	  phase	  high-­‐pressure	  liquid	  chromatography	  (HPLC).	  
The	  HPLC	  system	  consisted	  of	  a	  Shimadzu	  LC-­‐2010CHT	  (Shimadzu	  Scientific	  
Instruments,	  Inc.,	  Columbia,	  MA,	  USA)	  and	  a	  SPD-­‐M20A	  Prominence	  HPLC	  Photo	  
Diode	  Array	  Detector	  (Shimadzu	  Scientific	  Instruments,	  Inc.,	  Columbia,	  MA,	  USA	  ).	  
An	  ODS-­‐100	  C18	  analytical	  column	  (250	  ×	  4.6	  mm;	  5	  μm)	  was	  used	  for	  the	  analysis.	  
The	  mobile	  phase	  consisted	  of	  A	  (10	  mM	  ammonium	  acetate,	  pH	  5.2)	  and	  B	  
(acetonitrile),	  and	  the	  linear	  gradient	  was	  30-­‐90%	  B	  over	  12	  min	  at	  a	  flow	  rate	  of	  
1.0	  mL/min.	  	  UV	  absorption	  was	  measured	  at	  240	  nm,	  and	  the	  drug	  loading	  
efficiency	  (DL	  %)	  and	  encapsulation	  efficiency	  (EE	  %)	  of	  cabozantinib	  in	  DSPE-­‐
PEG2000	  micelles	  were	  calculated	  using	  the	  equations:	  
DL	  %	  =	  (Weight	  of	  the	  cabozantinib	  in	  micelles/	  Weight	  of	  the	  cabozantinib	  
and	  the	  DSPE-­‐PEG2000)	  ✕	  100%	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EE	  %	  =	  (Weight	  of	  the	  cabozantinib	  in	  micelles/	  Weight	  of	  fed	  cabozantinib)	  
✕	  100%	  
	  
2.3	  Micelle	  size	  and	  zeta	  potential	  measurements	  
	   The	  hydrodynamic	  diameter	  of	  the	  micelles	  was	  measured	  by	  dymanic	  light	  
scattering	  (DLS)	  at	  25	  °C	  on	  a	  ZetaPALS	  (Brookhaven	  Instruments	  Corp.,	  Holtsville,	  
NY),	  with	  measurements	  repeated	  three	  times.	  Zeta	  potential	  of	  micelles	  prepared	  
in	  10-­‐mM	  HBS	  was	  measured	  at	  25	  °C	  on	  a	  ZetaPALS	  (Brookhaven	  Instruments	  
Corp.,	  Holtsville,	  NY),	  with	  measurements	  repeated	  three	  times.	  
	  
2.4	  In	  vitro	  drug	  release	  profile	  of	  cabozantinib	  from	  DSPE-­‐Micelles	  
	   The	  release	  behavior	  of	  cabozantinib	  from	  micelles	  was	  evaluated	  using	  a	  
dialysis	  method	  under	  a	  sink	  conditions.	  Approximately	  5	  mL	  of	  the	  cabozantinib	  
micellar	  formulation	  or	  the	  free	  drug	  solution	  was	  transferred	  into	  dialysis	  tubing	  
(SnakeSkinTM,	  MWCO:	  3.5K)	  (Thermo	  Scientific	  Inc.,	  Rockford,	  IL,	  USA).	  To	  prepare	  
the	  aqueous	  solution	  of	  cabozantinib,	  the	  drug	  was	  first	  dissolved	  in	  DMSO	  and	  then	  
diluted	  with	  1-­‐mM	  HCl	  to	  reduce	  the	  DMSO	  content	  to	  below	  0.5%	  (v/v).	  The	  
dialysis	  tubing	  was	  closed	  at	  both	  ends	  with	  clips	  and	  placed	  in	  4.0	  L	  of	  phosphate	  
buffered	  saline	  (PBS)	  (pH7.4)	  at	  37	  °C.	  A	  sample	  of	  50	  μL	  was	  withdrawn	  from	  the	  
dialysis	  tubing	  at	  pre-­‐determined	  time	  intervals,	  and	  the	  PBS	  was	  changed	  every	  4	  h	  
to	  ensure	  sink	  condition.	  	  The	  drug	  amount	  in	  each	  sample	  was	  measured	  according	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to	  section	  2.2.4.	  
	  
2.5	  In	  vitro	  cytotoxicity	  of	  cabozantinib	  from	  DSPE-­‐Micelles	  
Two	  human	  malignant	  glioblastoma	  cell	  lines	  (U87	  and	  U251)	  and	  a	  human	  
lung	  adenocarcinoma	  epithelial	  cell	  line	  (A549)	  were	  used	  to	  investigate	  the	  in	  vitro	  
cytotoxicity	  of	  the	  cabozantinib	  micelles.	  The	  cell	  lines	  were	  maintained	  in	  DMEM	  
supplemented	  with	  10%	  FBS	  and	  1	  %	  penicillin/streptomycin	  at	  37	  °C	  in	  a	  
humidified,	  5%	  CO2	  atmosphere.	  Cancer	  cells	  in	  growth	  medium	  were	  seeded	  at	  a	  
concentration	  of	  3,000	  cells	  per	  well	  in	  96-­‐well	  flat-­‐bottomed	  plates	  and	  allowed	  to	  
attach	  overnight.	  The	  cabozantinib	  aqueous	  solution	  (<	  0.5%	  v/v	  DMSO)	  or	  micellar	  
solution	  was	  incubated	  with	  cells	  at	  different	  final	  concentrations	  from	  5	  to	  20	  μM.	  
Trichloroacetic	  acid	  (TCA)	  and	  10-­‐mM	  HBS	  and	  were	  added	  as	  positive	  and	  negative	  
control,	  respectively.	  Cell	  media	  were	  refreshed	  24	  or	  48	  h	  after	  the	  treatment,	  and	  a	  
resazurin-­‐based	  colorimetric	  assay	  was	  used	  to	  assess	  viability	  of	  cell	  cultures	  at	  72	  
h	  post	  treatment	  using	  GraphPad	  Prism	  6	  (GraphPad	  Software	  Inc.,	  La	  Jolla,	  CA).	  
	  
2.6	  Determination	  of	  cellular	  uptake	  of	  cabozantinib	  DSPE-­‐PEG2000	  micelles	  
In	  order	  to	  evaluate	  the	  cellular	  uptake	  and	  accumulation	  of	  cabozantinib	  
micelles,	  cell	  lines	  were	  seeded	  at	  a	  density	  of	  2	  ×	  105	  cells/mL	  in	  a	  12-­‐well	  plate.	  
The	  cells	  were	  incubated	  with	  free	  drug	  solution	  or	  cabozantinib	  micelles	  at	  final	  
drug	  concentrations	  of	  10	  or	  20	  μM	  for	  2	  h	  at	  conditions	  described	  in	  section	  2.5.	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Non-­‐internalized	  drug	  in	  the	  medium	  was	  removed,	  and	  the	  attached	  cells	  were	  
then	  washed	  three	  times	  with	  ice-­‐cold	  PBS.	  The	  cell	  pellets	  were	  collected	  at	  5000	  
rpm	  for	  10	  min	  at	  4	  °C	  after	  the	  trypsinization,	  and	  they	  then	  were	  resuspended	  in	  
0.5	  mL	  of	  methanol	  for	  the	  quantification	  following	  the	  procedures	  in	  section	  2.2.4.	  
	  
2.7	  Statistical	  analysis	  
All	  values	  are	  expressed	  as	  the	  mean	  ±	  standard	  deviation.	  One	  phase	  
exponential	  association	  was	  applied	  for	  the	  curve	  fitting	  of	  the	  in	  vitro	  drug	  release	  
kinetics	  to	  calculate	  the	  release	  half-­‐life	  (t1/2).	  Statistical	  analyses	  were	  performed	  
using	  two-­‐way	  ANOVA	  with	  GraphPad	  Prism	  6	  and	  the	  significance	  was	  set	  at	  P<	  
0.05.	  
	  
3.	  Results	  and	  Discussion	  
3.1	  Preparation	  of	  cabozantinib	  in	  DSPE-­‐PEG2000	  micelles	  and	  determination	  
of	  drug	  loading	  
The	  poorly-­‐water	  soluble	  drug	  cabozantinib	  was	  successfully	  encapsulated	  
into	  DSPE-­‐PEG2000	  micelles	  by	  a	  thin-­‐film	  rehydration	  method,	  and	  the	  resulting	  
purified	  micelle	  solution	  was	  clear	  without	  drug	  precipitates	  or	  aggregates	  (Figure	  
1A	  left).	  A	  lyophilization	  process	  was	  performed	  in	  this	  study	  to	  prepare	  the	  dry	  
dosage	  form	  and	  to	  enhance	  physical	  stability	  for	  long-­‐term	  shelf	  storage.	  The	  
lyophilized	  cake	  (Figure	  1A	  middle)	  could	  be	  redispersed	  in	  water	  (Figure	  1A	  right)	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within	  30	  s.	  	  
The	  formation	  of	  the	  drug-­‐loaded	  micelles	  was	  confirmed	  by	  the	  eluted	  
micelles	  peak	  at	  6.233	  min	  in	  the	  GPC	  (Figure	  1B),	  which	  was	  much	  earlier	  than	  the	  
PEG	  standard	  with	  a	  similar	  molecular	  weight	  (Mn	  3070)	  as	  the	  DSPE-­‐PEG2000	  
monomer.	  A	  peak	  with	  approximately	  3%	  of	  the	  total	  area	  under	  the	  curve	  was	  also	  
detected	  in	  the	  GPC	  at	  12.299	  min,	  which	  corresponded	  to	  the	  DSPE-­‐PEG2000	  
unimers	  loss	  by	  the	  micelle	  dissociation,	  probably	  due	  to	  the	  dilution	  below	  the	  
critical	  micelle	  concentration	  (CMC)	  by	  the	  HPLC	  system.	  The	  CMC	  of	  DSPE-­‐PEG2000	  
micelles	  is	  as	  low	  as	  approximately	  0.5	  –	  1.0	  uM	  in	  HEPES	  buffer	  [54]	  resulting	  from	  
the	  strong	  hydrophobic	  interaction	  among	  the	  saturated	  C18	  acyl	  chains	  [54,	  55].	  The	  
final	  concentration	  of	  the	  DSPE-­‐PEG2000	  in	  this	  micellar	  formulation	  was	  7	  mM,	  
which	  is	  about	  7000	  fold	  above	  the	  CMC,	  leading	  to	  a	  successful	  micelle	  formation	  
and	  efficient	  drug	  loading.	  	  
Drug	  leakage	  from	  colloidal	  drug	  delivery	  systems	  and	  subsequent	  drug	  
precipitation	  and	  degradation	  during	  extended	  periods	  of	  storage	  have	  been	  
observed	  in	  several	  studies	  due	  to	  the	  nanoparticle	  aggregation	  and	  the	  hydrolysis	  
of	  the	  building	  blocks	  of	  the	  polymers	  that	  formed	  the	  nanoparticles	  [56,	  57].	  
Lyophilization	  has	  been	  used	  to	  stabilize	  a	  variety	  of	  drug	  nanocarriers	  [58-­‐62].	  
Sugars	  such	  as	  trehalose,	  sucrose,	  glucose	  and	  mannitol	  are	  often	  added	  at	  5	  –	  20%	  
(w/v)	  into	  the	  particulate	  systems	  as	  cryo/lyoprotectants	  to	  spare	  the	  products	  
from	  the	  freezing/drying	  stress	  that	  may	  induce	  aggregation	  or	  fusion	  of	  
nanoparticles.	  	  However,	  collapse	  of	  the	  lyophilized	  cake	  was	  observed	  for	  some	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formulations	  containing	  glucose	  (5%	  and	  10%,	  w/v)	  and	  mannitol	  (5%)	  [63].	  In	  this	  
study,	  a	  lyohplized	  micellar	  formulation	  of	  cabozantinib	  was	  prepared	  without	  
adding	  cryo/lyoprotectants,	  and	  the	  reconstitution	  of	  the	  resultant	  lyophilized	  
polymer-­‐drug	  with	  water	  successfully	  regenerated	  the	  micelles.	  	  The	  GPC	  of	  the	  
reconstituted	  drug-­‐loaded	  micelles	  (Figure	  1C)	  was	  found	  to	  be	  same	  as	  that	  of	  the	  
freshly	  prepared	  micelle	  formulation.	  The	  ability	  of	  PEG-­‐DSPE	  micelles	  to	  
reconstitute	  without	  cryoprotectant	  is	  probably	  due	  to	  the	  large	  hydrophilic-­‐
lipophilic	  balance	  of	  the	  micelles.	  Successful	  reconstitution	  of	  the	  indisulam-­‐






































































Figure	  1.	  (A)	  Representative	  pictures	  of	  cabozantinib	  DSPE-­‐PEG2000	  micelles	  in	  
forms	  of	  freshly	  prepared	  solution	  (Fresh),	  lyophilized	  powder	  (LYO),	  and	  
reconstituted	  solution	  from	  the	  LYO	  (REC).	  Gel-­‐permeation	  chromatography	  of	  
Freshly	  prepared	  cabozantinib	  DSPE-­‐PEG2000	  micelles	  (B)	  and	  REC	  (C)	  with	  PEG	  
standard	  (M.W.:	  3,070	  g/mol)	  as	  an	  indicator	  of	  the	  DSPE-­‐PEG2000	  monomer.	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1H	  NMR	  measurements	  were	  used	  to	  further	  demonstrate	  the	  encapsulation	  
of	  the	  cabozantinib	  inside	  the	  micelle	  core	  formed	  by	  the	  DSPE	  segments	  [46,	  65].	  1H	  
NMR	  spectra	  of	  cabozantinib	  dissolved	  in	  CDCl3	  (Figure	  2A)	  and	  the	  DSPE-­‐PEG2000	  in	  
D2O	  (Figure	  2B)	  clearly	  showed	  the	  distinct	  resonance	  peaks	  of	  the	  drug	  and	  the	  
polymer,	  respectively,	  which	  include	  protons	  of	  methoxy	  groups	  (4.1240	  ppm	  and	  
4.1834	  ppm),	  aromatic	  rings	  (6.7053	  –	  8.4693),	  amino	  groups	  (10.2444	  ppm)	  and	  
cyclopropane	  (1.2754	  ppm)	  for	  cabozantinib,	  and	  the	  di-­‐saturated	  C18	  acyl	  chains	  
at	  1.2183	  ppm	  and	  PEG	  block	  at	  3.6241	  ppm	  for	  DSPE-­‐PEG2000.	  By	  comparison,	  only	  
prominent	  peaks	  corresponding	  to	  DSPE-­‐PEG2000	  could	  be	  observed	  in	  the	  1H	  NMR	  
spectrum	  of	  the	  cabozantinib	  loaded	  micelles	  (Figure	  2C)	  that	  were	  prepared	  with	  
D2O	  due	  to	  the	  restricted	  motion	  of	  the	  drug	  molecules	  in	  the	  micelles’	  hydrophobic	  
cores,	  indicating	  efficient	  drug	  incorporation.	  When	  the	  lyophilized	  cabozantinib	  
loaded	  micelles	  were	  reconstituted	  in	  the	  organic	  solvent,	  CDCl3,	  resonance	  peaks	  of	  
both	  the	  drug	  and	  polymer	  were	  present	  1H	  NMR	  spectrum	  (Figure	  2D)	  as	  a	  
consequence	  of	  the	  disrupted	  micelles	  structure	  in	  the	  organic	  solvent,	  which	  in	  


























































Figure	  2.	  1H	  NMR	  spectra	  of:	  (A)	  Cabozantinib	  in	  CDCL3,	  (B)	  DSPE-­‐PEG2000	  in	  D2O,	  (C)	  
Reconstituted	  cabozantinib	  loaded	  micelles	  in	  D2O,	  (d)	  Reconstituted	  cabozantinib	  
loaded	  micelles	  in	  CDCl3.	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The	  loading	  efficiency	  (DL	  %)	  and	  encapsulation	  efficiency	  (EE	  %)	  of	  the	  
cabozantinib	  into	  the	  DSPE-­‐PEG2000	  micelles	  were	  quantified	  by	  the	  reverse	  phase	  
HPLC	  and	  found	  to	  be	  5.45	  ±	  0.09%	  and	  78.37	  ±	  1.34	  %,	  respectively.	  Cabozantinib	  
in	  the	  neutral	  form	  was	  practically	  insoluble	  in	  water.	  Remarkably,	  the	  aqueous	  
solubility	  of	  cabozantinib	  was	  increased	  to	  2.23	  ±	  0.01	  mg/mL	  after	  being	  
encapsulated	  into	  the	  DSPE-­‐PEG2000	  micelles.	  Cabozantinib	  loaded	  micelles	  in	  the	  
lyophilized	  cake	  could	  be	  easily	  rehydrated	  with	  water,	  and	  the	  detected	  drug	  
amount	  was	  96.00	  ±	  0.87	  %	  of	  the	  freshly	  prepared	  micelles	  solution.	  This	  high	  drug	  
recovery	  indicates	  a	  promising	  prolonged	  shelf	  life	  of	  the	  lyophilized	  cabozantinib	  
micelles	  for	  clinical	  applications.	  	  
	  
3.2	  Micelle	  characterization	  
The	  average	  hydrodynamic	  size	  of	  the	  oblate	  spheroidal	  cabozantinib	  loaded	  
micelles	  was	  11.7	  nm	  with	  a	  narrow	  size	  distribution	  (Figure	  3),	  which	  is	  favorable	  
for	  sustained	  circulation	  for	  in	  vivo	  delivery	  of	  the	  drug-­‐incorporated	  micelles.	  It	  has	  
been	  reported	  that	  micelles	  with	  size	  in	  the	  nano-­‐scale	  range	  (10	  -­‐100	  nm)	  can	  
resist	  the	  systemic	  clearance	  by	  renal	  filtration	  and	  the	  reticuloendothelial	  system	  
after	  administration	  [51,	  66],	  thus	  providing	  a	  prolonged	  pharmacological	  effect.	  In	  
addition,	  cabozantinib	  molecules	  incorporated	  into	  the	  hydrophobic	  core	  of	  micelles	  
are	  protected	  from	  the	  liver	  enzyme	  metabolism.	  Consequently,	  drug	  transportation	  
to	  targeted	  extravascular	  tumor	  tissues	  through	  diffusion	  from	  the	  leaky	  blood	  
vessels	  [52]	  is	  expected	  to	  be	  significantly	  enhanced	  due	  to	  the	  prolonged	  systemic	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circulation	  of	  the	  drug-­‐loaded	  micelles.	  	  
The	  zeta	  potential	  value	  indicates	  the	  potential	  colloidal	  stability	  of	  the	  
micellar	  formulation.	  Colloidal	  systems	  with	  zeta	  potential	  above	  ±	  30	  mV	  have	  been	  
generally	  accepted	  as	  moderately	  stable	  to	  prevent	  aggregation.	  	  The	  zeta	  potential	  
of	  the	  cabozantinib-­‐loaded	  micelles	  was	  -­‐15.70	  ±	  1.24	  mV,	  indicating	  an	  incipient	  
instability.	  However,	  the	  hydrophilic	  PEG	  segment	  on	  the	  surface	  could	  prevent	  





























Figure	  3.	  Dynamic	  Light	  Scattering	  (DLS)	  of	  the	  freshly	  prepared	  cabozantinib	  
DSPE-­‐PEG2000	  micelles	  at	  25o	  C	  (size	  distribution	  in	  number).	  Hydrodynamic	  
diameter=	  11.7	  ±	  1.2	  nm.	  (Mean	  ±	  SD)	  (N	  =	  3).	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3.3	  In	  vitro	  drug	  release	  profile	  of	  cabozantinib	  from	  DSPE-­‐PEG2000	  micelles	  
The	  in	  vitro	  release	  behaviors	  of	  the	  micellar	  formulation	  of	  cabozantinib	  and	  
the	  free	  drug	  were	  evaluated	  in	  PBS	  (pH	  7.4)	  solution	  at	  37	  °C	  under	  the	  sink	  
conditions	  to	  simulate	  the	  significant	  dilution	  of	  the	  administered	  micelle	  solution	  
by	  physiological	  fluids.	  	  As	  shown	  in	  Figure	  4,	  approximately	  81%	  of	  cabozantinib	  in	  
the	  free	  drug	  solution	  was	  released	  within	  4h.	  DSPE-­‐PEG2000	  micelles	  containing	  
cabozantinib,	  on	  the	  other	  hand,	  exhibited	  sustained	  drug	  release	  over	  a	  period	  of	  
greater	  than	  10	  days,	  with	  only	  21.92%	  of	  the	  cabozantinib	  released	  in	  the	  first	  8h.	  
Release	  half-­‐times	  of	  the	  drug	  in	  both	  forms	  were	  calculated	  from	  a	  curve	  fitting	  
using	  one	  phase	  exponential	  association	  analysis.	  The	  t1/2	  was	  significantly	  
enhanced	  from	  less	  than	  10min	  to	  80h	  after	  the	  drug	  was	  incorporated	  into	  the	  
micelles	  formulation,	  and	  similar	  in	  vitro	  controlled	  drug	  release	  profiles	  of	  DSPE-­‐
PEG	  micelles	  have	  been	  reported	  when	  hydrophobic	  drugs	  such	  as	  doxorubicin	  [67]	  




































Cabozantinib free drug solution
	  
Figure	  4.	  In	  vitro	  drug	  release	  profiles	  of	  cabozantinib	  in	  free	  drug	  form	  (¢)	  and	  in	  
DSPE-­‐PEG2000	  formulation	  (n).	  (Mean	  ±	  SD;	  N=3).	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Repeat-­‐dose	  toxicity	  and	  toxicokinetic	  studies	  with	  cabozantinib	  in	  rats	  that	  
received	  daily	  oral	  gavage	  have	  shown	  debilitating	  side	  effects,	  including	  
hematopoietic,	  hepatic,	  gastrointestinal	  or	  renal	  toxicity	  [40].Polymeric	  micelles	  
that	  incorporate	  PEG	  segment	  have	  been	  employed	  as	  long-­‐circulating	  drug	  vehicles	  
[65,	  69,	  70],	  as	  the	  presence	  PEG	  in	  the	  outer	  hydrophilic	  shell	  spares	  micelles	  from	  
aggregation	  and	  also	  decreases	  the	  adsorption	  of	  protein	  such	  as	  immunoglobulins	  
to	  the	  hydrophobic	  surfaces,	  thus	  reducing	  the	  fast	  clearance	  of	  the	  micelles	  by	  RES	  
[71,	  72].	  Moreover,	  following	  the	  intravenous	  injection,	  the	  nanoscale	  drug-­‐loaded	  
micelles	  have	  been	  found	  to	  preferentially	  accumulate	  in	  the	  tumor	  tissues	  from	  
their	  leaky	  endothelial	  vasculature,	  due	  to	  the	  enhanced	  permeability	  and	  retention	  
effect	  [73-­‐75].	  Our	  study	  demonstrated	  a	  significantly	  prolonged	  in	  vitro	  release	  
profile	  of	  the	  cabozantinib	  from	  the	  micellar	  formulation	  due	  to	  the	  strong	  drug	  
interaction	  and	  association	  with	  the	  hydrophobic	  micelle	  core,	  which	  is	  responsible	  
for	  maintaining	  a	  steady-­‐state	  drug	  release	  at	  a	  partial	  level	  from	  day	  6,	  and	  
indicates	  a	  potentially	  enhanced	  in	  vivo	  drug	  stability	  and	  increased	  systemic	  
circulation.	  After	  intravenously	  administered	  into	  the	  patients,	  cabozantinib-­‐loaded	  
DSPE-­‐PEG2000	  micelles	  are	  expected	  to	  target	  the	  tumor	  tissue	  and	  then	  controllably	  
release	  the	  active	  chemotherapeutic	  agent.	  Consequently,	  the	  systemic	  toxicity	  of	  
the	  drug	  could	  be	  minimized	  as	  the	  chemotherapy	  exposure	  to	  normal	  tissues,	  
especially	  hematopoietic	  cells	  and	  epithelial	  cells	  in	  the	  gastrointestinal	  tract,	  is	  
reduced.	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3.4	  Cellular	  uptake	  of	  cabozantinib	  from	  DSPE-­‐PEG2000	  micelles	  
Human	  lung	  adenocarcinoma	  epithelial	  cell	  line	  A549	  and	  human	  malignant	  
glioblastoma	  cell	  lines	  U87	  and	  U251	  were	  treated	  with	  free	  cabozantinib	  solution	  
or	  drug	  loaded	  DSPE-­‐PEG2000	  micelles	  for	  2h,	  and	  the	  drug	  amounts	  internalized	  in	  
cells	  were	  then	  quantified	  using	  the	  RP-­‐HPLC.	  	  As	  shown	  in	  Figure	  5,	  micellar	  
formulation	  of	  cabozantinib	  significantly	  enhanced	  the	  cellular	  accumulation	  of	  the	  
drug	  in	  all	  cell	  lines	  under	  study	  at	  the	  concentration	  of	  10	  μM.	  Similarly,	  enhanced	  
cellular	  uptake	  of	  hydrophobic	  drug-­‐loaded	  micelles	  has	  been	  reported	  in	  the	  case	  
of	  doxorubincin	  [76].	  The	  enhanced	  intracellular	  uptake	  was	  possibly	  due	  to	  the	  
different	  internalization	  mechanisms	  employed	  by	  the	  micellar	  formulation	  and	  the	  
free	  drug.	  Several	  groups	  have	  investigated	  the	  mechanisms	  of	  micelle	  
internalization	  by	  cancer	  cells	  using	  biocompatible	  fluorescent	  micelles	  [77].	  Drug-­‐
loaded	  micelles	  have	  been	  shown	  to	  enter	  the	  cytoplasmic	  compartment	  by	  the	  
endocytosis	  process,	  followed	  by	  the	  diffusion	  of	  the	  incorporated	  molecules	  into	  
organelles	  such	  as	  lyposomes,	  mitochondria	  and	  the	  Golgi	  apparatus.	  In	  comparison,	  
free	  drug	  molecules	  slowly	  traversed	  through	  the	  cell	  membrane	  and	  then	  entered	  
the	  cytoplasmic	  space.	  To	  our	  surprise,	  no	  statistical	  significance	  was	  observed	  at	  
the	  fed	  cabozantinib	  concentration	  of	  20	  μM.	  We	  hypothesized	  that	  the	  increased	  
initial	  drug	  concentration	  may	  generate	  an	  elevated	  drug	  gradient	  to	  facilitate	  the	  
passive	  diffusion	  of	  the	  free	  drug	  solution,	  leading	  to	  intracellular	  drug	  uptake	  
comparable	  with	  drug-­‐loaded	  micelles.	  On	  the	  other	  hand,	  the	  relatively	  small	  
number	  of	  experiment	  replicate	  probably	  should	  also	  be	  taken	  into	  account.	  	  






































































































Figure	  5.	  Celluar	  uptake	  of	  cabozantinib	  in	  the	  micellar	  formulation	  (solid)	  or	  aqueous	  
solution	  (shaded)	  by	  (A)	  A549	  cells,	  (B)	  U87	  cells	  and	  (C)	  U251	  cells.	  (Mean	  ±	  SD;	  N=3)	  
(*:p<0.05;	  **:	  p<0.01).	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3.5	  In	  vitro	  cytotoxicity	  of	  cabozantinib	  from	  DSPE-­‐PEG2000	  Micelles	  
Cabozantinib	  is	  currently	  being	  tested	  in	  cancer	  patients	  with	  non-­‐small	  cell	  
lung	  cancer,	  glioblastoma,	  melanoma,	  ovarian	  cancer	  and	  hepatocellular	  carcinoma,	  
etc.	  	  We	  chose	  one	  human	  non-­‐small	  cell	  lung	  cancer	  cell	  line	  A549	  and	  two	  human	  
malignant	  glioblastoma	  cell	  lines	  U87	  and	  U251	  in	  this	  pilot	  study	  to	  investigate	  the	  
cytotoxicity	  of	  the	  cabozantinib-­‐loaded	  DSPE-­‐PEG2000	  micelles.	  	  The	  results	  of	  
cytotoxicity	  study	  on	  free	  cabozantinib	  and	  cabozantinib-­‐loaded	  micelles	  solution	  
against	  the	  three	  cell	  lines	  are	  shown	  in	  Figure	  6.	  Overall,	  we	  observed	  strong	  dose	  
and	  time-­‐dependent	  inhibitory	  activity	  in	  all	  cell	  lines	  under	  study	  from	  5	  to	  20	  μM.	  
Compared	  to	  the	  free	  drug	  solution,	  the	  cabozantinib	  micellar	  formulation	  exhibited	  
significantly	  enhanced	  cytotoxicity	  after	  24h	  or	  48h	  of	  incubation.	  Higher	  cytotoxic	  
activity	  has	  also	  been	  demonstrated	  in	  other	  anticancer	  drug-­‐loaded	  nanoparticles.	  
For	  example,	  a	  doxorubicin-­‐loaded	  polymeric	  nanoparticle	  was	  found	  to	  be	  over	  30	  
times	  more	  active	  drug-­‐resistant	  MCF-­‐7	  tumor	  cells	  than	  free	  drug	  [78],	  and	  it	  was	  
attributed	  to	  the	  increased	  intracellular	  drug	  concentration.	  Diao	  et	  al	  later	  reported	  
reversed	  multidrug	  resistance	  using	  doxorubicin-­‐loaded	  PEG-­‐PCL	  copolymer	  
micelles	  in	  multidrug-­‐resistant	  K562	  cells	  [76].	  Among	  the	  three	  human	  tumor	  cell	  
lines,	  the	  U87	  and	  A549	  cell	  lines	  were	  more	  sensitive	  to	  the	  treatment	  than	  the	  
U251	  cell	  line,	  probably	  due	  to	  varying	  levels	  of	  VEGFR-­‐2/MET	  expression	  and	  
intracellular	  drug	  concentration.	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Figure	  6.	  Cytotoxicity	  determined	  by	  Resazurin	  Assay	  in	  A549	  cells,	  U87	  cells	  and	  
U251	  cells	  after	  24	  h	  or	  48	  h	  treatment	  with	  cabozantinib	  loaded	  DSPE-­‐PEG2000	  
micelles	  (black)	  or	  cabozantinib	  solution	  (gray).	  (Mean	  ±	  SD;	  N=3)	  (*:	  p<	  0.05;	  **:	  
p<0.01;	  ****:	  p<0.0001).	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4.	  Conclusions	  
In	  the	  present	  work,	  we	  successfully	  solubilized	  cabozantinib,	  a	  dual	  
MET/VEGFR2	  inhibitor,	  in	  an	  11-­‐nm	  DSPE-­‐PEG2000	  micellar	  formulation	  with	  
encapsulation	  efficiency	  of	  approximately	  80	  %.	  	  The	  drug-­‐loaded	  micelles	  were	  
stabilized	  in	  the	  lyophilized	  form.	  Therefore,	  it	  could	  provide	  extended	  shelf	  life	  
without	  using	  cryo/lyoprotectants.	  The	  sustained	  in	  vitro	  release	  profiles	  indicated	  
a	  potentially	  prolonged	  in	  vivo	  circulation	  after	  administration	  for	  the	  long-­‐acting	  
chemotherapy.	  Compared	  with	  the	  free	  cabozantinib	  solution,	  drug-­‐loaded	  micelles	  
exhibited	  increased	  intracellular	  drug	  uptake	  and	  higher	  cytotoxicity	  in	  one	  human	  
lung	  adenocarcinoma	  epithelial	  cell	  line	  and	  two	  human	  malignant	  glioblastoma	  cell	  
lines.	  In	  conclusion,	  cabozantinib	  can	  be	  formulated	  as	  a	  highly	  concentrated	  drug	  in	  
an	  aqueous	  injectable	  solution	  above	  the	  solubility	  limit	  of	  the	  free	  drug,	  thus	  
lowering	  the	  required	  dosage	  volume.	  Therefore,	  administration	  of	  cabozantinib-­‐
incorporated	  micelles	  may	  serve	  as	  a	  promising	  approach	  to	  parenteral	  formulation	  
of	  a	  chemotherapeutic	  agent	  against	  human	  malignant	  solid	  tumors.	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1.	  Introduction	  
Radiotherapy	  is	  currently	  applied	  in	  approximately	  67%	  of	  all	  cancer	  patients,	  
either	  alone	  or	  in	  combination	  with	  chemotherapy	  and	  surgery	  [1].	  Radiation	  treatment	  
uses	  high-­‐energy	  waves	  such	  as	  x-­‐ray,	  γ-­‐ray, or	  electron	  beams	  to	  induce	  double-­‐strand	  
DNA	  breaks	  in	  cancer	  cells,	  thus	  disrupting	  tumor	  vessel	  and	  inhibiting	  tumor	  growth	  [2].	  
In	  spite	  of	  its	  therapeutic	  efficacy,	  radiation	  has	  been	  well	  known	  to	  suppress	  angiogenesis	  
[3]	  and	  destruct	  microvasculature	  as	  well,	  causing	  many	  severe	  complications	  including	  
teleangectasia,	  capillary	  rupture	  and	  thrombosis	  to	  capillaries	  or	  sinusoids,	  and	  fibrinoid	  
necrosis,	  thrombosis	  and	  acute	  arteritis	  to	  medium-­‐sized	  vessels[4,	  5].	  Moreover,	  the	  
pathologic	  effects	  of	  radiotherapy	  are	  also	  evident	  in	  appreciable	  low	  bone	  density	  and	  
bone	  fractures	  [6,	  7].	  
Deferoxamine	  (DFO)	  is	  a	  bacterial	  siderophore	  naturally	  synthesized	  by	  
Streptomyces	  pilosus	  and	  has	  the	  ability	  to	  strongly	  bind	  to	  the	  excess	  free	  iron	  ions	  in	  
plasma.	  Such	  bindings	  can	  prevent	  the	  iron-­‐driven	  free-­‐radical	  reactions	  that	  lead	  to	  
various	  deleterious	  events	  such	  as	  lipids	  peroxidation	  and	  damage	  of	  proteins	  and	  nucleic	  
acids[8-­‐10].	  DFO	  has	  been	  clinically	  used	  as	  a	  first-­‐line	  iron-­‐chelating	  agent	  to	  treat	  acute	  
iron	  overload	  and	  transfusion-­‐related	  blood	  poisoning	  [11-­‐18].	  Iron	  also	  serves	  as	  a	  co-­‐
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factor	  in	  a	  degradation	  process,	  known	  as	  prolyl	  hydroxylation,	  of	  the	  hypoxia-­‐inducible	  
factor-­‐1α	  	  (HIF-­‐1	  α).	  HIF-­‐1	  α	  has	  been	  reported	  to	  be	  associated	  with	  bone	  deposition	  and	  
normal	  skeletal	  development.	  In	  a	  rat	  model,	  HIF-­‐1	  α	  stimulates	  the	  release	  of	  the	  vascular	  
endothelial	  growth	  factor	  to	  subsequently	  promote	  angiogenesis,	  which	  is	  necessary	  for	  
bone	  formation[19].	  The	  iron-­‐removal	  ability	  of	  DFO	  has	  been	  experimentally	  implicated	  to	  
stimulate	  angiogenesis,	  accelerate	  bone	  regeneration	  and	  activate	  the	  HIF-­‐1	  α	  pathway	  by	  
inhibiting	  the	  prolyl	  hydroxylation	  process	  [20-­‐22].	  	  
Recently,	  a	  novel	  clinical	  application	  of	  DFO	  has	  been	  reported	  in	  reversing	  
radiation-­‐induced	  bone	  damages	  via	  targeting	  angiogenesis.	  In	  this	  application,	  adult	  rats	  
were	  first	  subjected	  to	  a	  human-­‐equivalent	  dose	  of	  radiotherapy	  to	  induce	  the	  lesion	  and	  
then	  received	  local	  DFO	  injection	  treatment.	  Compared	  with	  the	  untreated	  animals,	  the	  
treated	  group	  showed	  a	  substantially	  enhanced	  vascular	  proliferation	  illustrated	  by	  micro-­‐
computed	  tomography	  angiography	  [23].	  Some	  similar	  studies	  observed	  a	  nearly	  full	  
recovery	  in	  terms	  of	  callus	  size,	  quality,	  strength	  and	  a	  3-­‐fold	  increase	  in	  the	  bony	  union	  
rate	  after	  the	  localized	  DFO	  injection	  [24,	  25].	  
Despite	  such	  encouraging	  experimental	  results,	  two	  major	  limitations	  hinder	  a	  wide	  
clinical	  application	  of	  DFO	  therapy.	  One	  limitation	  is	  its	  poor	  oral	  bioavailability	  (~15%)	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due	  to	  its	  high	  hydrophilicity,	  charge	  and	  susceptibility	  to	  the	  highly	  acidic	  environment	  in	  
the	  stomach	  lumen	  [26-­‐28].	  DFO	  is	  therefore	  administered	  primarily	  via	  either	  
subcutaneous,	  intravenous	  infusion	  or	  occasionally	  by	  intramuscular	  injection.	  The	  other	  
limitation	  of	  DFO	  is	  its	  short	  plasma	  half-­‐life,	  which	  is	  typically	  5	  -­‐	  10	  min	  in	  humans	  after	  
intravenous	  bolus	  injections	  [29].	  Moreover,	  the	  amide	  bonds	  of	  DFO	  are	  also	  subject	  to	  the	  
proteolytic	  cleavage,	  accelerating	  the	  rapid	  renal	  excretion	  of	  DFO.	  Collectively,	  these	  
limitations	  necessitate	  continuous	  infusion	  or	  repeated	  injections	  of	  DFO,	  which	  might	  
raise	  issues	  in	  hypotension,	  tachycardia,	  neurotoxicity,	  ocular	  dysfunction	  and	  patients’	  
compliance	  [30-­‐32],	  rendering	  treatments	  ineffective.	  To	  achieve	  the	  extended	  release	  of	  
DFO,	  researchers	  have	  tested	  numerous	  delivery	  systems,	  including	  liposomal	  formulation	  
[33,	  34]	  and	  high-­‐molecular-­‐weight	  polymer-­‐DFO	  conjugates	  [35-­‐38].	  	  Particularly	  one	  
delivery	  system,	  drug	  conjugates	  prepared	  with	  starch	  or	  dextran,	  has	  led	  to	  both	  enhanced	  
tolerability	  and	  prolonged	  drug	  residence	  time	  following	  the	  intravenous	  infusion.	  	  
In	  this	  study,	  we	  set	  out	  to	  strategically	  enhance	  the	  therapeutic	  efficacy	  of	  the	  DFO	  
via	  covalently	  attaching	  the	  drug	  molecule	  hyaluronic	  acid	  (HA).	  HA	  plays	  critical	  role	  in	  
cell	  differentiation,	  tissue	  morphogenesis,	  proliferation	  and	  wound	  healing	  [39,	  40].	  HA-­‐
based	  biomaterials	  have	  been	  widely	  applied	  for	  tissue	  engineering	  and	  regenerative	  
medicine	  [41,	  42].	  	  For	  example,	  HA	  with	  high	  molecular	  weight	  is	  currently	  used	  as	  a	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symptom-­‐modifying	  treatment	  as	  a	  lubricant	  and	  shock-­‐adsorbent	  for	  human	  
osteoarthritis,	  the	  most	  common	  joint	  disorder,	  to	  improve	  chondrocytes	  density	  and	  
matrix	  appearance	  [43-­‐45].	  Herein,	  we	  first	  prepared	  a	  HA	  conjugated	  deferoxamine	  (HA-­‐
DFO)	  using	  a	  two-­‐step	  synthesis	  method.	  We	  then	  examined	  the	  in	  vitro	  release	  
characteristics	  and	  the	  potential	  cell	  toxicity	  of	  the	  HA-­‐DFO.	  	  Biodegradability	  of	  the	  HA-­‐
DFO	  conjugate	  was	  compared	  with	  the	  unmodified	  HA	  in	  a	  simulated	  physiological	  
medium.	  Our	  results	  suggested	  that	  HA-­‐DFO	  bio-­‐conjugate	  offered	  the	  sustained	  release	  of	  
the	  active	  DFO.	  Moreover,	  the	  combined	  therapeutic	  effects	  of	  DFO	  and	  HA	  could	  be	  
achieved	  after	  a	  local	  administration.	  	  
	  
2.	  Materials	  and	  Methods	  
2.1.	  Materials	  
Hyaluronan	  sodium	  salts	  (215-­‐kDa	  and	  752-­‐kDa)	  were	  purchased	  from	  Lifecore	  
Biomedical,	  Inc.	  (Chaska,	  MN).	  Dowex®	  50W	  X8,	  Tetrabutylammonium	  hydroxide	  solution,	  
deferoxamine	  mesylate,	  N-­‐(3-­‐dimethylaminopropyl)-­‐N′-­‐ethylcarbodiimide	  (EDC),	  1,4-­‐
piperazine-­‐bis	  (ethanesulfonic	  acid)	  (PIPES)	  and	  Hyaluronidase	  from	  bovine	  testes	  (EC	  
3.2.1.35,	  750-­‐3000	  U/mg	  )	  were	  purchased	  from	  Sigma	  Aldrich	  (St.	  Louis,	  MO).	  Sulfo-­‐ NHS	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was	  purchased	  from	  ChemPep,	  Inc.	  (Wellington,	  FL).	  8-­‐Hydroxyquinoline-­‐5-­‐sulfonic	  acid	  
monohydrate	  was	  purchased	  from	  TCI	  America	  (Portland,	  OR).	  Iron	  (III)	  chloride	  
(anhydrous,	  98%)	  was	  obtained	  from	  Alfa	  Aesar	  (Ward	  Hill,	  MA).	  Human	  umbilical	  vein	  
endothelial	  cells	  (ATCC®,	  Manassas,	  VA)	  were	  grown	  in	  endothelial	  cell	  growth	  media	  kit	  
from	  Lonza	  (Allendale,	  NJ).	  Double	  distilled	  water	  (ddH2O)	  was	  used	  in	  syntheses,	  
characterization	  and	  cell-­‐culture	  (sterilized	  by	  autoclaving).	  Organic	  solvents	  are	  of	  
analytical	  grade	  from	  Fisher	  Scientific	  (Lenexa,	  KS).	  
	  
2.2	  Synthesis	  of	  hyaluronic	  acid	  (HA)-­‐deferoxamine	  (DFO)	  conjugate	  (Figure	  1)	  
	   HA-­‐tetrabutylammonium	  salt	  (HA-­‐TBA)	  The	  HA-­‐TBA	  was	  prepared	  from	  the	  
hyaluronan	  sodium	  salts	  according	  to	  a	  previously	  disclosed	  ion-­‐exchange	  method	  [46].	  
Briefly,	  30	  mg	  of	  HA	  (215	  kDa	  or	  752	  kDa)	  was	  first	  dissolved	  in	  30	  mL	  of	  ddH2O	  in	  a	  round	  
bottom	  flask,	  and	  then	  approximately	  600	  mg	  of	  Dowex®	  50W	  X8	  cation	  exchange	  resin	  
was	  added	  into	  the	  flask	  and	  stirred	  overnight.	  The	  HA/resin	  mixture	  was	  filtered	  through	  
a	  syringe	  filter	  (5-­‐μm	  Nylon,	  Thermo	  Scientific,	  Rockwood,	  TN),	  and	  the	  pH	  of	  the	  filtrate	  
was	  adjusted	  with	  the	  TBA	  hydroxide	  solution	  until	  the	  color	  of	  the	  solution	  turned	  to	  light	  
pink.	  The	  resultant	  HA-­‐TBA	  solution	  was	  lyophilized	  to	  afford	  the	  dried	  HA-­‐TBA	  salt.	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   HA-­‐deferoxamine	  (HA-­‐DFO)	  Approximately	  30	  mg	  of	  lyophilized	  HA-­‐TBA	  was	  
dissolved	  in	  10	  mL	  of	  DMSO	  with	  vigorous	  stirring,	  followed	  by	  EDC	  (3	  eq;	  22.52	  mg)	  and	  
sulfo-­‐NHS	  (3	  eq;	  39.62	  mg)	  to	  activate	  the	  carboxylic	  acid	  group	  on	  HA.	  After	  2	  h,	  DFO	  (3	  
eq;	  94.87	  mg)	  in	  250	  μL	  of	  DMSO	  was	  added	  into	  the	  mixture.	  The	  reaction	  was	  carried	  out	  
for	  24	  h	  at	  ambient	  temperature.	  The	  resultant	  solution	  was	  first	  dialyzed	  against	  50-­‐mM	  
sodium	  chloride	  (MWCO	  10	  kDa)	  for	  24	  h	  with	  dialysis	  medium	  replaced	  every	  2h,	  and	  
then	  the	  dialysis	  was	  performed	  in	  ddH2O	  for	  72	  h	  before	  lyophilization	  to	  yield	  the	  HA-­‐
DFO	  in	  a	  dry	  form.	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2.31H	  Nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy	  
The	  HA	  sodium	  salts,	  DFO,	  and	  HA	  (215	  kDa	  or	  752	  kDa)	  were	  dissolved	  in	  
deuterium	  oxide	  (D2O)	  and	  their	  1H	  NMR	  spectra	  were	  collected	  on	  a	  Bruker	  Avance	  400	  
MHz	  NMR	  Spectrometer	  (Bruker	  Corporation,	  MA,	  USA).	  
	  
2.4	  Quantification	  of	  DFO	  in	  the	  HA-­‐DFO	  conjugates	  
DFO	  has	  been	  reported	  to	  chelate	  iron	  in	  the	  oxidation	  state	  of	  +3	  to	  form	  a	  1:1	  DFO-­‐
Iron	  (III)	  chelate	  complex,	  ferrioxamine	  [47],	  which	  has	  a	  maximum	  absorption	  at	  430	  nm	  
(Δε	  =	  2500M	  −1·cm−1)	  [48,	  49].	  The	  degree	  of	  conjugation	  (DS%)	  was	  determined	  
spectrophotometrically	  by	  converting	  the	  HA-­‐DFO	  to	  the	  iron-­‐saturated	  ferrioxamine	  using	  
a	  modified	  method[35].	  Typically,	  3	  mM	  of	  iron	  (III)	  chloride	  (FeCl3)	  was	  incubated	  with	  a	  
series	  of	  standard	  solutions	  of	  DFO	  (0.05–0.5	  mg/mL),	  1-­‐mg/mL	  HA	  (215	  kDa)-­‐DFO	  or	  HA	  
(752	  kDa)-­‐DFO	  at	  ambient	  temperature	  for	  16	  h,	  followed	  by	  recording	  the	  absorption	  at	  
430	  nm	  using	  a	  UV	  microplate	  reader	  (SpectraMax	  Gemini;	  Molecular	  Devices,	  Sunnyvale,	  
CA).	  The	  DS%	  of	  HA	  with	  DFO	  was	  determined	  by	  quantitating	  respective	  HA-­‐DFO-­‐
generated	  ferrioxamine	  species	  with	  the	  calibration	  curve	  of	  the	  ferrioxamine	  standard	  
solutions	  prepared	  from	  unmodified	  DFO.	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2.5	  Fourier	  Transform	  Infrared	  Spectroscopy	  (FTIR)	  
FTIR	  spectra	  of	  2	  mg	  of	  chelating	  materials	  and	  iron	  complexes	  were	  recorded	  on	  an	  
IRAffinity-­‐1	  FTIR	  (Shimadzu	  Scientific	  Instruments,	  KS).	  For	  each	  spectrum,	  100	  scans	  
were	  collected	  between	  500	  and	  4000	  cm-­‐1	  at	  a	  resolution	  of	  1	  cm-­‐1.	  
	  
2.6	  Determination	  of	  relative	  binding	  affinity	  for	  iron	  	   	  
	   The	  binding	  affinity	  of	  DFO	  and	  HA-­‐DFO	  for	  Fe	  (III)	  was	  determined	  using	  a	  
competitive	  spectrophotometric	  assay	  reported	  by	  Poreddy	  et	  al.,	  [35].	  In	  brief,	  1-­‐mM	  FeCl3	  
in	  1-­‐mM	  HCl	  solution	  was	  added	  into	  the	  same	  volume	  of	  10-­‐mM	  8-­‐hydroxyquinoline-­‐5-­‐
sulfonic	  acid	  (sodium	  sulfoxine)	  in	  20-­‐mM	  PIPES,	  and	  then	  the	  mixture	  was	  diluted	  with	  
20-­‐mM	  PIPES	  (pH	  7.0)	  to	  obtain	  a	  sodium	  (600	  μM)-­‐iron	  (III)	  (60	  μM)	  solution.	  Freshly	  
prepared	  1-­‐mM	  DFO	  (15	  μL)	  or	  1-­‐mM	  HA-­‐DFO	  conjugates	  (on	  DFO	  basis)	  (15	  μL)	  was	  
added	  into	  the	  sulfoxine-­‐Fe	  (III)	  solution,	  followed	  by	  gentle	  shaking	  on	  an	  orbital	  shaker	  
(Madell	  Technology	  Corp,	  Ontario,	  CA)	  for	  16	  h	  at	  ambient	  temperature.	  The	  absorbances	  
at	  570	  nm	  of	  resultant	  solutions	  were	  measured	  on	  a	  UV	  microplate	  reader	  (SpectraMax	  
Gemini;	  Molecular	  Devices,	  Sunnyvale,	  CA).	  A	  solution	  consisting	  of	  ddH2O	  instead	  of	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DFO/HA-­‐DFO	  served	  as	  a	  negative	  control.	  The	  percentage	  of	  Fe	  (III)	  stripped	  by	  the	  DFO-­‐
containing	  solutions	  from	  the	  sulfoxine-­‐Fe	  (III)	  was	  calculated	  using	  the	  equation:	  
Fe	  (III)	  Stripped%=	  [A0-­‐At]/[A0]	  ×	  100%	  
A0:	  Absorbance	  of	  negative	  control	  at	  570	  nm	  
At:	  Absorbance	  of	  test	  solution	  at	  570	  nm	  
	  
2.7	  In	  vitro	  release	  of	  DFO	  from	  the	  HA-­‐DFO	  conjugates	  	  	  	  
The	  evaluation	  of	  in	  vitro	  DFO	  release	  from	  the	  HA-­‐DFO	  conjugates	  was	  carried	  out	  
in	  4	  L	  of	  phosphate	  buffered	  saline	  (PBS)	  (pH	  7.4,	  10	  mM)	  at	  37	  °C	  and	  stirring	  at	  250	  rpm.	  
Solutions	  of	  free	  DFO	  solutions	  or	  HA-­‐DFO	  conjugates	  were	  transferred	  into	  a	  dialysis	  bag	  
(SnakeSkinTM,	  MWCO:	  10	  KDa)	  (Thermo	  Scientific	  Inc.,	  Rockfor,	  IL).	  The	  release	  medium	  
was	  replaced	  with	  fresh	  PBS	  every	  4	  h	  to	  maintain	  the	  sink	  condition.	  At	  predetermined	  
time	  points,	  a	  60-­‐μL	  solution	  was	  sampled	  and	  mixed	  with	  3	  mM	  of	  FeCl3	  (1:1	  v/v).	  The	  
amounts	  of	  DFO	  left	  in	  the	  solutions	  were	  quantified	  according	  to	  section	  2.4.	  
	  
2.8	  In	  vitro	  evaluation	  of	  Iron	  (III)-­‐retention	  capacity	  of	  the	  HA-­‐DFO	  conjugates	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The	  evaluation	  of	  Iron	  (III)-­‐retention	  capacity	  of	  the	  HA-­‐DFO	  conjugates	  was	  carried	  
out	  in	  4	  L	  of	  phosphate	  buffered	  saline	  (PBS)	  (pH	  7.4,	  10	  mM)	  at	  37	  °C	  and	  stirring	  at	  250	  
rpm.	  To	  spectrophotometrically	  quantify	  the	  amount	  of	  remained	  DFO	  in	  the	  samples,	  Fe	  
(III)	  chelate	  complex	  with	  free	  DFO,	  HA/DFO	  mixture	  or	  HA-­‐DFO	  was	  first	  prepared	  
according	  to	  the	  procedures	  described	  in	  section	  2.4,	  and	  then	  transferred	  into	  a	  dialysis	  
bag	  (SnakeSkinTM,	  MWCO:	  10	  KDa)	  (Thermo	  Scientific	  Inc.,	  Rockfor,	  IL).	  The	  release	  
medium	  was	  replaced	  with	  fresh	  PBS	  every	  4	  h	  to	  maintain	  the	  sink	  condition.	  A	  60-­‐μL	  
solution	  was	  sampled	  in	  predetermined	  time	  points,	  and	  the	  DFO-­‐Fe	  (III)	  chelate	  complex	  
left	  in	  the	  solution	  was	  quantified	  according	  to	  section	  2.4.	  
	  
2.9	  In	  vitro	  cytotoxicity	  of	  HA-­‐DFO	  in	  normal	  cells	  
The	  cytotoxicity	  of	  DFO	  and	  HA-­‐DFO	  to	  a	  normal	  human	  cell	  line	  was	  evaluated	  
using	  a	  cell	  growth	  inhibition	  assay	  in	  HUVECs	  cultured	  in	  EGMTM	  Complete	  Medium	  
supplemented	  with	  human	  Epidermal	  Growth	  Factor,	  hydrocortisone,	  bovine	  brain	  extract,	  
ascorbic	  acid,	  fetal	  bovine	  serum,	  and	  Gentamicin/Amphotericin-­‐B.	  HUVECs	  were	  grown	  in	  
96-­‐well	  plates	  at	  3,000	  cells/well	  (n=3	  plates,	  12	  wells/concentration).	  After	  a	  16-­‐h	  
incubation,	  DFO,	  HA-­‐215kDa-­‐DFO	  or	  HA-­‐752kDa-­‐DFO	  dissolved	  in	  PBS	  were	  added	  to	  each	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well	  with	  final	  concentrations	  ranging	  from	  0.01	  μM	  to	  100	  μM.	  Subsequently,	  a	  resazurin-­‐
based	  colorimetric	  assay	  was	  performed	  to	  quantify	  viability	  of	  cell	  cultures	  at	  72	  h	  post-­‐
treatment	  [50].	  
	  
2.10	  In	  vitro	  enzymatic	  degradation	  
The	  kinetics	  of	  enzymatic	  degradation	  of	  HA	  was	  studied	  by	  monitoring	  the	  
molecular	  weight	  change.	  First,	  2	  mg/mL	  of	  unmodified	  HA	  or	  HA-­‐DFO	  conjugate	  solutions	  
were	  prepared	  in	  4	  mL	  of	  PBS	  (10	  mM,	  pH7.4),	  and	  then	  hyaluronidase	  solution	  (0.35	  
mg/mL)	  was	  added	  into	  the	  reaction	  system.	  While	  the	  mixture	  was	  incubated	  at	  37	  °C,	  the	  
molecular	  weights	  of	  100-­‐	  μL	  aliquots	  of	  the	  samples	  were	  monitored	  by	  gel-­‐permeation	  
chromatography	  (GPC)	  at	  25	  °C	  on	  a	  Shimadzu	  2010CHT	  with	  a	  refractive	  index	  detector	  
(RID-­‐10A,	  Shimadzu	  Scientific	  Instruments,	  KS),	  using	  a	  Shodex	  OHpak	  SB-­‐806	  HQ	  column	  
(Showa	  Denko	  America,	  Inc.,	  New	  York,	  NY)	  with	  5-­‐mM	  ammonium	  acetate	  as	  the	  mobile	  
phase	  at	  a	  flow	  rate	  of	  0.8	  mL/min.	  	  	  
	  
2.11	  Preliminary	  animal	  experiments	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Three	  groups	  of	  rats	  (controls,	  DFO,	  HA-­‐DFO	  conjugates;	  n	  =	  5	  for	  each	  group)	  
underwent	  surgical	  external	  fixation	  and	  subsequent	  distraction.	  During	  the	  distraction	  
stage,	  the	  experimental	  deferoxamine	  group	  was	  treated	  with	  twice	  weekly	  injections	  into	  
the	  distraction	  gap	  compared	  to	  single	  dose	  application	  of	  a	  lyophilized	  HA-­‐DFO	  
conjugates.	  After	  21	  days	  of	  consolidation,	  mandibles	  were	  harvested	  and	  prepared	  for	  
histologic	  analysis.	  	  
	  
2.12	  Statistical	  analyses	  
Summarized	  values	  from	  multiple	  measurements	  are	  expressed	  as	  mean	  ±	  standard	  
deviation.	  Statistical	  analyses	  were	  performed	  using	  GraphPad	  Prism	  6	  software	  with	  a	  
significance	  threshold	  setting	  of	  P=	  0.05.	  Student’s	  t-­‐tests	  were	  applied	  to	  analyze	  the	  iron-­‐
binding	  affinity,	  and	  a	  two-­‐way	  ANOVA	  analysis	  was	  conducted	  for	  comparing	  cell	  viability	  
and	  the	  molecular	  weight	  of	  enzyme-­‐catalyzed	  hydrolysis	  products.	  
	  
3.	  Results	  
3.1	  Synthesis	  and	  quantification	  of	  HA-­‐DFO	  conjugates	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The	  primary	  amine	  group	  of	  DFO	  was	  covalently	  conjugated	  to	  the	  carboxylic	  acid	  
groups	  of	  the	  HA	  backbone	  using	  a	  modified	  EDC/sulfo-­‐NHS	  coupling	  chemistry.	  The	  
chemical	  structures	  of	  purified	  HA-­‐DFO	  conjugates	  were	  characterized	  with	  1H-­‐NMR	  
spectra.	  The	  successful	  conjugation	  was	  confirmed	  by	  the	  presence	  of	  the	  characteristic	  
peaks	  of	  DFO	  and	  HA	  in	  their	  1H-­‐NMR	  spectra	  (Figure	  2)	  and	  a	  significant	  change	  in	  
chemical	  shift	  of	  the	  methyl	  group,	  f,	  from	  2.71	  ppm	  in	  the	  spectrum	  of	  DFO	  to	  2.82	  in	  
spectra	  of	  HA-­‐215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO.	  
	  





Figure	  2.	  1H-­‐NMR	  spectra	  (D2O,	  400	  MHz)	  of	  (A)	  DFO,	  (B)	  HA,	  (C)	  HA-­‐215kDa-­‐DFO,	  (D)	  HA-­‐
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   Deferoxamine	  has	  a	  high	  binding	  affinity	  (Kd	  ≈	  10-­‐30	  M)	  [51,	  52]	  for	  ferric	  ions	  to	  
form	  a	  light-­‐amber	  ferric	  chelate,	  ferroxiamine,	  with	  a	  maximum	  absorption	  at	  430	  nm.	  
Upon	  chelating	  with	  ferric	  iron,	  both	  unmodified	  DFO	  and	  HA-­‐DFO	  conjugates	  exhibited	  
stronger	  absorption	  at	  430	  nm	  compared	  with	  the	  iron-­‐free	  forms	  (Figure	  3A	  and	  B).	  The	  
DS	  %	  of	  the	  DFO	  to	  HA	  backbones	  was	  observed	  to	  be	  molecular	  weight-­‐dependent	  and	  it	  
was	  found	  to	  be	  12.59	  ±	  1.85	  %	  (wt.	  %)	  and	  9.60	  ±	  0.28	  %	  (wt.%)	  for	  HA-­‐215kDa-­‐DFO	  and	  
HA-­‐752kDa-­‐DFO,	  respectively.	  Such	  a	  difference	  in	  DS%	  was	  probably	  due	  to	  the	  higher	  
accessibility	  of	  the	  reactive	  groups	  in	  the	  relatively	  less	  viscous	  HA-­‐215kDa.	  
	  






Figure	  3.	  	  UV-­‐Visible	  spectra	  of	  aqueous	  solution	  of	  Fe	  (III)-­‐DFO	  (0.6	  mg/mL),	  Fe	  (III)-­‐HA-­‐
215kDa-­‐DFO	  (3.0	  mg/mL).	  The	  spectra	  of	  FeCl3	  (3mM),	  DFO	  (0.6	  mg/mL),	  HA-­‐215kDa-­‐DFO	  
(3.0	  mg/mL)	  and	  the	  mixture	  of	  FeCl3	  with	  HA-­‐215kDa	  were	  also	  shown	  for	  comparison.	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3.2	  Characterization	  of	  HA-­‐DFO	  conjugates	  
FTIR	  spectroscopy	  was	  performed	  to	  study	  the	  effect	  of	  the	  iron	  chelation	  on	  the	  
structural	  changes	  of	  deferoxamine.	  Figure	  4	  and	  5	  show	  the	  FT-­‐IR	  spectra	  of	  the	  
unmodified	  DFO,	  the	  unmodified	  HA,	  HA-­‐215kDa-­‐DFO	  and	  the	  lyophilized	  ferrioxamine	  
prepared	  from	  DFO	  or	  HA-­‐DFO	  conjugates	  in	  the	  region	  of	  4000	  to	  400	  cm-­‐1.	  	  The	  FTIR	  
spectrum	  of	  DFO	  was	  collected	  and	  compared	  with	  its	  iron-­‐chelated	  form,	  ferrrioxamine.	  
Distinct	  spectrum	  changes	  at	  3500-­‐2900	  cm	  -­‐1	  and	  1700-­‐1500	  cm-­‐1	  ranges	  revealed	  
structural	  differences	  between	  deferoxamine	  and	  ferrrioxamine	  as	  a	  consequence	  of	  the	  
involvements	  of	  the	  hydroxaminc	  groups	  during	  iron	  chelating.	  As	  shown	  in	  the	  Figure	  4,	  
the	  sharp	  band	  at	  3307	  cm-­‐1	  (assigned	  as	  the	  N-­‐H	  of	  the	  secondary	  amide	  group)	  in	  DFO	  
decreased	  and	  shifted	  to	  3269	  cm-­‐1,	  forming	  a	  broad	  peak	  in	  ferrrioxamine	  due	  to	  the	  
prominent	  effect	  of	  iron-­‐chelation.	  Moreover,	  the	  wide	  peak	  at	  3095	  cm-­‐1	  (assigned	  as	  C-­‐NH	  
overtone	  of	  the	  secondary	  amide	  group)	  observed	  in	  DFO	  disappeared	  in	  the	  ferrioxamine	  ,	  
in	  which	  a	  small	  sharp	  peak	  at	  3080	  cm-­‐1	  corresponds	  to	  the	  assignment	  of	  C-­‐NH	  overtone	  
instead.	  In	  the	  lower	  frequency	  range,	  the	  stretching	  band	  of	  carbonyl	  group	  in	  
hydroxamate	  shifted	  from	  1622	  cm-­‐1	  in	  DFO	  to	  1606	  cm-­‐1	  in	  the	  DFO-­‐Iron	  (III)	  complex	  ,	  
indicating	  the	  metal-­‐oxygen	  atoms	  binding.	  These	  results	  are	  in	  great	  agreement	  with	  
(a) 
(b) 
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observations	  in	  other	  spectral	  analysis	  of	  DFO	  and	  its	  chelated	  form,	  ferrioxamine,	  using	  
the	  Thermal-­‐FTIR	  [53].	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As	  shown	  in	  the	  Figure	  5,	  the	  FTIR	  spectra	  of	  the	  unmodified	  HA	  (215	  kDa	  and	  752	  
kDa)	  and	  DFO	  overlapped	  to	  great	  extent	  at	  3600-­‐2800	  cm-­‐1	  and	  1650-­‐1000	  cm-­‐1	  intervals,	  
as	  both	  compounds	  share	  multiple	  functional	  groups.	  However,	  the	  broad	  band	  around	  
3273	  cm-­‐1	  can	  be	  exclusively	  assigned	  to	  hydrogen-­‐bonded	  O-­‐H	  and	  N-­‐H	  stretching	  in	  the	  
HA	  backbone.	  The	  sharp	  peaks	  at	  1614	  cm-­‐1	  and	  1411	  cm-­‐1	  result	  from	  the	  asymmetric	  C=O	  
stretching	  and	  symmetric	  C-­‐O	  stretching	  of	  the	  amide	  groups	  [54,	  55]	  of	  the	  native	  HA,	  
respectively.	  The	  FTIR	  spectrum	  of	  the	  HA-­‐DFO	  conjugates	  resolved	  the	  characteristic	  
peaks	  of	  DFO	  at	  2920	  cm-­‐1	  and	  2850	  cm	  -­‐1,	  and	  1151	  cm	  -­‐1	  and	  peaks	  of	  HA-­‐215kDa	  at	  3273	  
cm-­‐1,	  1076	  cm-­‐1,	  and	  1039	  cm-­‐1,	  resulting	  from	  the	  successful	  conjugation	  of	  DFO	  to	  HA.	  
Compared	  with	  the	  FTIR	  spectra	  of	  HA-­‐DFO	  conjugates,	  significant	  peak	  shifts	  were	  
observed	  in	  the	  spectra	  of	  HA-­‐DFO-­‐Fe	  (III)	  chelates	  prepared	  from	  both	  HA-­‐215kDa-­‐DFO	  
and	  HA-­‐752-­‐DFO	  conjugates.	  As	  the	  peak	  shifting	  upon	  iron	  chelation	  mostly	  occurred	  in	  
the	  highly	  overlapped	  region,	  it	  is	  very	  difficult	  to	  accurately	  assign	  peaks.	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s	  
Figure	  5.	  FT-­‐IR	  spectra	  of	  HA-­‐215kDa,	  HA-­‐215kDa-­‐DFO,	  HA-­‐215kDa-­‐DFO-­‐Iron	  (III)	  chelate,	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3.3	  Effect	  of	  polymer-­‐conjugation	  of	  DFO	  on	  binding	  affinity	  for	  Ferric	  Ion	  
The	  iron-­‐chelating	  properties	  of	  unmodified	  DFO	  and	  HA-­‐DFO	  conjugates	  were	  
assessed	  using	  a	  competitive	  iron-­‐binding	  experiment.	  A	  solution	  of	  sulfoxine	  was	  first	  
mixed	  with	  FeCl3	  to	  form	  a	  sulfoxine-­‐iron	  (III)	  complex	  (λmax	  =	  570	  nm).	  The	  subsequent	  
addition	  of	  the	  DFO	  or	  HA-­‐DFO	  displaced	  the	  sulfoxine	  to	  form	  a	  chelator-­‐ferric	  ion	  
complex	  that	  had	  weak	  absorbance	  at	  570	  nm.	  The	  reaction	  mixture	  was	  incubated	  at	  
ambient	  temperature	  for	  16	  h	  to	  strip	  chelated	  iron.	  As	  a	  result,	  the	  reduced	  absorption	  at	  
570	  nm	  is	  proportional	  to	  the	  iron	  affinity	  of	  chelator,	  and	  can	  be	  readily	  read	  out	  on	  a	  96-­‐
well	  microplate	  spectrophotometer.	  The	  structural	  modification	  to	  DFO	  via	  conjugation	  to	  
the	  high	  molecular	  weight	  HA	  was	  found	  to	  reduce	  iron-­‐chelating	  capabilities	  (Figure	  6).	  
Compared	  to	  unmodified	  DFO,	  HA-­‐215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO	  retained	  94.34	  %	  and	  
84.30%	  iron-­‐binding	  capacity,	  respectively.	  
	  






Figure	  6.Measurment	  of	  iron-­‐binding	  affinities	  of	  unmodified	  deferoxamine,	  HA-­‐215kDa-­‐
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3.4	  In	  vitro	  evaluation	  of	  Iron	  (III)-­‐retention	  capacity	  of	  the	  HA-­‐DFO	  conjugates	  	  
The	  release	  profiles	  of	  free	  DFO	  and	  HA-­‐DFO	  conjugates	  are	  shown	  in	  Figure	  7,	  and	  
their	  release	  kinetics	  were	  fitted	  using	  a	  first-­‐order	  model.	  The	  release	  half-­‐lives	  of	  free	  
DFO,	  is	  0.5	  h.	  Compared	  with	  the	  unmodified	  DFO	  samples,	  sustained	  release	  of	  the	  DFO	  
were	  observed	  for	  the	  HA-­‐DFO	  conjugates.	  The	  remained	  percentages	  of	  DFO	  in	  the	  HA-­‐
215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO	  were	  78%	  and	  81%	  after	  two-­‐day	  dialysis,	  respectively,	  
due	  to	  the	  stable	  amide	  bonds	  formed	  between	  the	  drug	  molecules	  and	  the	  HA	  backbones.	  
	  





Figure	  7.	  In	  vitro	  release	  profiles	  of	  deferoxamine,	  HA-­‐215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO	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3.5	  In	  vitro	  evaluation	  of	  Iron	  (III)-­‐retention	  capacity	  of	  the	  HA-­‐DFO	  conjugates	  	  
The	  release	  profiles	  of	  DFO,	  HA/DFO	  mixture	  and	  HA-­‐DFO	  conjugates	  in	  the	  Fe	  (III)-­‐
chelated	  forms	  are	  shown	  in	  Figure	  8.	  The	  Fe	  (III)	  chelate	  complexes	  with	  unmodified	  DFO	  
and	  HA/DFO	  mixture	  were	  not	  retained	  in	  the	  dialysis	  bag,	  and	  their	  release	  kinetics	  were	  
fitted	  using	  a	  first-­‐order	  model	  with	  release	  half-­‐lives	  of	  0.52	  h	  and	  0.64	  h,	  respectively.	  In	  
comparison,	  a	  biphasic	  release	  pattern	  was	  shown	  in	  the	  release	  kinetics	  profiles	  of	  HA-­‐
DFO	  conjugates	  with	  an	  initial	  burst	  release	  of	  approximately	  20%	  of	  the	  loading	  dose	  
within	  1	  h,	  probably	  due	  to	  the	  release	  of	  the	  complex	  on	  the	  surface	  of	  HA-­‐DFO	  conjugate	  
nanparticles.	  Thereafter,	  sustained	  release with	  half-­‐lives	  of	  4.35	  d	  and	  14.17	  d	  were	  
observed	  for	  HA-­‐215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO,	  respectively.	  
	  
	  





Figure	  8.	  In	  vitro	  release	  profiles	  of	  Fe	  (III)	  chelate	  complexes	  prepared	  from	  	  
deferoxamine,	  HA-­‐215kDa-­‐DFO	  and	  HA-­‐752kDa-­‐DFO	  in	  PBS	  at	  37	  °C	  (Mean	  ±	  SD;	  N=3).	  	  






























	   207	  
3.6	  In	  vitro	  cytotoxicity	  of	  HA-­‐DFO	  in	  normal	  HUVEC	  cells	  
The	  cell	  viability	  tests	  in	  the	  presence	  of	  free	  DFO	  or	  HA-­‐DFO	  conjugates	  
demonstrated	  a	  concentration-­‐dependent	  cytotoxicity	  to	  HUVECs	  (Figure	  9).	  The	  free	  DFO	  
was	  significantly	  more	  toxic	  to	  the	  HUVECs	  from	  5-­‐50	  μM,	  compared	  with	  the	  HA-­‐DFO	  
conjugates.	  Particularly,	  after	  incubating	  the	  cells	  with	  either	  free	  DFO	  for	  72	  h,	  the	  cell	  
viability	  was	  approximately	  79.38	  %	  at	  5	  μM,	  and	  it	  decreased	  to	  52.79%	  at	  a	  DFO	  
concentration	  of	  50	  μM.	  At	  the	  equivalent	  HA-­‐DFO	  dose	  range,	  however,	  the	  survival	  rates	  
of	  cells	  treated	  with	  HA-­‐215kDa-­‐DFO	  were	  1.14	  -­‐	  1.53	  fold	  higher	  than	  that	  of	  the	  free	  DFO-­‐
treated	  cells.	  Similar	  increased	  cell	  viability	  was	  observed	  in	  the	  HA-­‐752kDa-­‐DFO	  group,	  
and	  the	  apparent	  toxic	  effects	  of	  both	  two	  HA-­‐DFO	  conjugates	  could	  only	  be	  observed	  at	  
high	  DFO	  concentration	  above	  50	  μM.	  
	  






Figure	  9.	  Cell	  viability	  assay	  of	  deferoxamine	  and	  two	  HA-­‐DFO	  conjugates	  in	  normal	  
HUVEC	  cells	  (Mean	  ±	  SD;	  N=3;	  *p	  <	  0.05).	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3.7	  In	  vitro	  enzymatic	  degradation	  
The	  effects	  of	  hyaluronidase	  on	  the	  molecular	  weight	  of	  unmodified	  HA	  and	  HA-­‐DFO	  
conjugates	  are	  shown	  in	  Figure	  10.	  The	  molecular	  weights	  of	  both	  unmodified	  HA	  and	  HA-­‐
DFO	  conjugates	  decreased	  within	  1	  h	  to	  less	  than	  10%	  of	  their	  initial	  molecular	  weights	  
and	  to	  approximately	  5%	  as	  the	  incubation	  proceeded.	  No	  significant	  difference	  in	  the	  
enzyme-­‐catalyzed	  hydrolysis	  degree	  was	  found	  between	  unmodified	  HA	  and	  the	  HA-­‐DFO	  
conjugates.	  Moreover,	  by	  the	  end	  of	  the	  incubation	  at	  72h,	  the	  retained	  molecular	  weight	  of	  
the	  unmodified	  HA-­‐215kDa,	  HA-­‐215kDa-­‐DFO,	  HA-­‐752kDa	  and	  HA-­‐752kDa-­‐DFO	  were	  
7.83%,	  7.82%,	  8.23%	  and	  6.63%,	  respectively.	  These	  findings	  established	  that	  chemical	  
modification	  of	  the	  HA	  with	  DFO	  did	  not	  affect	  the	  biodegradability	  of	  HA	  in	  simulated	  
physiological	  environments.	  
	  





Figure	  10.	  Comparison	  of	  the	  enzymatic	  hydrolysis	  of	  unmodified	  HA	  and	  HA-­‐DFO	  
conjugates	  by	  GPC	  measurement	  in	  PBS	  (10	  mM,	  pH7.4)	  at	  37	  °C	  with	  and	  without	  
hyaluronidases.	  (Mean	  ±	  SD;	  N=3;	  *p	  <	  0.05).	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3.	  8	  Preliminary	  animal	  experiments	  
A	  proliferation	  of	  osteocytes	  was	  observed	  in	  both	  the	  HA-­‐DFO	  conjugate	  and	  DFO-­‐
treated	  groups	  when	  compared	  with	  the	  regenerate	  of	  the	  control	  group.	  Deferoxamine	  
affected	  a	  significant	  increase	  in	  osteocytes	  and	  an	  increase	  in	  bone	  volume	  fraction,	  with	  
subsequent	  decreased	  osteoid	  volume	  fraction.	  The	  data	  also	  demonstrated	  no	  significant	  
difference	  in	  empty	  lacunae.	  After	  3	  weeks,	  the	  mice	  treated	  with	  the	  HA-­‐DFO	  conjugates	  
had	  slightly	  faster	  proliferation	  of	  osteocytes	  than	  the	  standard	  DFO	  injection	  group.	  	  
	  
4.	  Discussion	  
Our	  motivation	  to	  design	  a	  macromolecular	  DFO	  complex	  using	  HA	  stems	  from	  its	  
inherent	  biocompatibility,	  its	  exceptional	  viscoelastic	  and	  its	  therapeutic	  properties	  in	  the	  
treatment	  of	  arthritis	  and	  wound	  healing.	  The	  relatively	  simple	  chemical	  structure	  of	  HA	  
allows	  us	  to	  perform	  further	  modifications	  to	  create	  versatile	  drug	  carriers	  with	  controlled	  
release	  profiles.	  Chemical	  modifications	  of	  HA	  generally	  focus	  on	  four	  structural	  sites,	  
including	  the	  reducing	  end,	  N-­‐acetyl	  groups,	  hydroxyl	  groups,	  and	  carboxylic	  acid	  groups.	  
Carbodiimide-­‐mediated	  conjugations	  using	  EDC	  to	  couple	  HA	  to	  primary	  amine-­‐containing	  
molecules	  have	  been	  reported	  to	  result	  in	  low	  reaction	  yields	  [56,	  57],	  which	  may	  be	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caused	  by	  a	  fast	  formation	  of	  a	  stable	  N-­‐acylurea	  adducts	  from	  OèN	  rearrangement	  [57,	  
58].	  Cross-­‐linking	  strategies	  that	  require	  first	  forming	  modified	  HA	  with	  a	  variety	  of	  
functional	  groups,	  such	  as	  thiol	  [59,	  60],	  sym-­‐collidine	  [61]	  and	  adipic	  acid	  dihydrazide	  [62,	  
63],	  on	  the	  other	  hand,	  have	  been	  shown	  to	  effectively	  graft	  poorly	  water	  soluble	  
therapeutic	  agents	  to	  the	  carboxylic	  acid	  groups	  of	  HA.	  However,	  alterations	  physical	  
characteristics	  of	  HA,	  such	  as	  decreased	  solubility	  or	  receptor-­‐recognition,	  have	  been	  
associated	  with	  the	  cross-­‐linking	  method.	  Alternative	  carbodiimide-­‐catalyzed	  approaches	  
include	  reacting	  the	  primary	  amine	  group	  with	  the	  carboxyl	  group	  on	  HA	  using	  
hydroxybenzotriazole	  or	  N-­‐hydroxysuccinimide	  in	  an	  organic	  solvent/water	  mixture	  to	  
prevent	  the	  OèN	  rearrangement	  [64,	  65].	  In	  this	  study,	  we	  used	  a	  two-­‐step	  approach	  for	  
HA-­‐DFO	  conjugation,	  which	  relies	  on	  first	  forming	  the	  tetrabutylammonium	  salt	  of	  
hyaluronic	  acid	  (HA-­‐TBA).	  HA-­‐TBA	  posses	  excellent	  DMSO-­‐solubility	  and	  thus	  remarkably	  
stabilize	  the	  HA-­‐NHS	  active	  ester	  during	  the	  HA-­‐DFO	  conjugation	  reaction	  performed	  in	  
DMSO,	  resulting	  in	  the	  facile	  grafting	  DFO	  to	  HA	  backbones	  without	  generating	  the	  N-­‐
acylurea	  adduct.	  
Deferoxamine	  consists	  of	  an	  aliphatic	  chain,	  two	  secondary	  amide	  groups,	  and	  three	  
bidentate	  hydroxamic	  groups;	  the	  last	  component	  serves	  as	  a	  chelator	  for	  trivalent	  iron.	  
Upon	  iron	  binding,	  the	  hydroxyl	  groups	  deprotonate	  and	  tform	  a	  stable	  octahedral	  complex	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with	  three	  asymmetrical	  chelation	  rings	  around	  ferric	  iron.	  To	  verify	  that	  the	  binding	  
behavior	  of	  DFO	  molecules	  was	  not	  altered	  after	  being	  immobilized	  to	  the	  high	  molecular	  
weight	  HA,	  the	  spectra	  properties	  of	  the	  HA-­‐DFO-­‐Fe	  (III)	  complex	  was	  recorded	  and	  
compared	  with	  that	  of	  the	  DFO-­‐Fe	  (III)	  complex.	  Indeed,	  the	  virtually	  identical	  spectra	  
profiles	  in	  the	  characteristic	  absorption	  region	  revealed	  that	  the	  HA-­‐DFO	  conjugate	  
chelated	  to	  the	  ferric	  ions	  in	  a	  similar	  manner	  as	  the	  free	  DFO	  molecules.	  	  
Compared	  with	  the	  unmodified	  DFO	  molecules,	  HA-­‐DFO	  conjugate	  exhibited	  
decreased	  iron-­‐binding	  capability,	  which	  was	  probably	  caused	  by	  restricted	  movements	  
and	  spatial	  arrangement	  of	  the	  hydroxamic	  groups	  on	  the	  DFO.	  Poreddy	  et	  al.,	  [66]	  
synthesized	  several	  libraries	  of	  structural	  DFO	  analogues	  that	  had	  modifications	  on	  the	  
spacer	  and	  the	  C-­‐terminal.	  They	  also	  prepared	  a	  number	  of	  DFO	  variants	  of	  non-­‐amide,	  
reverse-­‐amide,	  or	  hybrid.	  Compared	  with	  the	  unmodified	  DFO,	  two	  thirds	  of	  these	  DFO	  
analogues	  remain	  varying	  and	  relatively	  low	  binding	  affinities	  from	  17%	  to	  62%.	  In	  
comparison,	  both	  HA-­‐DFO	  conjugates	  made	  using	  our	  synthetic	  approach	  retained	  much	  
higher	  iron-­‐binding	  affinities,	  which	  were	  at	  least	  84%	  of	  the	  unmodified	  DFO	  (Figure	  5).	  
Such	  improved	  iron-­‐binding	  affinity	  observed	  in	  the	  present	  study	  was	  achieved	  by	  
modifying	  the	  terminal	  amino	  group	  in	  DFO,	  which	  is	  located	  five	  methylene	  groups	  away	  
from	  the	  nearest	  iron-­‐binding	  hydroxamic	  groups.	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The	  development	  of	  high-­‐molecular-­‐weight	  DFO-­‐polymer	  conjugates	  has	  been	  
suggested	  as	  an	  efficient	  approach	  for	  extending	  the	  retention	  of	  the	  DFO	  and	  sparing	  the	  
rapid	  clearance	  of	  the	  chelator.	  In	  some	  cases,	  the	  DFO	  is	  covalently	  attached	  to	  
biocompatible	  polymers	  such	  as	  polysaccharide	  (e.g.	  dextran	  and	  hydroxyethyl-­‐starch)	  via	  
a	  reductive	  amination	  [35]	  and	  poly	  (ethylene	  glycol)	  [36]	  through	  an	  amide	  linkage.	  These	  
polymer-­‐based	  macromolecular	  DFO	  retained	  the	  iron-­‐binding	  properties	  and	  exhibited	  
significantly	  reduced	  cytotoxicity	  in	  normal	  cells.	  In	  the	  present	  study,	  we	  observed	  that	  
the	  hyaluronan	  derivatives	  of	  the	  DFO	  exhibited	  significantly	  prolonged	  release	  profiles	  in	  
the	  simulated	  physiological	  medium	  compared	  with	  the	  free	  DFO,	  due	  to	  the	  stable	  amide	  
bond	  between	  the	  DFO	  and	  the	  HA	  backbone.	  Therefore,	  the	  HA-­‐DFO	  conjugate	  could	  
provide	  an	  enhanced	  therapeutic	  index	  and	  maintain	  the	  effective	  drug	  levels	  in	  the	  region	  
of	  interest	  after	  a	  local	  injection,	  ultimately	  averting	  the	  undesired	  systemic	  toxicity	  
through	  reducing	  the	  necessary	  drug	  dose.	  	  
Deferoxamine	  is	  known	  for	  its	  acute	  [14-­‐16]	  and	  chronic	  [67]	  toxicity,	  seriously	  
diminishing	  its	  clinical	  values.	  The	  DFO-­‐induced	  cytotoxicity	  has	  been	  previously	  reported	  
in	  human	  neuroblastoma	  cells	  and	  astrocytoma	  cells,	  and	  two	  mechanisms	  of	  the	  DFO	  
toxicity	  have	  been	  proposed	  [68,	  69].	  	  Becton	  et	  al.,	  suggested	  that	  cytotoxicity	  of	  the	  DFO	  
was	  related	  to	  its	  strong	  iron-­‐binding	  affinity,	  leading	  to	  a	  cytosolic	  iron	  deficiency	  [68].	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Lee	  et	  al.,	  on	  the	  other	  hand,	  implicated	  an	  oxidation	  process	  producing	  hydroxyl	  radicals	  
that	  leads	  to	  DFO	  cytotoxicity	  [69].	  Conjugation	  of	  DFO	  to	  a	  large,	  biocompatible	  polymer	  
such	  as	  dextran	  [35]	  or	  poly	  (ethylene	  glycol)	  [36]	  has	  been	  reported	  to	  efficiently	  reduce	  
its	  toxicity.	  Our	  cell	  viability	  results	  are	  in	  consistent	  with	  these	  previous	  observations,	  and	  
the	  lower	  toxicity	  of	  the	  HA-­‐DFO	  conjugate	  may	  be	  attributed	  to	  its	  different	  cellular	  
internalization	  pathways.	  HA-­‐based	  nanoconjugates	  are	  mainly	  internalized	  by	  the	  CD44-­‐
expressing	  cells	  by	  an	  active	  transport	  mechanism	  via	  the	  HA	  receptors-­‐CD44	  in	  
conjunction	  with	  a	  clathrin-­‐dependent	  endocytic	  pathway	  [70,	  71].	  	  As	  HUVEC	  cells	  
overexpress	  CD44H	  on	  the	  cell	  membrane	  [72],	  we	  hypothesize	  that	  HA-­‐DFO	  molecules	  
first	  bound	  to	  its	  surface	  receptor,	  CD44H,	  on	  the	  membrane	  of	  the	  HUVEC	  cells,	  and	  then	  
were	  translocated	  into	  cells	  in	  a	  vesicular	  form.	  The	  internalized	  vesicles	  loaded	  with	  HA-­‐
DFO	  may	  fuse	  with	  endosomes	  for	  degradation	  or	  further	  delivery	  into	  other	  subcellular	  
compartments,	  such	  as	  Golgi	  network	  or	  endoplasmic	  reticulum.	  We	  conjecture	  that	  the	  
unique	  celluar	  internalization	  pathway	  of	  the	  HA-­‐DFO	  may	  delay	  or	  reduce	  the	  cytosolic	  
exposure	  of	  active	  DFO	  molecules,	  thus	  diminishing	  its	  cytotoxicity.	  On	  the	  other	  hand,	  
Rossi	  et	  al.	  [36]	  proposed	  that	  the	  reduced	  toxicity	  of	  the	  polymer-­‐based	  DFO	  to	  the	  HUVEC	  
cells	  probably	  resulted	  from	  its	  lack	  of	  capability	  to	  permeate	  the	  cell	  membrane.	  The	  exact	  
mechanism	  for	  the	  decreased	  cytotoxicity	  of	  the	  HA-­‐DFO	  conjugates	  remains	  to	  be	  fully	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elucidated	  by	  further	  investigation	  with	  the	  microscopy	  of	  living-­‐cell	  labeled	  with	  
fluorescent	  antibodies.	  	  	  
The	  in	  vivo	  degradation	  of	  HA	  is	  controlled	  by	  three	  types	  of	  enzymes,	  including	  two	  
exoglycosidases	  (β-­‐glucuronidase	  and	  β-­‐N-­‐acetyl	  glucosaminidase)	  and	  an	  
endoglycosidase,	  hyaluronidase,	  which	  acts	  collaboratively	  with	  the	  first	  two.	  During	  this	  
course,	  the	  HA	  backbone	  is	  enzymatically	  cleaved	  by	  hyaluronidases	  at	  β-­‐N-­‐
acetylhexosamine-­‐[1→4]	  glycosidic	  bonds	  into	  smaller	  oligosaccharides	  [73],	  followed	  by	  
further	  degradations	  with	  the	  exoglycosidases	  for	  clearance	  through	  multiple	  metabolic	  
pathways	  [74,	  75].	  Botzki	  et	  al.,	  [76]	  has	  proposed	  an	  acid/base	  reaction	  mechanism	  for	  the	  
hydrolysis	  of	  HA	  by	  testes-­‐type	  hyaluronidases.	  The	  Glu-­‐149	  residue	  of	  hyaluronidase	  is	  a	  
proton	  donor,	  while	  the	  N-­‐acetyl	  carbonyl	  group	  of	  the	  HA	  acts	  as	  a	  nucleophile	  to	  form	  a	  
inter-­‐molecule	  covalent	  oxazolinium	  intermediate,	  which	  is	  later	  hydrolyzed	  by	  water	  
molecule.	  	  HA	  derivatives	  prepared	  by	  full	  esterification	  of	  carboxylic	  groups	  in	  D-­‐
glucoronic	  acid	  unit	  have	  been	  found	  to	  result	  in	  delayed	  degradation	  by	  the	  testicular	  
hyaluronidase	  [77],	  which	  was	  believed	  to	  caused	  by	  the	  restricted	  cleavage	  of	  β	  (1→4)	  
glycoside	  bonds.	  Based	  on	  our	  results,	  HA-­‐DFO	  conjugationes	  with	  partially	  modified	  
carboxylic	  acid	  groups	  did	  not	  compromise	  the	  susceptibility	  of	  HA	  to	  the	  enzymatic	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hydrolysis,	  consistent	  with	  what	  other	  research	  groups	  found	  with	  thiolated	  HA	  (1.32	  
wt.%)	  [60].	  	  
	   Distraction	  osteogenesis	  is	  a	  powerful	  reconstructive	  technique	  for	  bone	  growth	  
and	  repair.	  An	  angiogenic	  means	  of	  enhancing	  the	  efficacy	  of	  this	  metabolically	  demanding	  
procedure	  would	  be	  beneficial	  in	  expanding	  its	  therapeutic	  potential.	  We	  posit	  that	  the	  
angiogenic	  effect	  of	  deferoxamine,	  an	  iron	  chelator	  that	  has	  been	  shown	  to	  increase	  
angiogenesis,	  will	  improve	  bone	  regeneration	  by	  means	  of	  augmentations	  in	  quality	  and	  
quantity	  of	  bone	  and	  bone-­‐producing	  cells.	  Although	  no	  statistically	  significant	  difference	  
was	  observed,	  mice	  treated	  with	  one	  time	  application	  of	  lyophilized	  HA-­‐DFO	  conjugates	  
showed	  faster	  proliferation	  rate	  of	  osteocytes	  than	  the	  mice	  treated	  with	  twice-­‐weekly	  
injections	  of	  DFO.	  Moreover,	  only	  one	  dose	  of	  the	  HA-­‐DFO	  conjugate	  was	  determined	  
sufficient	  to	  stimulate	  the	  proliferation	  osteocytes,	  which	  makes	  it	  a	  promising	  candidate	  as	  
a	  translational	  medicine.	  	  
	  	  
5.	  Conclusions	  
	   In	  this	  study,	  we	  synthesized	  a	  novel	  HA-­‐based	  iron	  chelator	  using	  TBA	  modified	  HA	  
for	  the	  facile	  amidation	  in	  an	  organic	  solvent	  to	  prevent	  the	  side	  reactions,	  and	  the	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resultant	  HA-­‐DFO	  conjugates	  retained	  high	  iron-­‐binding	  capability.	  Compared	  with	  the	  free	  
DFO-­‐Fe	  (III)	  complex,	  the	  complexes	  prepared	  using	  the	  HA-­‐DFO	  conjugates	  exhibited	  
sustained	  release	  profiles	  in	  the	  physiological	  environments	  attributed	  to	  the	  stable	  amide	  
bond,	  thus	  limiting	  body	  exposure	  to	  the	  toxic	  free	  DFO	  molecules.	  We	  also	  observed	  
significantly	  decreased	  cytotoxicity	  to	  normal	  cells	  and	  excellent	  biodegradability	  of	  the	  
HA-­‐DFO	  conjugates.	  Collectively,	  these	  attractive	  properties	  render	  HA-­‐DFO	  conjugate	  a	  
potential	  candidate	  to	  promote	  pathologic	  fracture	  healing	  and	  bone	  regeneration.	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1.	  Introduction	  
Melanoma	  is	  a	  deadly	  skin	  cancer,	  killing	  more	  than	  9,000	  Americans	  in	  2012.	  	  
Incidence	  is	  rising	  rapidly,	  to	  the	  point	  where	  1	  in	  50	  Americans	  will	  develop	  
melanoma	  [1].	  	  Stage	  at	  diagnosis	  is	  the	  main	  determinant	  of	  survival.	  	  While	  5-­‐year	  
survival	  for	  localized	  melanoma	  is	  98%,	  involvement	  of	  regional	  lymph	  nodes	  drops	  
survival	  to	  62%,	  and	  in	  distant	  metastatic	  disease	  survival	  is	  only	  15%	  [1].	  
The	  main	  reason	  is	  that	  very	  early	  disease	  can	  generally	  be	  successfully	  
treated	  with	  simple	  excision.	  	  However,	  once	  it	  has	  spread	  to	  the	  lymph	  nodes	  and	  
beyond,	  melanoma	  becomes	  very	  hard	  to	  treat	  and	  survival	  decreases	  accordingly.	  
This	  applies	  to	  “locally	  advanced”	  melanoma	  with	  lymph	  node	  involvement	  as	  well	  
as	  widespread	  metastatic	  disease.	  	  One	  important	  reason	  for	  this	  is	  that	  melanoma	  
is	  notoriously	  resistant	  to	  chemotherapy.	  	  Conventional	  chemotherapy	  does	  not	  
result	  in	  high	  levels	  of	  penetration	  into	  tumors	  or	  lymph	  nodes.	  Therefore	  efficacy	  is	  
limited	  by	  systemic	  toxicity.	  	  It	  has	  long	  been	  a	  goal	  to	  increase	  relative	  penetration	  
of	  chemotherapy	  into	  tumors	  and	  lymph	  nodes.	  Here	  we	  report	  the	  first	  use	  of	  a	  
novel	  peri-­‐-­‐tumor	  injectable	  chemotherapy	  compound	  in	  an	  in-­‐vivo	  murine	  model	  
for	  locally	  advanced	  melanoma.	  We	  seek	  to	  answer	  the	  question	  of	  whether	  
increased	  peri-­‐tumoral	  dose	  translates	  into	  a	  measurable	  in-­‐vivo	  response.	  
	  
2.	  Materials	  and	  Methods	  
2.1	  Materials	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All	  chemicals	  were	  obtained	  from	  commercial	  suppliers	  and	  used	  without	  
further	  purification	  unless	  otherwise	  noted.	  Hyaluronan	  (HA;	  35	  kDa)	  was	  
purchased	  from	  Lifecore	  Biomedical	  (Chaska,	  MN)	  as	  sodium	  hyaluronate,	  which	  
was	  cultured	  and	  produced	  by	  a	  microbial	  fermentation	  process.	  Cisplatin	  (CDDP)	  
was	  obtained	  from	  AK	  Scientific	  (Union,	  CA).	  All	  other	  chemicals	  and	  cell	  culture	  
supplies	  were	  purchased	  from	  Sigma-­‐Aldrich	  Co	  (St.	  Louis,	  MO)	  or	  Fisher	  Scientific	  
(Pittsburgh,	  PA).	  Distilled	  water	  was	  used	  in	  syntheses,	  cell	  culture	  (sterilized	  by	  
autoclaving)	  and	  animal	  experiments	  (sterilized	  by	  autoclaving).	  	  Human	  melanoma	  
cell	  lines	  A-­‐2058	  was	  were	  obtained	  from	  American	  Type	  Culture	  Collection	  (ATCC,	  
MA)	  and	  cultured	  according	  to	  ATCC	  protocol.	  
	  
2.2 	  Methods	  
2.2.1	  Synthesis	  of	  hyaluronan-­‐cisplatin	  conjugates	  
HA-­‐Cisplatin	  (HA-­‐Pt)	  conjugate	  was	  prepared	  as	  previously	  described	  [2].	  
Briefly,	  HA	  (50	  mg)	  and	  CDDP	  (40	  mg)	  were	  dissolved	  in	  a	  total	  of	  80	  mL	  double	  
distilled	  water	  (ddH2O)	  and	  stirred	  in	  the	  dark	  for	  96	  hr	  at	  ambient	  temperature	  
(~25°C).	  By	  the	  end	  of	  the	  reaction,	  the	  mixture	  was	  filtered	  through	  a	  0.22	  μm	  
nylon	  membrane	  filter	  (Fisher	  Scientific;	  Pittsburgh,	  PA),	  followed	  by	  dialysis	  
(MWCO	  10,000	  Da;	  Pierce,	  IL)	  against	  ddH2O	  for	  24	  hr	  in	  dark	  with	  4	  water	  changes.	  
The	  crude	  HA-­‐Pt	  conjugate	  was	  concentrated	  by	  evaporation	  under	  reduced	  
pressure	  and	  then	  stored	  at	  room	  temperature	  in	  dark.	  	  
	   232	  
The	  CDDP	  substitution	  degree	  was	  determined	  by	  an	  Inductively	  Coupled	  
Plasma	  Mass	  Spectrometry	  (ICP-­‐MS,	  Agilent	  Technologies	  7500a)	  using	  terbium	  as	  
internal	  standard.	  High	  purity	  argon	  (>99.996%)	  was	  used	  as	  carrier	  gas.	  The	  
calibration	  concentrations	  of	  platinum	  included	  1,	  10,	  20,	  40,	  and	  50	  ppb.	  	  
	  
2.2.2	  Induction	  of	  human	  melanoma	  xenografts	  
Human	  melanoma	  cell	  line	  A-­‐2058	  was	  cultured	  in	  Dulbecco’s	  Modified	  Eagle	  
Medium	  (DMEM)	  supplemented	  with	  10%	  (v/v)	  fetal	  bovine	  serum	  and	  1%	  (v/v)	  L-­‐
glutamine-­‐alanine	  in	  at	  37°C	  in	  a	  humidified	  atmosphere	  containing	  5%	  CO2.	  A-­‐2058	  
cells	  were	  trypsinized	  and	  suspended	  in	  cell	  culture	  grade	  phosphate	  buffered	  
saline	  (1×,	  PH	  7.4)	  at	  a	  concentration	  of	  5×107	  cells/mL	  for	  tumor	  inoculation.	  
All	  experimental	  procedures	  were	  approved	  by	  the	  University	  of	  Kansas	  
Institutional	  Animal	  Care	  and	  Use	  Committee	  (IACUC).	  Female	  athymic	  nude	  mice	  
(~25	  g,	  Charles	  River	  Laboratories;	  Wilmington,	  MA)	  were	  anesthetized	  with	  2%	  
isoflurane	  in	  oxygen,	  and	  100	  μL	  of	  A-­‐2058	  cell	  suspension	  was	  subcutaneously	  
injected	  in	  the	  distal	  aspect	  of	  left	  mouse	  thigh	  and	  upper	  hind	  limb	  using	  a	  27-­‐ga	  
needle	  to	  establish	  the	  tumor	  xenografts.	  Tumor	  growth	  was	  monitored	  twice	  per	  
week	  via	  bi-­‐dimensional	  measurement	  with	  a	  digital	  caliper,	  and	  the	  tumor	  volume	  
was	  calculated	  using	  equation:	  
	  
Tumor	  volume	  (mm3)	  =	  0.52×(width)2×(length)	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2.2.3	  Treatment	  	  
Female	  Nu/Nu	  nude	  mice	  bearing	  melanoma	  tumors	  of	  roughly	  50~100	  mm3	  
were	  randomly	  divided	  into	  five	  groups,	  including	  a	  non-­‐treated	  group	  (N=	  7)	  and	  
four	  treatment	  groups	  (N=6-­‐8).	  Three	  doses	  of	  10	  mg/kg	  CDDP	  or	  HA-­‐Pt	  (on	  
cisplatin	  basis)	  were	  administered	  weekly	  via	  tail	  vein	  for	  i.v.	  CDDP	  (N=6)	  group	  
and	  i.v.	  HA-­‐Pt	  (N=7)	  group;	  or	  subcutaneously	  near	  the	  tumor	  for	  s.c.	  CDDP	  (N=6)	  
and	  s.c.	  HA-­‐Pt	  (N=8)	  group.	  Following	  the	  treatment,	  the	  primary	  tumor	  size	  was	  
measured	  twice	  weekly,	  and	  animals	  were	  euthanized	  once	  the	  tumor	  volumes	  
reached	  3000	  mm3	  or	  in	  the	  presence	  of	  necrosis	  or	  ulceration	  unrelated	  to	  tumor	  
growth,	  or	  if	  weight	  loss	  >20%	  occurred.	  
	  
2.3	  Statistical	  analyses	  
Tumor	  volumes	  and	  body	  weights	  for	  all	  five	  experimental	  groups	  were	  
analyzed	  and	  expressed	  at	  mean	  ±	  standard	  deviation.	  Statistical	  analyses	  were	  
conducted	  using	  unpaired	  t-­‐test	  by	  GraphPad	  Prism	  5	  software	  with	  significance	  set	  
at	  p	  <	  0.05.	  
	  
3.	  Results	  	  
3.1	  Synthesis	  and	  characterization	  of	  HA-­‐Pt	  conjugate	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Cisplatin	  was	  efficiently	  conjugated	  to	  HA	  with	  a	  conjugation	  degree	  of	  20%	  
wt	  through	  formation	  of	  ester	  linkages	  with	  polycarboxyl	  groups	  of	  the	  HA	  polymer	  
[2]	  The	  conjugate	  exhibited	  an	  in	  vitro	  release	  half-­‐life	  of	  merely	  10	  hours	  [2].	  A	  
diameter	  of	  7.55±1.72	  nm	  of	  individual	  particles	  or	  25.2	  ±	  4.43	  nm	  of	  large	  clusters	  
formed	  by	  HA-­‐Pt	  conjugate	  was	  revealed	  using	  Transmission	  Electron	  Microscopy	  
[2].	  
	  
3.2 Therapeutic	  efficacy	  
The	  maximum	  tolerated	  dose	  (MTD)	  of	  cisplatin	  has	  been	  determined	  at	  10	  
mg/kg	  body	  weight	  in	  mice	  [3].	  The	  anti-­‐tumor	  effect	  of	  HA-­‐Pt	  and	  CDDP	  at	  MTD	  
was	  evaluated	  by	  measuring	  tumor	  volume	  and	  survival	  times	  in	  nude	  mice	  bearing	  
A2058	  tumor	  xenografts.	  	  Skin	  tumors	  were	  observed	  in	  hind	  legs	  of	  nude	  mice	  
within	  one	  week	  after	  tumor	  cell	  injection,	  and	  tumor	  volume	  typically	  reached	  
~100	  mm3	  in	  two	  weeks.	  Following	  treatment,	  tumor	  burden	  was	  monitored	  up	  to	  
nine	  weeks.	  	  For	  mice	  receiving	  no	  anticancer	  treatment,	  average	  tumor	  size	  was	  
1,600	  mm3	  by	  week	  5	  (Figure	  1A)	  and	  an	  average	  of	  19-­‐fold	  increase	  in	  tumor	  
volume	  was	  observed	  from	  week-­‐1	  to	  week-­‐4	  (Figure	  1B).	  In	  contrast,	  tumors	  in	  
animals	  treated	  with	  s.c.	  HA-­‐Pt	  (p<	  0.01)	  or	  i.v.	  HA-­‐Pt	  (p<	  0.05)	  developed	  at	  a	  
significantly	  slower	  rate	  during	  the	  same	  period,	  with	  week-­‐4	  tumor	  volumes	  83%	  
smaller	  than	  those	  in	  the	  non-­‐treatment	  group	  (Figure	  1A).	  Animals	  that	  received	  s.c.	  
CDDP	  and	  i.v.	  CDDP	  showed	  delayed	  tumor	  initial	  progression,	  but	  by	  week	  4	  their	  
tumors	  had	  respectively	  re-­‐grown	  by	  12-­‐fold	  and	  7-­‐fold	  versus	  week-­‐1	  sizes.	  In	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addition,	  100%	  of	  the	  animals	  in	  two	  CDDP	  treated	  groups	  were	  euthanized	  within	  
5	  weeks	  (Figure	  2)	  either	  due	  to	  deteriorating	  body	  condition	  (Figure	  3B)	  or	  
necrosis	  of	  the	  injection	  site	  on	  the	  tail	  induced	  by	  the	  extravasation	  side	  effect	  of	  
CDDP.	  By	  comparison,	  one	  mouse	  that	  was	  treated	  with	  s.c.	  HA-­‐Pt	  showed	  complete	  
tumor	  eradication	  and	  the	  mouse	  lived	  through	  this	  study	  (Figure	  3D).	  	  Other	  s.c.	  
HA-­‐Pt	  mice	  were	  euthanized	  primarily	  due	  to	  weight	  loss,	  not	  tumor	  growth	  or	  
ulceration.	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Figure	  1.	  (A)	  Tumor	  growth	  after	  treatment	  with	  s.c.	  HA-­‐Pt,	  i.v.	  HA-­‐Pt,	  s.c.	  CDDP,	  i.v.	  
CDDP,	  and	  untreated	  control.	  CDDP	  and	  HA-­‐Pt	  on	  equivalent	  platinum	  basis	  (10	  
mg/kg)	  were	  injected	  either	  by	  i.v.	  tail	  vein	  or	  s.c	  around	  tumor,	  6≤N≤8.	  	  (B)	  Tumor	  
Volume	  (V/V	  initial)	  at	  week-­‐four	  after	  treatment,	  5≤N≤8.	  (*:	  p	  <	  0.05;	  **:	  p	  <	  0.01)	  





Figure	  2.	  Survival	  curve	  after	  treatment	  with	  untreated	  control,	  CDDP,	  or	  HA-­‐Pt,	  
respectively.	  	  CDDP	  and	  HA-­‐Pt	  on	  equivalent	  platinum	  basis	  (10	  mg/kg)	  were	  
injected	  either	  by	  i.v.	  tail	  vein	  or	  s.c	  around	  tumor,	  6≤N≤8.	  Of	  note,	  untreated	  and	  
conventionally	  treated	  animals	  were	  euthanized	  either	  due	  to	  tumor	  size	  or	  severe	  
necrosis	  at	  the	  injection	  site,	  while	  the	  s.c.	  HA-­‐Pt	  animals	  were	  euthanized	  due	  to	  
weight	  loss	  and	  body	  condition	  score<2.	  *	  Body	  condition	  scoring	  (BCS)	  [4]	  is	  a	  
useful	  tool	  for	  evaluating	  overall	  condition	  of	  the	  mouse.	  	  






Figure	  3.	  	  Nude	  mice	  bearing	  human	  A2058	  melanoma	  tumor	  xenografts	  with	  
untreated	  control	  (A,	  BCS*=2,	  tumor	  size	  =	  2429	  mm3),	  i.v.	  CDDP	  (B,	  BCS	  =1,	  tumor	  
size	  =	  502	  mm3),	  s.c.	  HA-­‐Pt	  (C	  &D,	  BCS	  =	  3,	  tumor	  size	  =	  0	  mm3).	  	  BCS	  of	  1	  or	  2	  
indicates	  that	  the	  mouse	  is	  emaciated	  or	  under-­‐conditioned,	  respectively.	  A	  mouse	  
with	  BCS	  of	  3,	  in	  comparison,	  is	  well	  conditioned.	  
	   239	  
4.	  Discussion	  
Locally	  advanced	  cancer	  refers	  to	  cancers	  that	  have	  spread	  from	  where	  they	  
started	  to	  nearby	  tissues	  or	  lymph	  nodes	  [5].	  Such	  cancers	  generally	  cannot	  
adequately	  be	  treated	  by	  surgical	  resection	  alone.	  	  This	  report	  presents	  the	  results	  
of	  a	  locally-­‐delivered	  chemotherapy	  treatment	  in	  a	  murine	  model	  for	  locally	  
advanced	  melanoma.	  	  	  
Although	  treatment	  of	  melanoma	  has	  demonstrated	  incremental	  
improvement	  over	  the	  last	  few	  decades,	  in	  2011	  the	  5-­‐year	  death	  rate	  for	  stage	  3	  
locally	  advanced	  melanoma	  with	  lymphatic	  metastases	  was	  still	  37.6%	  [1].	  Over	  
6000	  people	  are	  diagnosed	  with	  stage	  3	  melanoma	  per	  year	  in	  the	  US	  [6].	  	  There	  is	  
at	  present	  no	  chemotherapy	  approved	  for	  direct	  delivery	  into	  locally	  advanced	  
melanoma.	  	  Current	  standard-­‐of-­‐care	  treatment	  relies	  on	  surgery,	  and,	  in	  certain	  
cases,	  local	  radiation	  and/or	  immunomodulators	  such	  as	  interferon-­‐α	  or	  
interleukin-­‐2.	  	  	  	  Chemotherapy	  is	  generally	  reserved	  for	  disease	  that	  has	  progressed	  
to	  distant	  metastases.	  	  Even	  so,	  traditional	  chemotherapeutic	  agents	  have	  not	  shown	  
prolonged	  responses	  in	  most	  patients.	  	  	  
While	  newer	  agents	  have	  shown	  promise,	  none	  has	  yet	  demonstrated	  
sustained	  efficacy	  for	  most	  treated	  patients.	  	  For	  instance	  the	  BRAF	  inhibitor	  
vermurafenib	  has	  recently	  demonstrated	  a	  4-­‐month	  survival	  advantage	  in	  patients	  
with	  unresectable	  melanoma	  [7].	  	  The	  immune	  modulator	  ipilimumab,	  an	  anti-­‐
CTLA4	  monoclonal	  antibody,	  has	  been	  shown	  to	  promote	  antitumor	  immunity	  and	  
improve	  survival	  rates	  in	  patients	  with	  metastatic	  melanoma	  [8].	  	  A	  metanalysis	  
	   240	  
showed	  a	  6-­‐month	  increase	  in	  overall	  survival	  time	  for	  ipilimumab	  compared	  to	  
chemotherapy	  [9].	  	  	  In	  patients	  with	  stage	  III	  and	  stage	  IV	  unresectable	  melanoma,	  
combining	  ipilumimab	  with	  a	  gp100	  peptide	  vaccine	  showed	  a	  four-­‐month	  survival	  
advantage	  versus	  vaccine	  alone	  (10.1	  months	  vs.	  6.4	  months)	  [8].	  	  	  	  Though	  not	  yet	  
approved,	  numerous	  vaccines	  are	  currently	  being	  developed	  for	  the	  treatment	  of	  
melanoma,	  including	  dendritic	  cell	  vaccines	  and	  herpes	  simplex	  virus	  oncolytic	  
“vaccines”.	  	  
Current	  immune	  treatments	  such	  as	  ipilumimab	  carry	  risks	  for	  significant	  
side	  effects	  including	  hepatic	  and	  gastrointestinal	  toxicity,	  endocrine	  dysfunction	  
and	  permanent	  retinal	  damage	  [10].	  	  Ocular	  side	  effects	  include	  conjunctivitis,	  
scleritis,	  uveitis	  [10],	  decreased	  visual	  actuity,	  photophobia,	  and	  painful	  tearing	  [11],	  
as	  well	  as	  Graves	  opthalmopathy	  [10,	  12].	  	  	  
Traditional	  chemotherapy	  is	  not	  typically	  used	  in	  locally	  advanced	  melanoma,	  
but	  it	  can	  play	  a	  role	  in	  treating	  distant	  metastases.	  	  Cisplatin,	  also	  known	  as	  CDDP,	  
is	  one	  such	  potential	  chemotherapy	  candidate.	  CDDP	  is	  a	  DNA-­‐damaging	  
chemotherapeutic	  agent	  that	  induces	  apoptosis	  in	  tumor	  cells.	  	  CDDP	  achieves	  
higher	  concentrations	  in	  melanoma	  tissue	  than	  plasma.	  	  In	  a	  patient	  receiving	  IV	  
CDDP	  for	  cutaneous	  melanoma	  metastases,	  platinum	  levels	  in	  tumor	  tissue	  were	  
three	  times	  higher	  than	  plasma	  [13].	  	  Although	  widely	  used	  across	  a	  broad	  variety	  of	  
cancers,	  CDDP	  has	  played	  only	  a	  limited	  role	  in	  melanoma	  treatment.	  CDDP	  has	  not	  
shown	  great	  efficacy	  as	  melanoma	  monotherapy,	  likely	  due	  to	  dosing	  limitations.	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CDDP	  has	  been	  studied	  in	  combination	  with	  other	  melanoma	  treatments	  
including	  immunotherapy	  [14-­‐16],	  gene	  therapy	  [17-­‐19],	  and	  other	  small-­‐molecule	  
anticancer	  agents	  [3,	  20,	  21].	  	  These	  studies	  have	  used	  both	  murine	  and	  human	  
melanoma	  lines	  in	  mouse	  xenotransplantation	  models,	  and	  have	  demonstrated	  
synergistic	  inhibitory	  effects	  resulting	  in	  significant	  retardation	  or	  even	  complete	  
tumor	  growth	  inhibition.	  The	  enhanced	  cytostatic/cytotoxic	  effects	  might	  be	  
attributed	  to	  coupling	  tumor	  cell	  apoptosis	  induced	  by	  CDDP	  with	  anti-­‐
proliferatitive,	  antiangiogenic	  or	  anti-­‐cell	  cycle	  effects	  of	  other	  agents.	  The	  precise	  
mechanisms	  underlying	  the	  synergies	  have	  not	  yet	  been	  fully	  elucidated.	  
Of	  note,	  when	  augmented	  anti-­‐tumor	  effects	  were	  found	  in	  combination	  
immuno-­‐chemo	  studies,	  they	  typically	  used	  intensive	  CDDP	  treatment	  schedules	  
that	  would	  not	  likely	  be	  tolerated	  by	  human	  patients.	  [17]	  Delivering	  chemotherapy	  
directly	  to	  tumor	  and	  local	  lymph	  nodes	  could	  result	  in	  much	  more	  of	  the	  
chemotherapy	  actually	  getting	  to	  where	  it	  is	  needed.	  	  This	  might	  be	  even	  more	  
advantageous	  in	  treating	  locally	  advanced	  disease.	  	  
Here	  we	  present	  a	  new	  method	  for	  achieving	  very	  high	  doses	  of	  CDDP	  in	  
locally	  advanced	  melanomas.	  	  We	  previously	  reported	  synthesis	  of	  an	  injectable	  
hyaluronan–CDDP	  nano-­‐conjugate	  (HA-­‐Pt)	  using	  the	  FDA-­‐approved	  biocompatible	  
carrier	  hyaluronan	  (HA)	  [22].	  	  HA-­‐Pt	  can	  be	  administered	  subcutaneously	  as	  a	  peri-­‐	  
or	  intra-­‐tumoral	  injection.	  As	  such,	  it	  has	  the	  potential	  to	  enhance	  drug	  
accumulation	  in	  the	  primary	  tumor	  and	  adjacent	  lymph	  nodes,	  while	  simultaneously	  
reducing	  overall	  systemic	  exposure	  [2,	  22].	  	  Nodal	  penetration	  is	  important	  since	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local	  nodes	  are	  where	  most	  tumor	  metastases	  start.	  	  HA-­‐Pt	  has	  previously	  
demonstrated	  improved	  anti-­‐tumor	  efficacy	  in	  in	  vivo	  murine	  models	  of	  locally	  
advanced	  head	  and	  neck	  squamous	  cell	  carcinoma	  [23]	  and	  breast	  cancer	  [24].	  	  The	  
present	  study	  provides	  the	  first	  experimental	  evidence	  that	  HA-­‐Pt	  can	  inhibit	  
human	  melanoma	  growth	  in	  mice.	  	  	  
HA-­‐conjugation	  may	  be	  especially	  helpful	  because	  HA	  is	  a	  ligand	  for	  the	  
tumor-­‐associated	  surface	  receptor	  CD44.	  	  Numerous	  studies	  have	  shown	  that	  CD44	  
is	  expressed	  in	  both	  primary	  and	  metastatic	  melanoma	  [25,	  26].	  	  CD44	  is	  the	  main	  
hyaluronic	  acid	  surface	  receptor	  on	  melanoma	  cells,	  and	  CD44	  expression	  increases	  
during	  melanoma	  progression	  [27].	  	  CD44	  expression	  in	  melanoma	  cells	  has	  also	  
been	  associated	  with	  worsening	  Clark’s	  stage	  [25].	  	  Although	  CD44-­‐hyaluronic	  acid	  
interaction	  has	  been	  reported	  to	  induce	  melanoma	  cell	  proliferation	  [27],	  when	  the	  
hyaluronan	  in	  question	  is	  conjugated	  to	  a	  poison	  it	  is	  would	  not	  appear	  likely	  to	  
promote	  tumor	  survival.	  Furthermore,	  a	  recent	  report	  found	  that	  not	  only	  was	  CD44	  
expressed	  in	  all	  tumor	  stromal	  cells	  studied,	  but	  CD44	  expression	  by	  tumor	  stromal	  
precursors	  played	  vital	  roles	  in	  tumor	  migration,	  incorporation,	  and	  functionality	  
[12].	  Therefore	  HA-­‐Pt	  could	  potentially	  target	  tumor	  stroma	  as	  well	  as	  neoplastic	  
cells.	  	  
The	  ability	  to	  shrink	  melanomas	  via	  direct	  injection	  of	  HA-­‐Pt	  could	  be	  of	  
clinical	  interest	  in	  several	  circumstances,	  including	  augmentation	  or	  even	  
substitution	  for	  complete	  lymph	  node	  dissection	  (CLND)	  or	  radiation,	  preoperative	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shrinkage	  of	  very	  large	  primary	  tumors,	  palliative	  shrinkage	  of	  large	  or	  awkwardly	  
located	  metastases,	  and	  synergistic	  combination	  with	  immunotherapy.	  
Radiation	  therapy	  has	  been	  used	  as	  adjuvant	  therapy	  following	  CLND,	  and	  as	  
alternate	  therapy	  for	  affected	  regional	  lymph	  nodes.	  	  When	  used	  as	  adjuvant	  
therapy	  after	  lymphadenectomy,	  only	  10%	  of	  patients	  who	  received	  radiation	  
developed	  regional	  reoccurrence	  after	  five	  years,	  as	  opposed	  to	  40%	  of	  patients	  who	  
did	  not	  receive	  radiation	  [28].	  	  Another	  study	  demonstrated	  doubling	  of	  disease-­‐free	  
survival	  time	  when	  radiation	  therapy	  was	  used	  to	  treat	  regional	  lymph	  nodes	  [29].	  	  
Radiation	  has	  also	  been	  used	  in	  the	  treatment	  of	  skin	  metastases;	  however,	  
treatments	  of	  over	  6	  Gy	  were	  needed	  to	  elicit	  response	  rates	  above	  90%	  [30].	  Since	  
cisplatin	  has	  been	  shown	  to	  sensitize	  cancer	  cells	  to	  ionizing	  radiation,	  targeting	  
CDDP	  to	  nodes	  via	  HA-­‐Pt	  could	  be	  useful	  [31].	  	  This	  might	  be	  especially	  helpful	  in	  
patients	  who	  are	  not	  candidates	  for	  full-­‐dose	  systemic	  CDDP	  or	  high-­‐dose	  radiation.	  
Furthermore,	  because	  complete	  lymph	  node	  dissection	  is	  associated	  with	  
serious	  morbidities,	  including	  lymphedema,	  bleeding,	  infection,	  and	  deep	  vein	  
thrombosis	  [32],	  some	  patients	  are	  unable	  or	  unwilling	  to	  undergo	  CLND	  despite	  
positive	  sentinel	  lymph	  node	  or	  other	  risk	  factors	  for	  nodal	  involvement.	  Such	  
patients	  may	  benefit	  from	  such	  a	  treatment	  that	  can	  deliver	  a	  large	  dose	  to	  the	  local	  
nodes	  with	  relatively	  low	  systemic	  exposure	  and	  a	  correspondingly	  high	  therapeutic	  
index.	  
Shrinking	  very	  large	  melanomas	  prior	  to	  surgery	  could	  improve	  cosmesis	  
and	  also	  improve	  cure	  rates	  especially	  in	  certain	  areas	  the	  body	  such	  as	  the	  face,	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hands	  or	  feet	  where	  wide	  margins	  are	  hard	  to	  achieve.	  	  	  Similarly,	  patients	  with	  
large	  or	  obstructive	  metastases	  could	  potentially	  benefit	  from	  direct	  injection	  of	  HA-­‐
Pt	  for	  palliative	  tumor	  masses	  shrinkage.	  Doing	  so	  might	  provide	  benefit	  with	  fewer	  
side	  effects	  than	  such	  conventional	  treatments	  as	  high-­‐dose	  chemotherapy	  or	  
repeated	  surgical	  debulking.	  	  
Mouse	  and	  human	  studies	  have	  explored	  combined	  use	  of	  platinum-­‐based	  
antineoplastic	  drugs	  (e.g.	  cisplatin	  or	  carboplatin)	  and	  immunotherapy	  (e.g.	  
interleukin-­‐2	  or	  interferon-­‐alpha	  2a).	  	  	  One	  combination	  therapy	  demonstrated	  
synergistic	  inhibition	  of	  advanced	  B16-­‐F1	  melanoma	  growth	  in	  syngeneic	  mice	  [15]	  
and	  another	  combination	  therapy	  study	  showed	  at	  least	  additive	  benefit	  with	  mostly	  
moderate	  toxicity	  in	  two	  consecutive	  phase	  II	  trials	  with	  a	  total	  of	  85	  patients[16].	  	  
In	  our	  murine	  melanoma	  study,	  local	  administration	  of	  HA-­‐Pt	  showed	  improved	  
efficacy	  versus	  standard	  i.v.	  CDDP.	  	  HA-­‐Pt	  may	  therefore	  potentially	  be	  of	  benefit	  in	  
sequential	  chemo/immunotherapy	  protocols.	  	  
	  
5.	  Conclusions	  
Although	  further	  work	  is	  needed,	  these	  data	  provide	  preliminary	  support	  for	  
the	  proposition	  that	  HA-­‐Pt	  may	  potentially	  play	  a	  role	  in	  treating	  locally	  advanced	  
melanoma	  and	  other	  similar	  conditions.	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1.	  Introduction	  
Previous	  work	  on	  core/shell	  magnetic	  nanoparticles	  (MNPs)	  focused	  on	  the	  
enhancement	  of	  the	  aqueous	  dispersity	  and	  biocompatibility	  of	  the	  as-­‐synthesized	  
MNPs,	  as	  well	  as	  evaluation	  of	  therapeutic	  efficacy	  of	  MNPs-­‐mediated	  hyperthermia	  
treatment	  against	  breast	  tumors.	  MNPs	  can	  also	  be	  utilized	  in	  the	  active	  targeting	  of	  
tumor	  cells,	  via	  attaching	  to	  a	  targeting	  moiety	  to	  enable	  preferential	  accumulation	  
within	  the	  tumors.	  The	  folate	  receptor	  (FR)	  is	  an	  anchored	  cell	  surface	  receptor	  that	  
is	  highly	  expressed	  on	  many	  human	  cancer	  cells	  such	  as	  breast,	  ovarian,	  cervical,	  
brain	  and	  colorectal	  tumors	  [1,	  2].	  Folate,	  a	  non-­‐immunogenic	  vitamin,	  is	  a	  key	  
factor	  for	  DNA	  replication	  and	  binds	  to	  FR	  with	  high	  affinity	  [2-­‐4].	  Therefore,	  the	  
Folic	  acid/FA	  interaction	  can	  be	  harnessed	  to	  facilitate	  the	  entrance	  of	  theranostic	  
agents	  into	  cancer	  cells	  via	  receptor-­‐mediated	  endocytosis	  [5,	  6],	  thus	  enhancing	  the	  
diagnosis	  accuracy	  and	  therapeutic	  efficacy.	  For	  future	  multifunctional	  magnetic	  
nanoparticle	  (MNPs)	  delivery,	  it	  would	  be	  advantageous	  to	  develop	  folate	  receptor-­‐
targeting	  core/shell	  MNPs	  that	  are	  specifically	  internalized	  by	  tumor	  cells.	  In	  the	  
present	  study,	  we	  have	  synthesized	  folic	  acid-­‐modified	  core/shell	  MNPs,	  and	  they	  
exhibited	  excellent	  aqueous	  dispersity	  and	  increased	  intracellular	  uptake	  by	  a	  FR-­‐
positive	  human	  breast	  tumor	  cell	  line.	  Future	  work	  will	  focus	  on	  in	  vivo	  evaluation	  
of	  body	  distribution	  and	  tumoral	  uptake	  of	  the	  FA-­‐MNPs,	  as	  well	  as	  the	  efficacy	  in	  
augmenting	  magnetic	  resonance	  imaging	  (MRI)	  contrast	  and	  mediating	  
hyperthermia	  against	  human	  breast	  tumors.	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2.	  	  Preliminary	  in	  vitro	  experiments	  
2.1	  Materials	  
All	  chemicals	  were	  used	  as	  received	  without	  further	  purification	  unless	  
otherwise	  noted.	  Carboxylic	  PEG	  amine	  (NH2–PEG–COOH)(≥99.5%)	  was	  purchased	  
from	  Jenkem	  Technology	  (Beijing,	  China).	  Methoxyl	  PEG	  carboxylic	  acid	  (OMe-­‐PEG)	  
was	  obtained	  from	  Nanocs	  (New	  York,	  NY,	  USA).	  Folic	  acid	  (crystalline)	  was	  
purchased	  from	  Alfa	  Aesar	  (Ward	  Hill,	  MA,	  USA).	  N-­‐(3-­‐Dimethylaminopropyl)-­‐N′-­‐
ethylcarbodiimide	  (EDC),	  N-­‐Hydroxysuccinimide	  (NHS)(98%),	  (3-­‐Aminopropyl)	  
triethoxysilane	  (silane-­‐amine)(99%),	  acetone	  (≥99.5%),	  triethylamine	  
(TEA)(≥99.5%)	  and	  toluene	  (anhydrous,	  99.8%)	  were	  purchased	  from	  Sigma-­‐
Aldrich	  Co	  (St.	  Louis,	  MO,	  USA).	  Methanol	  (≥99.9%)	  and	  N,N-­‐Dimethylformamide	  
(99.8%,	  Extra	  Dry)	  were	  obtained	  from	  Fisher	  Scientific	  (Pittsburgh,	  PA,	  USA).	  
Ethanol	  (200	  proof)	  was	  purchased	  from	  Decon	  Labs,	  Inc	  (King	  of	  Prussia,	  PA,	  USA).	  
Double	  distilled	  water	  (ddH2O)	  was	  used	  in	  syntheses,	  characterization,	  cell	  culture,	  
and	  animal	  experiments	  (sterilized	  by	  autoclaving).	  Dimethyl	  sulfoxide-­‐D6	  (DMSO-­‐
D6)	  was	  purchased	  from	  Cambridge	  Isotope	  (Andover,	  MA,	  USA).	  Cell	  culture	  
medium,	  Dulbecco's	  Modified	  Eagle	  Medium	  (DMEM),	  and	  Fetal	  Bovine	  Serum	  (FBS)	  
were	  purchased	  from	  Life	  Technologies	  (Grand	  Island,	  NY,	  USA).	  	  
	  
2.2	  Methods	  
2.2.1	  Preparation	  of	  folic	  acid-­‐PEG	  conjugate	  (FA-­‐PEG-­‐COOH)	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The	  folic	  acid-­‐PEG	  conjugate	  was	  synthesized	  as	  reported	  earlier	  with	  a	  
minor	  modification	  [7].	  In	  brief,	  folic	  acid	  (102	  mg,	  0.23	  mmol)	  dissolved	  in	  10	  mL	  of	  
anhydrous	  N,N-­‐Dimethylformamide	  (DMF)	  was	  activated	  with	  EDC	  (5	  eq;	  178	  mg)	  
and	  NHS	  (5	  eq;	  132	  mg)	  at	  ambient	  temperature	  overnight	  under	  an	  argon	  
atmosphere.	  The	  mixture	  was	  then	  reacted	  with	  NH2–PEG–COOH	  (0.1	  equi;	  50	  mg)	  
dissolved	  in	  5	  mL	  of	  DMF	  in	  the	  presence	  of	  TEA	  (3	  equi;	  16	  μL).	  	  The	  mixture	  was	  
stirred	  at	  ambient	  temperature	  for	  4	  h,	  and	  then	  was	  added	  into	  40-­‐mL	  ice-­‐cold	  
acetone.	  Unreacted	  folic	  acids	  were	  removed	  by	  centrifugation,	  and	  the	  resultant	  
supernatant	  was	  dialyzed	  against	  ddH2O	  for	  24	  h	  (Spectra/Por	  6,	  MWCO:	  1000),	  
followed	  by	  lyophilization	  to	  render	  the	  dry	  powder	  of	  FA-­‐PEG-­‐COOH.	  	  	  
	  
2.2.2	  Preparation	  of	  aminosilane	  -­‐modified	  core/shell	  FePt@Fe3O4	  
MNPs	  (silane-­‐MNPs)	  
Core/shell	  FePt@Fe3O4	  MNPs	  were	  modified	  with	  silane-­‐amine	  through	  a	  
ligand	  exchange	  reaction	  using	  a	  modified	  method	  published	  by	  Zhang	  et.	  al.[8].	  
Briefly,	  200	  μL	  of	  as-­‐synthesized	  nanoparticles	  in	  hexane	  (30	  mg/mL)	  were	  washed	  
with	  10	  mL	  of	  ethanol	  and	  centrifuged	  at	  10,000×g	  for	  15	  min.	  	  After	  the	  
supernatant	  was	  discarded,	  precipitated	  MNPs	  were	  re-­‐suspended	  in	  300	  μL	  of	  
hexane.	  The	  washing	  step	  was	  repeated	  three	  times	  and	  the	  precipitated	  
nanoparticles	  were	  then	  dried	  with	  speedvap	  overnight	  to	  remove	  residual	  solvents.	  
The	  dried	  nanoparticles	  were	  dispersed	  in	  1.5	  mL	  of	  anhydrous	  toluene,	  followed	  by	  
adding	  300	  μL	  of	  silane-­‐amine	  and	  1	  mL	  of	  TEA.	  The	  mixture	  was	  stirred	  at	  50°	  C	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overnight,	  followed	  by	  centrifugation	  (10,000×g	  for	  15	  min)	  to	  collect	  the	  silane-­‐
grafted	  MNPs	  (silane-­‐MNPs).	  The	  silane-­‐MNP	  precipitates	  were	  washed	  with	  
ethanol	  three	  times	  and	  then	  dried	  with	  speedvap	  at	  35°	  C.	  	  
	  
2.2.3	  Modification	  of	  silane-­‐MNPs	  with	  PEG-­‐FA	  or	  PEG-­‐MNPs	  
12	  mg	  of	  FA-­‐PEG-­‐COOH	  was	  dissolved	  in	  4-­‐mL	  sodium	  borate	  buffer	  (0.01M,	  
pH	  8.0)	  and	  then	  activated	  with	  4	  equivalent	  of	  EDC	  (3	  mg)/NHS	  (2.5	  mg)	  for	  2	  h	  at	  
ambient	  temperature.	  The	  activated	  mixture	  was	  added	  with	  3-­‐mg	  silane-­‐MNP	  
dispersed	  in	  DMSO	  and	  then	  stirred	  overnight.	  FA-­‐PEG	  modified	  MNPs	  were	  
collected	  following	  the	  procedures	  described	  in	  the	  section	  2.2.2.	  To	  prepare	  a	  non-­‐
targeted	  PEGylated	  MNPs	  as	  control,	  methoxyl	  PEG	  carboxylic	  acid	  was	  used	  instead	  
of	  FA-­‐PEG-­‐COOH.	  
	  
2.2.4	  1H	  Nuclear	  magnetic	  resonance	  (NMR)	  spectroscopy	  
The	  FA,	  NH2–PEG–COOH	  and	  FA-­‐PEG-­‐COOH	  were	  dissolved	  in	  DMSO-­‐D6	  and	  
their	  1H	  NMR	  spectra	  were	  collected	  on	  a	  Bruker	  Avance	  400	  MHz	  NMR	  
Spectrometer	  (Bruker	  Corporation,	  MA,	  USA).	  
	  
2.2.5	  Fourier	  Transform	  Infrared	  Spectroscopy	  (FTIR)	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FTIR	  spectra	  of	  approximately	  2	  mg	  of	  dried	  polymers	  or	  MNPs	  were	  
recorded	  using	  an	  IRAffinity-­‐1	  FTIR	  (Shimadzu	  Scientific	  Instruments,	  KS,	  USA).	  For	  
each	  spectrum,	  45	  scans	  were	  collected	  between	  400	  and	  4000	  cm-­‐1	  at	  a	  resolution	  
of	  1	  cm-­‐1.	  	  
	  
2.2.6	  Hydrodynamic	  diameter	  measurements	  	  
FA-­‐MNPs	  or	  PEG-­‐MNPs	  were	  dispersed	  at	  0.5	  mg/mL	  in	  PBS,	  and	  dynamic	  
light	  scattering	  (DLS)	  measurements	  of	  the	  hydrodynamic	  diameters	  of	  MNP	  
dispersions	  were	  performed	  at	  25	  °C	  using	  a	  ZetaPlus	  Particle	  Size	  Analyzer	  
(Brookshaven	  Instrument,	  NY,	  USA).	  All	  measurements	  were	  repeated	  five	  times.	  
	  
2.2.7	  In	  vitro	  cytotoxicity	  
A	  metastatic	  murine	  breast	  cancer	  cell	  line,	  MDA-­‐MB-­‐231,	  purchased	  from	  
ATCC®	  was	  cultured	  in	  DMEM	  supplemented	  with	  10%	  (v/v)	  FBS	  and	  1%	  L-­‐
glutamine.	  Cells	  were	  trypsinized	  and	  seeded	  into	  96-­‐well	  plates	  at	  3,000	  cells/well	  
(n=3	  plates,	  12	  wells/concentration)	  and	  incubated	  overnight.	  FA-­‐MNPs	  or	  PEG-­‐
MNPs	  dispersed	  in	  PBS	  were	  added	  to	  each	  well	  with	  final	  concentrations	  of	  5	  
μg/mL	  to	  1	  mg/mL.	  A	  resazurin-­‐based	  colorimetric	  assay	  was	  used	  to	  measure	  
viability	  of	  cell	  cultures.	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2.2.8	  Cellular	  uptake	  
To	  investigate	  the	  intracellular	  uptake	  of	  MNPs,	  MDA-­‐MB-­‐231	  cells	  were	  
seeded	  in	  12-­‐well	  plates	  at	  3×105	  cells/well	  and	  then	  incubated	  with	  FA-­‐MNP	  or	  
PEG-­‐MNP	  suspensions	  in	  PBS	  at	  0.3	  mg/mL	  for	  24	  h.	  The	  same	  volume	  of	  the	  PBS	  
without	  MNPs	  was	  added	  to	  cell	  cultures	  as	  a	  control.	  After	  three	  washes	  with	  PBS,	  
the	  cells	  were	  detached	  with	  trypsin	  and	  then	  re-­‐suspended	  in	  DMEM	  for	  cell	  
counting	  using	  a	  hemocytometer.	  To	  measure	  the	  intracellular	  uptake	  of	  MNPs,	  the	  
cell	  suspensions	  were	  centrifuged	  at	  8,000×g	  for	  10	  min,	  and	  cell	  pellets	  were	  
digested	  in	  30%	  HCl	  at	  70	  °C	  for	  1h.	  MNPs	  in	  cells	  were	  quantified	  on	  an	  inductively	  
coupled	  plasma	  mass	  spectrometer	  (ICP-­‐MS)	  (7500a,	  Agilent	  Technologies,	  CA,	  USA)	  
for	  iron	  content,	  and	  samples	  collected	  from	  untreated	  cells	  were	  used	  as	  a	  negative	  
control.	  All	  measurements	  were	  repeated	  three	  times.	  	  
	  
2.3	  Statistical	  analyses	  
Tumor	  size	  ratio	  for	  the	  four	  experimental	  groups	  were	  analyzed	  and	  
expressed	  at	  mean	  ±	  standard	  deviation.	  Statistical	  significance	  was	  determined	  by	  
the	  two-­‐way	  ANOVA	  with	  P<	  0.05	  using	  the	  GraphPad	  Prism	  6	  software.	  
	  
3.	  Preliminary	  results	  	  
3.1	  Synthesis	  and	  characterization	  of	  core/shell	  FePt@Fe3O4	  MNPs	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3.1.1	  Synthesis	  of	  FA-­‐PEG	  
Folic	  acid	  was	  covalently	  linked	  to	  the	  amino	  group	  of	  the	  heterobifunctional	  
PEG,	  NH2-­‐PEG-­‐COOH,	  via	  an	  EDC/sulfo-­‐NHS	  coupling	  chemistry.	  The	  successful	  
conjugation	  was	  confirmed	  by	  the	  presence	  of	  characteristic	  peaks	  of	  FA	  and	  NH2-­‐
PEG-­‐COOH	  in	  the	  1H-­‐NMR	  spectrum	  of	  the	  purified	  FA-­‐PEG	  (Figure	  1C).	  Moreover,	  
upon	  amidation,	  the	  chemical	  shift	  of	  the	  α	  hydrogen	  proton	  adjacent	  to	  the	  amino	  
group	  of	  NH2-­‐PEG-­‐COOH	  moved	  from	  2.97	  ppm	  (Figure	  1B)	  to	  a	  higher	  frequency.	  
The	  peak	  of	  the	  corresponding	  methyl	  group	  in	  the	  FA-­‐PEG-­‐COOH	  was	  not	  observed	  
in	  the	  1H-­‐NMR	  spectrum	  (Figure	  1C),	  probably	  as	  it	  overlapped	  with	  the	  water	  
residue	  peak.	  	  






Figure	  1.	  1H-­‐NMR	  spectra	  (DMSO-­‐D6,	  400	  MHz)	  of	  (A)	  Folic	  acid,	  (B)	  Amine-­‐PEG-­‐
COOH,	  (C)	  FA-­‐PEG-­‐COOH.	  The	  peak	  at	  δ	  =	  2.54	  or	  3.33	  in	  each	  spectrum	  corresponds	  
to	  the	  solvent	  residue	  of	  DMSO	  or	  water,	  respectively.	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3.1.2	  Surface	  modification	  of	  core/shell	  MNPs	  with	  folic	  acid	  and	  PEG	  	  
The	  surface	  of	  as-­‐synthesized	  core/shell	  MNPs	  was	  first	  grafted	  with	  amino	  
groups	  via	  a	  facile	  silanization	  reaction,	  which	  in	  turn	  enabled	  immobilizing	  FA-­‐PEG	  
or	  OMe-­‐PEG	  through	  the	  EDC/NHS-­‐catalyzed	  reaction	  between	  the	  amino	  groups	  on	  
MNPs	  and	  the	  carboxyl	  terimus	  of	  PEG	  molecules.	  FTIR	  spectra	  of	  FA,	  FA-­‐PEG,	  PEG-­‐
MNPs	  and	  FA-­‐MNPs	  are	  shown	  in	  Figure	  2.	  The	  high-­‐intensity	  bands	  at	  1605	  and	  
1692	  cm-­‐1	  in	  Figure	  2A	  were	  two	  characteristic	  peaks	  of	  FA,	  and	  they	  were	  also	  
found	  in	  the	  spectra	  of	  FA-­‐PEG	  (Figure	  2B)	  and	  FA-­‐MNPs	  (Figure	  2D),	  indicating	  a	  
successful	  FA	  modification.	  The	  FTIR	  peaks	  between	  840	  and	  1040	  cm-­‐1	  of	  the	  
purified	  MNPs	  dry	  power	  (Figure	  2C	  and	  D)	  were	  assigned	  to	  the	  Si-­‐O-­‐Fe	  stretching.	  
In	  addition,	  the	  ether	  group	  C-­‐O-­‐C	  stretching	  band	  and	  the	  vibration	  band	  were	  
resolved	  at	  1100	  cm-­‐1	  and	  1360	  cm-­‐1,	  respectively,	  and	  these	  two	  peaks	  were	  
observed	  in	  all	  three	  PEG-­‐containing	  moieties	  (Figure	  2B	  to	  D).	  These	  results	  are	  in	  
great	  agreement	  with	  observations	  in	  another	  study	  performed	  by	  Zhang	  et	  al	  [8].	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3.2	  Hydrodynamic	  size	  measurements	  
Both	  surface-­‐modified	  MNPs	  were	  well	  dispersed	  in	  aqueous	  solutions	  due	  to	  
the	  PEG-­‐coating	  on	  the	  surface.	  The	  hydrodynamic	  diameters	  of	  FA-­‐MNPs	  and	  PEG-­‐
MNPs	  are	  63.9	  ±	  3.8	  nm	  and	  113.8	  ±	  10.8	  nm,	  respectively	  (Figure	  3),	  making	  them	  
ideal	  candidates	  for	  accumulation	  into	  the	  defective	  vascular	  architecture	  of	  the	  
breast	  tumor	  region	  via	  the	  enhanced	  permeability	  and	  retention	  effect.	  The	  
significantly	  smaller	  size	  of	  the	  FA-­‐MNPs	  was	  probably	  caused	  by	  deprotonation	  of	  
the	  carboxylic	  acid	  groups	  of	  the	  surface-­‐attached	  folic	  acid,	  thus	  increasing	  the	  
aqueous-­‐dispersity	  of	  FA-­‐MNPs.






Figure	  3.	  DLS	  of	  PEG-­‐MNPs	  (green)	  and	  FA-­‐MNPs	  (brown)	  in	  PBS	  at	  25o	  C	  (size	  
distribution	  in	  number).	  Insert:	  Representative	  images	  of	  FA-­‐MNP	  (left)	  and	  PEG-­‐
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3.3	  In	  vitro	  cytotoxicity	  and	  intracellular	  uptake	  and	  of	  PEG-­‐MNPs	  and	  FA-­‐
MNPs	  
A	  resazurin	  cell	  viability	  assay	  was	  performed	  in	  a	  human	  breast	  tumor	  cell	  
line,	  MDA-­‐MB-­‐231,	  to	  assess	  the	  toxicity	  of	  the	  PEG-­‐MNPs	  and	  FA-­‐MNPs.	  Compared	  
with	  FA-­‐MNPs,	  the	  PEG-­‐MNPs	  exhibited	  significantly	  lower	  cytotoxicity	  at	  
concentrations	  ranging	  from	  0.01	  to	  0.5	  mg/mL,	  as	  shown	  in	  Figure	  4.	  Cells	  treated	  
with	  PEG-­‐MNPs	  were	  approximately	  72	  %	  viable	  at	  a	  high	  concentration	  of	  0.5	  
mg/mL	  after	  incubation	  for	  72	  h,	  suggesting	  its	  non-­‐toxic	  nature.	  In	  comparison,	  FA-­‐
MNPs	  substantially	  inhibited	  cell	  growth.	  A	  cell	  viability	  of	  only	  69%	  was	  observed	  
even	  when	  cells	  were	  incubated	  with	  0.01	  mg/mL	  of	  FA-­‐MNPs	  for	  the	  same	  
duration.	  	  






Figure	  4.	  Effects	  of	  the	  PEG-­‐MNPs	  and	  FA-­‐MNPs	  on	  the	  proliferation	  of	  FR-­‐positive	  
human	  breast	  cancer	  MDA-­‐MB-­‐231	  cells.	  After	  72-­‐h	  incubation,	  the	  relative	  number	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The	  capability	  of	  the	  FA-­‐MNPs	  to	  target	  FR-­‐positive	  tumors	  was	  also	  
evaluated	  in	  MDA-­‐MB-­‐231	  cell	  line.	  The	  ICP-­‐MS	  iron	  analysis	  of	  digested	  cell	  pellets	  
after	  a	  24-­‐h	  FA-­‐MNPs	  treatment	  showed	  significantly	  enhanced	  intracellular	  
accumulation	  with	  122.1	  ±	  20.9	  pg/cell	  (Figure	  5),	  approximately	  2	  folds	  higher	  
than	  that	  of	  the	  cells	  treated	  with	  PEG-­‐MNPs	  at	  an	  equivalent	  concentration.	  	  	  







Figure	  5.	  Intracellular	  uptake	  of	  the	  PEG-­‐MNPs	  and	  FA-­‐MNPs	  by	  MDA-­‐MB-­‐231	  cells	  
after	  a	  24-­‐h	  incubation	  at	  the	  concentration	  of	  0.3	  mg/mL.	  (Iron	  analysis	  by	  ICP-­‐MS:	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4.	  Future	  work	  
Our	  in	  vitro	  results	  indicate	  that	  folic	  acid-­‐modified	  core/shell	  magnetic	  
nanoparticles	  appear	  to	  be	  a	  promising	  targeting	  delivery	  system	  to	  enhance	  the	  
MNP	  accumulation	  in	  breast	  tumors	  that	  overexpress	  the	  folic	  acid	  receptor.	  This	  
FA-­‐MNPs	  can	  be	  exploited	  as	  a	  potent	  theranostic	  agent	  to	  enhance	  the	  MRI	  contrast	  
and	  increase	  the	  antitumor	  efficacy	  of	  the	  MNP-­‐mediated	  hyperthermia.	  Therefore,	  
future	  work	  will	  focus	  on	  in	  vivo	  evaluation	  of	  its	  theranostic	  efficiency	  in	  breast	  
cancer	  xenograft	  models	  in	  mice.	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